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MUC1 has conventionally been studied as an epithelial cell surface molecule.  Its 
glycosylation and expression change when those cells are transformed into adenocarcinomas.  
These changes have led to focus on MUC1 as a tumor antigen and also its role in adhesion to 
blood vessels and signaling within the tumor cell.  The recent discovery that T cells also express 
MUC1 on their surface extends the physiological role of MUC1, with the possibility that 
functions observed in tumors may be reproduced on T cells. 
Expression of MUC1 on T cells was first characterized in terms of timing, location and 
structure.  T cells activated both in vivo and in vitro express MUC1.  Expression in vitro is 
maintained over long time periods as the T cell population acquires the memory phenotype.  
Activated T cells induced to polarize by inflammatory conditions focus MUC1 expression to 
their leading edge, the sensory compartment of polarized T cells.  Reactivity with glycosylation-
sensitive antibodies and induction of glycosyltransferases indicates that the glycosylation of 
MUC1 on T cells is similar to that on normal epithelial cells. 
A MUC1-negative T cell line was transfected with MUC1 cDNA and used as a model to 
investigate consequences of MUC1 expression on the T cell surface.  Interaction of MUC1+ T 
cells with resting or activated endothelial cells revealed that MUC1 aids in adhesion under both 
normal and inflammatory conditions.  Analysis of interactions with individual adhesion 
molecules demonstrated MUC1 specific enhancement of binding to ICAM-1 but inhibition of 
 v
binding to E-selectin.  Phosphorylation of the MUC1 intracytoplasmic tail is constitutive but 
decreases upon interaction with activated endothelium.  MUC1 expression on T cells is also 
associated with differential phosphorylation of proteins in the molecular weight ranges of 39 
kDa, ~80 kDa and 190 kDa, with the ~80 kDa band identified as β-catenin. 
While human T cells express MUC1 on their surface upon activation, this does not 
appear to be a characteristic of mouse T cells from the human MUC1 transgenic mouse model.  
However, as recent work indicates that mouse T cells express mouse Muc-1 after activation, 
human and mouse T cells may similarly depend on MUC1 for normal functioning.   
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1.0 INTRODUCTION 
1.1 MUC1 Structure 
 MUC1 is expressed both as a transmembrane and a secreted glycoprotein. Though it is 
encoded as a single molecule, the type I transmembrane form is a heterodimer (Figure 1.0-1).  
The two proteins that make up MUC1 differ greatly in size with most of MUC1 larger fragment 
being composed of a tandemly repeated 20 amino acid sequence 
PDTRPAPGSTAPPAHGVTSA. This serine, threonine and proline rich sequence can be 
repeated up to 100 times in a single MUC1 molecule, commonly occurring between 41-85 times 
(1, 2).  This region is referred to as VNTR for variable number of tandem repeats. 
 
Figure 1.0-1  Structure of MUC1.  The 72 amino acid cytosolic tail is shown in purple.  The 28 amino acid 
transmembrane domain is shown in green.  The VNTR region is shown in blue while the remaining 
extracellular portions of MUC1 shown in tan.  The extensive O-linked glycosylation in the VNTR region is 
indicated with the stick figures. 
 The biosynthesis of MUC1 proceeds via distinct steps (3).  The newly synthesized protein 
receives several N-glycans adjacent to its transmembrane region following co-translational 
transfer of high-mannose glycans during synthesis in the endoplasmic reticulum.  Within 1 2 
minutes, while still in the endoplasmic reticulum, MUC1 undergoes proteolytic cleavage.  
Ligtenberg et al (4) showed in 1992 that the 2 cleavage products remain non-covalently 
associated so that the smaller transmembrane fragment anchors the larger piece. A proteolytic 
cleavage site, FRPG/SVW, located 65 amino acids upstream of the transmembrane domain was 
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identified recently (5).  After cleavage, the precursors move through the Golgi where the N-
glycans become more complex and O-glycosylation is started on the VNTR region.  O-
glycosylation increases the molecular weight dramatically within the first 30 minutes of 
synthesis.  MUC1 becomes partially sialylated on its O-linked oligosaccharides before leaving 
the Golgi as a premature form.  Completely and incompletely sialylated MUC1 are both 
expressed on the cell surface (6).  Trafficking of MUC1 to the cell surface is thought to be 
controlled by at least two signals, one contained in Cys-Gln-Cys motif at the junction of the 
MUC1 cytoplasmic tail and transmembrane domains, and a second in the extracellular domain 
but outside of the VNTR region (7). 
To become fully sialylated the premature form recycles several times from the cell 
surface to the trans-Golgi and back to the surface.  Complete sialylation occurs within 3 hours 
(3).  The recycling of MUC1 is constitutive so that even after full sialylation a mature MUC1 
molecule will complete 10 cycles before being lost approximately 24 hours after synthesis.  
MUC1 on the surface of normal cells is completely sialylated, while on tumor cells the surface 
MUC1 is a combination of completely and incompletely sialylated molecules.  It was suggested 
that this is due to greater abundance of MUC1 on tumor cells and/or less efficient sialylation 
process compared to normal cells (6).   
 NMR studies using peptides composed of one to three tandem repeats have shown that as 
the number of repeats increases the structure of MUC1 becomes more ordered.  Indeed, intrinsic 
viscosity measurements indicate that the peptide composed of three repeats has a rod-like 
structure (8), suggesting that MUC1 on the cell surface would project outwards rather than exist 
in a globular shape.  Further NMR studies established that in each repeat the immunodominant 
APDTR sequence exists on a protruding knob-like structure on the MUC1 backbone (9).  When 
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multiple repeats are examined, the overall effect is a rod with evenly spaced knobs throughout 
the entire VNTR region.  Most antibodies against MUC1 bind to this epitope making it 
immunodominant on the native MUC1 molecule (10). 
 Because of the large number of repeats in the VNTR region, MUC1 can extend 300-500 
nm above the cell surface, towering over other cell surface molecules.  Twenty-five percent of 
the amino acids in the VNTR region are either serine or threonine that can be O-glycosylated. On 
either side of the VNTR region are several degenerate repeats (11, 12).  Recently, Engelmann, et 
al. provided genetic evidence of variation in the 20 amino acid sequence within the VNTR 
domain (12).  By sequencing PCR products followed by minisatellite variant repeat analysis of 
the 5 and 3 peripheral areas of the VNTR region in 33 samples taken from normal and 
cancerous cells, they found that the same sequence variation consistently occurred in the same 
repeats, indicating that the variation predates the duplication event that has led to the elongated 
VNTR domain.  The proline (triplet code, cca) in position 13 of the tandem repeat sequence 
PDTRPAPGSTAPPAHGVTSA could be altered to glutamine (caa), alanine (gca) or threonine 
(aca), possibly generating an additional glycosylation site.  The other location of sequence 
change is in the immunodominant epitope, APDTR, in which the DT (gacacc) is substituted with 
ES (gagagc).  This was the most commonly seen sequence variation within the diverse 
population studied.  However, in only four of the 24 repeats sequenced from each of 33 samples 
was this variation found in the majority of samples. This particular variation within the 
immunodominant peptide sequence could be regarded as a source of additional epitopes with 
immunogenic potential; nevertheless, since this mutated (ES) sequence is less commonly seen 
than the conserved DT sequence found in the majority of repeats, one should expect the majority 
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of responses to be directed towards the highly conserved and overwhelmingly abundant tandem 
repeat sequences. 
The smaller subunit (~ 20 kDa) of MUC1 contains a short extracellular portion, a 
transmembrane region and a short intracellular tail.  In its extracellular domain is one site for N-
linked glycosylation (2, 13).  The transmembrane region carries cysteines that may be used for 
fatty acid acetylation to help anchor MUC1 in a cells membrane (11).  In the cytosolic tail are 
potential sites of phosphorylation and intracellular protein binding that prompted research into 
the possibility that MUC1 could be a signaling molecule (reviewed in section 3.1.2). This is 
especially of interest because the exact function of MUC1 is still being deciphered.   
Alternative splicing of MUC1 mRNA can lead to multiple forms being expressed by a 
single cell type.  When the full-length cDNA and genomic organization of MUC1 were initially 
published they showed that two different amino terminal signal sequences could be produced.  
The longer form, referred to as MUC1/A has an additional 27 base pairs when compared to 
MUC1/B (11, 13).  Whether MUC1/A or MUC1/B was produced depends on whether a guanine 
or adenine is present 8 nucleotides downstream of exon 1, in the first intron.  When guanine is 
present, the longer MUC1/A is synthesized and the number of repeats is higher.  Conversely, 
when adenine is present the shorter isoform MUC1/B is made and there are fewer repeats (14).  
In 2001 Obermair et al, looking at cervical carcinoma cells, found two novel MUC1 splice 
variants (15).  These were shorter than the variants described for normal MUC1 and were named 
MUC1/C and MUC1/D.  Both are a result of alternative splice acceptor sites when joining exons 
one and two.  Splice variants of MUC1 lacking the VNTR region (MUC1/Y, MUC1/X, and 
MUC1/Z) have also been reported.  MUC1/Y transcripts and protein were found in primary 
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breast cancer tissue (16).  MUC1/X (17) and MUC1/Z (18), both larger than MUC1/Y by 18 
amino acids, were reported in cancer cell lines. 
Soluble MUC1 is found in human milk (19, 20) and in barely detectable amounts in the 
serum of healthy men and women (21, 22). This form may be produced when a splice donor site 
downstream of the VNTR region is not used during transcription, allowing translation of a stop 
codon prior to the transmembrane region (13).  In 1996 a monoclonal antibody was generated 
against this novel out peptide sequence (23).  With this antibody, soluble MUC1 was detected in 
supernatant of a cancer cell line and in sera of cancer patients.  However, mouse mammary 
epithelial cells transfected with full-length human MUC1 in which alternative splicing could not 
occur (24), still produced soluble MUC1 lacking the cytosolic tail.  This supports a second 
mechanism that that MUC1 might be released from the surface of cells by proteolytic cleavage 
(25).  TACE (TNFα converting enzyme) is considered the likely protease responsible for the 
cleavage (26).  Other potential mechanisms for producing soluble MUC1 are cleavage by 
external proteases or simple dissociation of the heterodimeric complex.  The involvement of 
external proteases is not likely given that addition of proteolytic inhibitors has no effect on 
amounts of shed MUC1 (27).  Simple dissociation seems unlikely as well, given that MUC1 
remains a stable heterodimer during repeated recycling through the cell for further glycosylation 
and sialylation (6, 14).  Furthermore, when a mutated form of MUC1 that lacks the site of initial 
proteolytic cleavage is expressed as a single protein, it is still released from the cell (4). 
1.2 MUC1 Glycosylation 
 Because of the differences in MUC1 glycoforms expressed on normal and cancerous 
epithelium, there has been a great effort to understand MUC1 O-linked glycosylation.  The 
majority of MUC1 glycosylation occurs in the VNTR region on the two serines and/or three 
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threonines in each repeat.  The most common carbohydrate addition to one of these amino acids 
is a core 2 structure (Figure 1.0-2B), an N-acetyl galactosamine that has a galactose branching 
from its third carbon and N-acetyl glucosamine branching from its sixth carbon.  In normal 
MUC1 these branches are elongated and effectively cloak the peptide backbone.  Only a minor 
fraction of normal MUC1 glycosylation consists of just core 1 additions (28).  The core 1 
structure (Figure 1.0-2A) is an N-acetyl galactosamine that has only the galactose branching 
from its third carbon, no addition to carbon 6.  This yields a less effective cloaking of the peptide 
backbone and is predominantly seen on the tumor form of MUC1.   
 
Figure 1.0-2  Core structures in MUC1.  Core 1 (A) is common to the tumor form of MUC1 while core 2 (B) is 
common to the normally glycosylated form of MUC1. 
 While N-linked glycosylation occurs at known consensus sites, O-linked glycosylation 
motifs have not been identified.  However human GalNAc transferases responsible for initiating 
O-linked glycosylation on MUC1 have been studied in vitro (29) and the in vivo products 
analyzed (30) using recombinant enzymes and MUC1 peptides.  Regardless of whether the 
peptide contained one or five repeats [PDTRPAPGSTAPPAHGVTSA], in vitro only three of the 
five Ser/Thr sites per repeat were glycosylated.  No glycosylation was seen on the Ser in GVTSA 
or Thr in DTR. Interestingly, the enzyme kinetics varied for the site being glycosylated, e.g. 
GalNAc-Transferase2 (T2) being the fastest of the transferases tested to glycosylate ST in 
GSTAP but slowest on T in GVTSA (29).  Examining human milk however, all five potential 
sites were glycosylated in vivo with an average of 2.7 sites per repeat (30).  The discrepancy 
between in vitro and in vivo work could be attributed to additional GalNAc transferases working 
GalNAc
Galβ1-3 
Ser/Thr
GlcNAcβ1-6
GalNAc
Galβ1-3
Ser/Thr
B.A.
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in vivo and an enhancing effect of previous glycosylation on subsequent glycosylation.  This 
effect was demonstrated with a recombinant GalNAc-T4 that could glycosylate Ser in GVTSA 
and Thr in PDTR but only if the peptide had been previously O-glycosylated (31).  Furthermore, 
transferases GalNac-T1, -T2 and -T3 glycosylated in vitro single MUC1 tandem repeat peptides 
at 0  4 sites.  There were distant and neighboring effects on subsequent glycosylation, as well as 
enzymatic competition between transferases and core synthesizing enzymes that could help 
explain the MUC1 glycosylation differences between normal and cancer cells (32).   
Subsequent to receiving the initial GalNAc on a serine or threonine (referred to as Tn 
antigen), galactose can be added by the core 1 β3-galactosyltransferase to make the core 1 
disaccharide Galβ1-3GalNAc (also called T antigen).  This can be a precursor to the branched 
core 2 O-glycan, Galb1-3(GlcNAcβ1-6)GalNAcα1-Ser/Thr.  Other core structures can be found 
on MUC1 (28) and this will vary by cell type and differentiation state.  However, the most 
common core type is the core 2 formed by adding galactose to carbon 3 and GlcNac to carbon 6 
from the initially added GalNAc.  These branching saccharides on carbons 3 and 6 can in turn be 
elongated.  Fucose can also be added to subterminal and internal GlcNAc in α4 and α3 linkages.  
In cancerous cells expressing MUC1 the saccharide chains added to Ser/Thr do not extend 
beyond the core-type level (core 1 disaccharides accumulate) and sialylated glycans are more 
common than neutral glycans, in contrast to MUC1 from normal cells.  This is attributed to lack 
of core 2 specific β-6-N-acetylglucosaminyltransferase activity (C2GnT) and an increase in α3 
and/or α6-sialyltransferase activity.  The latter terminates elongation of core 1 disaccharides by 
adding sialic acid to carbon 3 or carbon 6 of galactoses.  In contrast to the short trisachharides 
(NeuAcα2-3Galβ1-3GalNAc and NeuAcα2-6(Galβ1-3)GalNAc) commonly seen on tumor 
MUC1, normal cells would synthesize long polylactosamine-type chains (up to 16 
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monosaccharides have been observed in human milk MUC1) (28).  Additional studies are 
continuing to explore this highly dynamic regulation of O-glycosylation (33, 34).   
1.3 Trafficking of T cells 
The trafficking of T cells to sites within the body allows the immune system to 
specifically target its defenses.  Endothelium at inflammatory sites express particular adhesion 
molecules that allow recruitment of T cells activated within secondary lymphoid organs that also 
express unique endothelial adhesion molecules (35-42).  The inflammatory trafficking process 
can be broken down into sequential major steps, beginning with T cell adhesion to vascular walls 
(38, 40-42).  First is the tethering and rolling of T cells at a slower speed along the sides of blood 
vessels.  Villous projections from the T cell surface express adhesion receptors that contact 
ligands on the lumen walls to slow T cell transit through the vessel.  These initial interactions 
predominantly involve selectins which can bind with high tensile strength in an easily reversible 
and transient manner to their ligands, carbohydrate structures presented by a variety of proteins.  
L (leukocyte) -selectin is utilized by T cells while E (endothelial) - and P (platelet) -selectins are 
employed by inflamed endothelium. 
Having slowed down the T cell, the next step in trafficking involves further interactions 
with other molecules on the vessel wall.  Activating factors such as chemokines on the 
endothelial surface act through G protein-coupled receptors on the T cell.  Signaling by these 
receptors rapidly activates integrin adhesion molecules already present on the T cell surface to 
enhance their binding capacity.  This leads to the third step in trafficking, the firm arrest of T 
cells to the wall of the blood vessel which allows the T cell to better resist shear forces exerted 
by blood flow.  Integrins vital to leukocyte arrest are LFA-1 (Lymphocyte Function-associated 
antigen; αLβ2; CD11a-CD18), Mac-1 (αMβ2; CD11b-CD18), VLA-4 (α4β1) and α4β7 (42, 
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43).  These bind to members of the immunoglobulin supergene family (IgSF) of receptors.  
Intercellular adhesion molecules -1 (ICAM-1; CD54) and -2 (ICAM-2; CD102) bind to the LFA-
1 and Mac-1 β2 integrins; vascular cell adhesion molecule-1 (VCAM-1; CD106) binds to VLA-
4; mucosal addressin cell adhesion molecule-1 (MAdCAM-1) binds to α4β7 (36, 38, 40, 44).  
Arrest mediated by the integrins and their receptors is reversible but on a much longer time scale 
(occurring over minutes), than rolling interactions (occurring over seconds).  As a result the T 
cell can return to the bloodstream unless signaled to initiate the final step of trafficking, 
transendothelial migration into tissue.  Migration occurs at junctions between endothelial cells in 
a process involving other adhesion molecules (42, 45) in a manner still being elucidated. 
1.4 Adhesion molecules on endothelium  
1.4.1 Selectin family 
On the endothelial cell surface are multiple adhesion molecules whose expression and 
regulation help direct the accumulation of leukocytes.  The three members of the selectin family 
all participate in lymphocyte trafficking into inflammatory sites.  The selectin family is 
responsible for the initial attachment and rolling along the surface of endothelial cells and 
selectin expression is limited to the vasculature and leukocytes.  (46, 47).  L-selectin (CD62L) is 
expressed on microvilli of monocytes, granulocytes and majority of lymphocytes.  P-selectin 
(CD62P) and E-selectin (CD62E) expression occur on the endothelial surface but only after 
activation by inflammatory cytokines which translocate P-selectin from secretory granules and 
induce E-selectin expression.  Because of this regulation, only inflamed tissues will provide 
these important leukocyte recruiting molecules.   
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The genes for all three selectins are found in a ~300kb gene cluster on human 
chromosome one (48).  The selectins are type I transmembrane proteins (Figure 1.0-3) that share 
significant homology in the extracellular regions (46).  The transmembrane and cytoplasmic 
regions have the least homology, reflecting individualized intracellular trafficking.  The most 
conserved domain is the lectin binding region, suggesting that the selectins bind similar ligands, 
carbohydrate structures on sialylated and fucosylated glycoproteins, though there are defined 
differences in ligands for each selectin (49-53).  Each selectin has a different number of 
repeating complement regulatory (CR) homology domains, thus extending each a different 
distance above the cell surface (51).  Selectins contain sites for N-linked glycosylation which can 
account for greater than 30% of their mass (54).   
 
 
Figure 1.0-3 Structure of selectins.  Selectins consist of an N-terminal lectin domain (red), an epidermal 
growth factor (EGF) domain (orange) followed by differing numbers of consensus repeats with homology to 
complement regulatory (CR) proteins (green):  nine for P-selectin, six for E-selectin or two for L-selectin, a 
transmembrane domain (blue) and a cytoplasmic domain (purple).   
1.4.2 E-selectin  
E-selectin interaction with MUC1 discussed later in this work warrants a closer look at 
this selectin.  Cloning of the single gene encoding E-selectin (55) revealed the sequence of 
domains illustrated in Figure 1.0-3, with six repeated CR motifs.  The 3 untranslated region 
contains sequence associated with molecules transiently expressed in response to inflammation.  
The 610 amino acid sequence indicates a type I transmembrane protein that would be cleaved to 
589 amino acids with an expected mass of 64kD.  Eleven putative sites for N-linked 
glycosylation as well as other possible post-translational modifications lead to larger actual size 
of the molecule, around 100 -115kD.  The cytosolic tail contains six serines and two tyrosines 
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available for interaction with intracellular proteins.  Message for E-selectin can be detected in 
IL-1 activated human endothelial cells within an hour of stimulation, peaking after 2-4 hours and 
declining to baseline levels by approximately 24 hours.  Protein expression on the cell surface 
correlates with message.  The protein and message are quickly degraded suggesting that high 
turnover also contributes to regulating E-selectin expression (55).   
In the hopes of blocking harmful inflammatory responses, there has been a focus on 
examining the ligand binding structure of E-selectin.  Using the tetrasaccharide selectin ligand 
sialyl Lewis X (sLex; α-D-Neu5Ac-[2,3]-β-D-Gal-[1,4]-[α-L-Fuc-(1,3)]-β-D-GlcNAc-O-[CH2]8 
COOMe) Erbe et al mapped a finite region of E-selectins lectin domain vital to recognizing 
carbohydrates (56).  A β−sheet within the lectin domain and a pair of nearby loops contain 
amino acids whose positively charged side chains are required for recognizing sLex, probably via 
interacting with the sialic acid carboxylate group.  This work was later substantiated with crystal 
structure studies (57, 58) showing the three dimensional structure of E-selectins lectin and EGF 
domains.  Following deglycosylation of these domains, which does not interfere with binding, 
the amino acids essential for ligand recognition were determined to be in the lectin region nearby 
bound calcium.  This places them in close approximation with the sialic acid and fucose 
structures of bound sLex.  Similar studies looking at the lectin domain of P-selectin showed that 
its binding relied on some amino acids in the same region; however, there were subtle disparities 
in binding due to differences within the lectin domain.  Chimeric P- and E-selectin molecules 
showed that carbohydrate binding specificity was contained completely within the lectin domain, 
as a result the lectin domain is sufficient to discriminate between counter-receptors (53).  More 
recent studies examining binding by E-selectin to sLex show that sialylation and sulfation at 
position three of the galactose in sLex enhances binding and that the position of fucose in the 
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tetrasaccharide is important (59).  This is consistent with the indispensable activity of 
fucosyltransferase VII (FucTVII) in generating selectin ligands (46, 51, 60).   
The conservation of E-selectins cytosolic region across species indicates that it plays a 
role in the function of E-selectin on endothelium.  Using anti-E-selectin antibody Lorenzon et al 
showed that binding E-selectin without cross-linking led to transient increases in intracellular 
calcium levels in activated endothelial cells.  Similarly, actin reorganized into stress fibers upon 
antibody binding while anti-sLex antibodies inhibited neutrophil mediated actin reorganization 
(61).  When activated endothelial cells bound leukocytes, the distribution of E-selectin switched 
from diffuse to clustered in areas around bound leukocytes and the tail became associated with 
the actin cytoskeleton.  Actin associated proteins filamin, α-actinin, paxillin, vinculin and focal 
adhesion kinase (FAK) were co-purified with E-selectin isolated from activated endothelial cells 
(62).  This E-selectin mediated association with cytoskeletal proteins and cytoskeletal 
rearrangement is important to the ability of the endothelial cell to resist mechanical stress due to 
the tethered leukocyte in the blood stream.   
1.4.3 Immunoglobulin gene superfamily (IgSF) adhesion molecules 
In addition to members of the selectin family, five molecules in the immunoglobulin gene 
superfamily (IgSF) act in adhering leukocytes to endothelium: platelet-endothelial cell adhesion 
molecule-1 (PECAM-1; CD31), MAdCAM-1, VCAM-1, ICAM-2, and ICAM-1 (36, 37, 40, 63, 
64).  While MAdCAM expression is fairly limited to endothelium of mucosal tissues, the 
remaining members are found on endothelium throughout the body.  MAdCAM-1, PECAM-1 
and ICAM-2 are constitutively expressed on endothelium while VCAM-1 expression is induced 
and ICAM-1 expression is upregulated by inflammatory cytokines.  The essential module in the 
structure of these molecules is the immunoglobulin (Ig) domain, the number of which varies for 
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each.  The size of these adhesion molecules ranges from the smallest, ICAM-2 having core 
protein size of 29 kD to the largest, PECAM-1 with a core protein size of 80kD.  Each protein 
contains sites for N-linked glycosylation that increase its molecular weight.  MAdCAM-1 is 
unique in that it also contains a mucin-like region that is extensively O-glycosylated.   
Members of the IgSF that bind to integrins, MAdCAM-1, VCAM-1, ICAM-2 and ICAM-
1, contain two disulfide bonds in Ig domain 1 that aid in uniting the integrin binding region (65).  
The second Ig domain helps adjust domain 1 for binding integrins and extends it above the cell 
surface.  Both the protein and crystal structures of the two N-terminal domains of integrin 
binding IgSF members appear similar; however MAdCAM-1 and VCAM-1 use a flat surface of 
Ig domain 1 to present a key acidic amino acid for integrin binding while the ICAMs use a more 
jutting surface (65).  This is a reflection of the different integrins each pair can bind.  ICAMs 
bind to the β2 integrins: ICAM-2 to LFA-1 and ICAM-1 to LFA-1 and Mac-1.  MAdCAM-1 
binds to α4β7, in addition to its selectin binding property via the mucinlike region.  VCAM-1 
can bind to α4β7 as well but is a much stronger receptor for VLA-4 (α4β1) (37, 40, 63).  Unlike 
the integrin binding members, PECAM-1 is a homotypic adhesion molecule in the IgSF.  Its 
expression on endothelium is localized at cell-cell junctions and it likely binds to PECAM-1 
expressed on leukocytes to aid not only adhesion but also transmigration (64). 
1.4.4 Intercellular Adhesion Molecule-1 (ICAM-1) 
ICAM-1 is a well characterized adhesion molecule critically important in the adherence 
of leukocytes to endothelium.  Cloning of the gene and cDNA placed it in the IgSF of adhesion 
receptors (66-69).  It is encoded in seven exons over a 12kbp stretch with no indications of 
alternative splicing.  ICAM-1 has five of the IgSF characteristic immunoglobulin domains, each 
encoded in a distinct exon.  These extracellular domains are followed by a 24 amino acid 
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transmembrane region and short cytosolic tail of 28 amino acids.  The core protein is 55kDa but 
eight N-linked glycosylation sites are differentially used by various cell types to heavily 
glycosylate ICAM-1 in the Ig domains 2-4.  As a result the final protein ranges in size from 80-
114 kDa, though endothelial ICAM-1 has less heterogeneity (67).  On the cell surface ICAM-1 is 
expressed as a homodimer via hydrophobic areas in the transmembrane and third Ig domain.  
The dimeric form of ICAM-1 is a stronger ligand for the integrin LFA-1 than the monomeric 
form (70).  Expression of dimerized ICAM-1 was also observed during crystal structure studies 
on ICAM-1s Ig domains 1 and 2 (71, 72).   
Expression of ICAM-1 is regulated at multiple levels and differs among cell types.  The 
5 regulatory region contains various cis-acting elements (66).  Binding sites for three 
transcription factors as well as two different transcription start sites complete with consensus 
TATA boxes are found upstream of the translation initiation sequence.  Choice of transcription 
start sites varies between different cells and inductive agents.  A variety of signal transduction 
pathways can upregulate and downregulate ICAM-1 expression   Cytokine induction and steady 
state levels of ICAM-1 expression occur partially at the transcriptional level with the κB 
enhancer being the most important element (69).  The effects of inflammatory cytokines on 
endothelium have been extensively studied (73).  Tumor necrosis factor α (TNF α) and 
interleukins 1 α and 1β have been shown to upregulate ICAM-1 on human umbilical vein cells 
(HUVEC) in a manner dependent on protein synthesis (74).  Post-transcriptional regulation of 
ICAM-1 is a minor component but can occur through mRNA stabilization, post-translational 
modifications and proteolytic cleavage from the cell surface (69). 
ICAM-1 was the first member of the IgSF shown to bind to an integrin despite not having 
the typical Arg-Gly-Asp (RGD) motif present in most integrin ligands (67, 68, 75, 76).  It binds 
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to two members of the β2 subfamily, LFA-1 and Mac-1.  These are both found on leukocytes 
and the structure of ICAM-1 may allow binding to both at the same time (69).  Each binding site 
is on a separate Ig domain, with LFA-1 binding to the N-terminus of Ig domain 1 and Mac-1 
binding to Ig domain 3.  Interestingly, N-glycosylation within the two sites of Ig domain 3 
inhibits Mac-1 binding so that cell binding to ICAM-1 is increasingly LFA-1 dependent as the 
size of N-glycan chains increase (77).  Conservation of the LFA-1 binding site between species 
points to LFA-1 being a very important in vivo ligand (69).  The crystal structures of ICAM-1s 
two N-terminal Ig domains show that the negatively charged glutamate critical to binding LFA-1 
is exposed on either side of the dimerized ICAM-1 so that the ligand binding regions are on 
opposite faces of ICAM-1.  This structure implied that the ICAM-1 homodimer can bind a 
similarly dimerized LFA-1 (71, 72) and is specially fit to resist distortion due to stress forces.   
Signaling by ICAM-1 does occur despite its lack of inherent tyrosine kinase activity or 
binding of Src family kinases.  However, establishing the definite mechanism is complicated by 
the large range of studies conducted using a wide variety of ICAM-1 expressing cells and 
ICAM-1 ligands (74, 78).  Cross-linking ICAM-1 with ligand expressing cells or antibodies can 
each initiate signaling in endothelial cells of the pulmonary, nervous and peripheral circulatory 
systems as well as endothelial lines.  In HUVEC, cross-linking ICAM-1 leads to activation of the 
MAP kinases ERK1 and ERK2, but not Jun amino-terminal kinase (JNK), and to activation of 
the activator protein-1 (AP-1) transcription factor, but not NFκB activity (74).  Endothelial 
surface protein and chemokine expression are affected downstream of ICAM-1 binding.  Lawson 
et al showed that anti-ICAM-1 antibody cross-linking induced ERK-1 and the AP-1 transcription 
factor activity in HUVEC and led to increased VCAM-1 expression (79).  Also in HUVEC, 
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synthesis and secretion of the chemokines IL-8 and RANTES was induced via activation of 
ERK1 and ERK 2 following ICAM-1 cross-linking (80).   
1.5 Adhesion molecules on T cells binding to endothelium 
1.5.1 Selectin-counter receptors 
The selectin counter-receptors on T cells are used to bind E-selectin and P-selectin 
expressed on activated endothelium.  These selectin receptor structures are presented on proteins 
which have undergone post-translational modifications (glycoproteins, proteoglycans, 
glycolipids (51) and sialomucins (42)).  Required fucosylation and sialylation indicate that 
fucose and α-2,3-linked sialic acid are universally used by endothelial selectins (47, 51, 81, 82).  
The well established and much studied α2,3sialylated, α1,3 fucosylated tetrasaccharide, sLex, 
can bind all selectins, but is not sufficient to confer binding to a selectin.  Specificity of cell-cell 
interactions is imparted by individual proteins presenting the glycan counter-receptor structures 
and this aids in directing leukocyte trafficking.  Diverse proteins presenting carbohydrate 
structures may alternatively space or combine them to impart an unique three dimensional 
arrangement for binding specificity, or modifications may occur to the protein itself.  For 
example, P-selectin ligands must contain sulfation though this is not required for E-selectin 
ligands (51).   
A great deal of what is known concerning the carbohydrate structures recognized by 
selectins has come from study of the P-selectin glycoprotein ligand-1 (PSGL-1) (46), a 
sialomucin believed to be the primary ligand for P-selectin on leukocytes and expressed on all T 
cells (46, 47, 81, 83).  PSGL-1 was identified in 1992 as a ligand for P-selectin (83) and later as a 
ligand for E-selectin (84, 85).  However, expression of this protein alone is not enough to endow 
selectin-mediated cell adhesion.  Studies of the structural requirements for P-selectin binding 
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showed a necessity for fucose, sialic acid and O-linked glycosylation, while N-linked glycans 
were unnecessary (83, 84).  Co-transfection of PSGL-1 with specific glycosyltransferases 
showed that binding to both P- and E-selectin required core 2 O-linked glycans to be sialylated 
and fucosylated (86).  In addition to these carbohydrate structures, tyrosine sulfation on the N-
terminus of the protein backbone of PSGL-1 is required for binding to P-selectin (87, 88) but not 
to E-selectin (86).  Given the variety of factors influencing selectin binding of PSGL-1 its been 
proposed that selectin binding to counter-receptors is based on a three-dimensional structure 
rather than a linear recognition site (47).  Extensive analysis of PSGL-1 expressed by a myeloid 
cell line showed that most of the O-linked saccharides have a core 2 motif and are a combination 
of neutral and sialylated structures.  Only 14% are α-1,3-fucosylated and contain sLex (89), a 
fairly small amount given the PSGL-1 dependency of P-selectin binding (51, 81, 83).  X-ray 
crystallography of P- and E-selectin in complex with sLex or PSGL-1 has illustrated some of the 
molecular interactions occurring with selectin counter-receptors (90).  On P- and E-selectin the 
binding site for sLex is highly conserved but P-selectin has neutral amino acids in that region 
while those of E-selectin are charged.  Both selectins bind sLex in a comparable orientation and 
with predominantly electrostatic interactions.  While the galactose of sLex interacts with identical 
amino acids of P- and E-selectin, the sialic acid residue and fucose of sLex participate differently 
so that contacts with E-selectin are more extensive.  P-selectin has vital contacts with sulfated 
tyrosines that are not seen with E-selectin.  These differences between P- and E-selectin are 
conserved across species and point to their importance in bestowing selectin-ligand binding 
specificity.   
Synthesis of the selectin counter-receptors require activity of different glycosyltransferase 
enzymes expressed in the Golgi apparatus of a T cell.  They are categorized based on the type of 
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sugar each adds to its substrate.  Depending on the type, relative amounts, location of enzymes 
expressed and substrates available, a cell can express a broad diversity of glycan products (81).  
The enzymes core 2 β1,6-N-acetylglucosamine transferase (core 2 GlcNAcT; C2GnTase) and 
α(1-3) fucosyltransferase-VII (FucT-VII) are involved in generating carbohydrate structures on 
T cells for endothelial selectin binding (46, 81, 82, 86).  Synthesis of P-selectin counter-receptors 
is dependent on core 2 GlcNAcT activity (84, 86, 87) but less so for the E-selectin counter-
receptors, for structural reasons not yet defined (81, 91).  In contrast, FucT-VII is absolutely 
required for synthesis of both E- and P-selectin counter-receptors on cell surface glycoproteins 
(60, 81, 82, 92, 93).  Interestingly, lower levels of activity are required to make P-selectin ligands 
as compared to E-selectin ligands in T lymphoblasts (93).  The presence of α2-3-sialic acid also 
determines binding of selectins to counter-receptors.  Of the six sialyltransferases only ST3Gal-
IV has been determined important to E- and P-selectin binding (49).  The regulation of 
expression of glycosyltransferase enzymes in T cells is influenced by their cytokine environment 
during activation, which then leads to differences in expression of endothelial selectin counter-
receptors and ability to subsequently migrate (94-99). 
1.5.2 Integrins 
Integrins are transmembrane cell surface adhesion molecules composed of non-
covalently interacting α and β chains.  These form metalloprotein heterodimers, expressed on 
cells throughout the human body, which can be categorized based on which β chain is used.  A 
separate categorization method divides the integrins into two groups depending on whether their 
α chain contains the I (inserted or interactive) domain (100).  This ~200 amino acid I domain 
contains a metal (Mg2+ or Mn2+) binding site and, in cooperation with the bound metal (101), 
functions as the chief ligand binding site for I domain containing integrins.  The 19 α chains and 
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eight β chains so far identified are known to form 24 or 25 different integrins (100, 102, 103).  
Of these, the four members of the β2 family, LFA-1, Mac-1, αdβ2 (CD11d/CD18) and αXβ2 
(CD11c/CD18; p150,95) along with the β7 family are all exclusively expressed on leukocytes 
(102, 104, 105).  Different leukocytes express different combinations of integrins and expression 
changes as the cells develop and migrate throughout their life cycle.   
 The structure of integrins (Figure 1.0-4) has shed light on how their ligand binding occurs 
and is regulated (102-104).  The N-termini of both the α and β chains extend above the cell 
surface and form a globular head that is linked to the plasma membrane by the stalks of each 
chain.  The α chain contains at its N-terminus seven repeating 60 amino acid stretches that fold 
into a β-propellor structure which contains Ca2+ binding sites.  β2 integrins belong to the group 
of integrins that contains the metal (Mg2+ or Mn2+) binding I domain and it is located in the third 
repeat of the β-propellor region of the α chain.  Interestingly, recent studies with LFA lacking 
the I domain have shown that it is not required for expression of the heterodimer on the cell 
surface and deletion of the I domain locks LFA-1 in the active conformation, suggesting that the 
I domain also regulates conversion between high and low affinity states (106).  The mechanism 
of how divalent cation binding affects cell adhesion is not yet clear but involves metal 
coordinating residues within the I domain that shift between ligand bound and unbound forms of 
integrins.  This corroborates the physiological importance of cations to integrin mediated cell 
adhesion (102, 103).  The β2 chain contains an I-like domain, which has a similar metal binding 
site as the α chain I domain.  This I-like domain is situated closely to the α chain I domain and 
also is important to ligand binding.  Following the transmembrane portions, β2 integrins have 
short cytosolic tails that lack intrinsic enzyme activity but do have sequences important for 
interaction with intracellular proteins used in linking to the cytoskeleton and signaling (α-actinin, 
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talin, filamin, vinculin, Rack1 (104, 107)).  The tail GFFKR motif is believed to serve as a hinge 
that keeps integrins in a low affinity conformation until an activating signal is received by a T 
cell to switch to a high affinity shape  (104). 
 
Figure 1.0-4  Features of β2 integrins. The αβ heterodimeric structure is common to all integrins. The α chain 
includes seven extracellular N-terminal homologous repeats organized into a β propeller structure. The α 
chain I domain is shown in pink with the embedded MIDAS (metal ion-dependent adhesion site) motif in 
orange, and the β chain I-like domain with MIDAS motif is shown in corresponding fashion.  The GFFKR 
sequence (green) in the cytoplasmic tail of the α subunit is involved in heterodimer assembly and regulation 
of ligand recognition. The heterodimer is illustrated in the “closed” or inactive state that undergoes tertiary 
and quaternary changes in response to inside-out signals.  From (104), reproduced with permission of AM 
SOC FOR BIOCHEMISTRY & MOLECULAR BIOL via Copyright Clearance Center. 
T cells have to be able to freely circulate through the blood and then quickly adhere to 
endothelium at inflamed sites.  Integrins, especially the β2 integrin LFA-1 and β1 integrin very 
late antigen-4 (VLA-4), are critical to this lymphocyte function.  Integrins on the lymphocyte 
surface are kept in an inactive, low affinity conformation.  Chemokines presented on inflamed 
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endothelium mediate signaling through the lymphocytes to activate integrins in a manner still 
being illuminated (108).  The ability to bind to ligand involves both structural changes to the 
integrin heterodimer as well as changes in cell surface distribution.  The I domain of the α chain 
undergoes conformational changes when the integrins bearing them are activated, going from a 
closed/inactive shape to an open/active shape that alters the entire integrin conformation (101).  
Additional evidence of conformational regulation of LFA-1 binding activity comes from studies 
manipulating the divalent cation environment (removing calcium, adding magnesium) to activate 
binding to ICAM-1 and from studies effecting intracellular signaling to integrins by activating 
other cell surface receptors (100, 104).  The inside-out signaling path(s) to activate β2 integrins 
has not been fully mapped but include cytohesin-1, GRP-1, the small GTPase Rho, protein 
kinase Cs, Rack1 (receptor for activated PKC), and MARCKS (myristolated alanine-rich C 
kinase substrate) (104, 107).   
Changes in cell surface distribution leading to clustering of LFA-1 causes increased 
avidity for its ligand.  In the inactive state LFA-1 is anchored to the cell cytoskeleton.  Upon 
release LFA-1 can laterally move and form clusters on the cell surface increasing avidity for 
ICAM-1 (100, 107).  Clustering is mediated by a number of intracellular molecules, including 
signaling proteins (SLAP 130, GTPase Rap-1, the Rac-1 GEF protein Vav-1) and cytoskeletal 
proteins (α-actinin, talin vinculin, filamin).  The cytosolic protease calpain that cuts many 
cytoskeletal proteins is also vital to clustering.  In T cells, activation of the cell through a variety 
of stimuli (T cell receptor, extracellular calcium, chemokines) leads to clustering on the cell 
membrane.  It has been shown that the density of ligand influences whether affinity or avidity is 
most important in cell adhesion.  Studying chemokine mediated lymphocyte arrest in vitro and in 
vivo, Constantin et al showed that when ICAM-1 is available at high density then high affinity 
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LFA-1 is sufficient for adhesion despite lack of mobility (108).  It is when ligand is at low 
density that mobility of LFA-1 is crucial to adhesion.  The distinction could be made by 
inhibiting phosphatidylinositol 3-OH kinase which regulates LFA-1 mobility but not affinity 
(108).  It seems that physiological ligand binding by integrins is likely not mediated exclusively 
through changes in affinity or avidity but by both.   
In addition to inside-out signaling regulating integrin function, integrins can also mediate 
outside-in signaling to alter gene transcription via Jun activating domain binding protein 1 
(JAB1) and stabilizing mRNA transcripts (105, 109). LFA-1 on primary T cells can mediate 
outside-in signaling to organize the F actin cytoskeleton and enhance binding to ICAM-1; both 
conformational alterations and clustering were required.  Though the mechanism behind this has 
yet to be mapped out, (110) LFA-1 has been linked to phosphorylation of intracellular proteins.  
Rodriguez-Fernandez et al showed in T cells that LFA-1 activation by monoclonal antibodies or 
by binding to ICAM-1 led to phosphorylation of focal adhesion kinase (FAK) and proline-rich 
tyrosine kinase 2 (PYK-2) (111), as detected in anti-phosphotyrosine immunoprecipitates from T 
cell lymphoblasts.  Activation of FAK and PYK-2 also occurred in response to LFA-1 binding 
ICAM-1 in a cytoskeletal dependent manner, as evident from interference by actin and tubulin 
disrupting agents.  These findings were concomitant with cell morphology switching from 
spherical to a polarized appearance.   
Intracellular signals generated by LFA-1 in response to binding to ICAM-1 embody a 
range of intracellular changes such as phosphorylation of phospholipase Cγ1, phospholipids 
hydrolysis, PKC activation, intracellular calcium mobilization and serine and tyrosine kinase 
activation (111, 112).  Since integrins have no catalytic activity they use a number of different 
non-receptor kinases that include FAK, PYK-2, c-Src, Abl and Syk (112).  In T cells, cross-
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talk between integrins has been demonstrated and is further evidence of the ability of integrins 
to mediate outside-in signaling.  In this process integrins can modulate each others adhesive 
function.  Porter et al showed that activation of LFA-1 by ICAM-1 binding decreased α4β1 
ability to bind to VCAM-1 and fibronectin (113).  α5β1 binding was also decreased but to a 
lesser degree.  Interestingly, activation of the β1 integrins did not modulate LFA-1 binding to 
ICAM-1 indicating a specific inhibition by LFA-1 rather than a common mechanism following 
integrin activation.  The β1 integrins could modulate each other in that blocking α4β1 integrin 
binding enhanced α5β1 binding.  Investigating the mechanism for the observed cross-talk 
eliminated changes in β1 integrin expression, redistribution or conformation (113).  Further 
exploration of the regulation of β1 integrins by LFA-1 used the I domain-deleted LFA-1.  This 
constitutively active form activated both α4β1 and α5β1 through clustering of β1 integrins and 
not by increasing their affinity.  The need for clustering in activating β1 integrins but not for 
inhibiting β1 integrins might be due to different expression levels of LFA-1 and the interaction 
with intracellular mediators of cross-talk (106).  Much work remains to be done to identify the 
molecules involved in LFA-1 cross talk but protein kinase C and calmodulin-dependent kinase II 
have been implicated in β1- β1 and β3  β1 integrin cross-talk (102).  Clearly the outside-in 
signaling by integrins is complicated by the cell type studied, range and expression level of 
integrins displayed and of cytosolic mediators but clarifying the pathways involved will greatly 
aid in understanding how T cells respond to extracellular signals to alter their function. 
1.6 Polarization of T cells During Interactions with Endothelium 
Shifting from a spherical to polarized morphology is a required initial step prior to T cell 
migration through endothelium.  It allows T cells to produce cell body movement from internal 
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cytoskeletal forces (114).  During this process the cell forms two compartments, the leading edge 
(contacts the endothelial surface) and the trailing edge (uropod extending above the T cell body).  
On the leading edge are active integrins (β1 and β2), chemokine receptors, and ganglioside 
GM3-enriched rafts.  Within the cytosol nearby the leading edge are polymerized actin filaments, 
Rho GTPases, the protein kinase FAK and vinculin, α-actinin, talin.  The uropod surface 
displays adhesion molecules ICAM-1, -2 -3 and PSGL-1, CD 43, 44, and ganglioside GM1- 
enriched rafts.  Within it are the ERM family of proteins (ezrin, radixin, moesin), motor protein 
myosin II, the Golgi apparatus, the microtubule organizing center (MTOC) and protein kinase C 
(114-117).  These differentially localized components are indicative of the unique roles of the 
leading edge and uropod.  The leading edge acts as a sensory organ to respond to polarizing 
stimuli and guide migration of the T cell.  The uropod acts as an adhesive structure to facilitate 
interactions with other cells.   
Presentation of chemokine to T cells and subsequent polarization and migration was 
investigated by Pelletier et al who showed that SDF1α bound to fibronectin and this bound 
chemokine could induce polarization of Jurkat cells (118).  Migration assays indicated that a 
distinct edge of SDF1 α was needed to orient the cells in a particular direction.  A uniform 
SDF1 α concentration still allowed directed migration, despite the absence of gradient, but in 
whatever direction the cell happened to polarize.  Pelletier et al proposed that matrix bound 
chemokine is still functional for inducing polarization.  Consistent with this idea, the polarized 
chemokine receptors were detected along the leading edge at the basal surface of the cells 
contacting fibronectin (118).  Nieto et al also reported that chemokine receptors on polarized 
cells are located on the flattened cell-substratum contact area and that polarization of chemokine 
receptors to the leading edge relies on integrin mediated cell adhesion (119). 
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Localization of ICAM-1 and -3 on the uropod would recruit additional lymphocytes.  del 
Pozo et al describe the upward projection of the uropod above the cell bodies of adherent T cells 
and the subsequent attachment of additional T cells to the elevated uropod (120).  Following 
binding of a cell at the uropod the adherent T cell could then migrate and carry the attached 
cell(s) with it.  This was observed not only with in vitro stimulated PHA lymphoblasts but also 
with cells activated in vivo (CD45RO+ cells isolated from PBL, tumor infiltrating lymphocytes 
and lymphocytes from the synovial fluid of rheumatoid arthritis patients) (120).   
Cell polarization occurs via chemokines  produced by different leukocytes and by 
endothelial cells, and their subsequent signaling pathways (121).  Chemokines bind to a family 
of heterotrimeric G-protein-linked heptahelical receptors that are expressed in various 
combinations on different leukocytes.  Complex signaling pathways initiated by the 
heterotrimeric G proteins are still being mapped but include protein serine/threonine and tyrosine 
kinases, adenyl cyclase, phospholipases A, C, D, the phosphatidylinositol 3-kinase (PI3K) lipid 
kinase, the Rho family of small GTPases and intracellular second messengers (calcium, cyclic 
AMP and phosphoinositides) (114).   
Chemokine signaling ultimately results in complete rearrangement of the T cells 
cytoskeleton to quickly switch from a spherical non-motile phenotype to an elongated bell-
shaped polarized morphology (114).  Central to this is concentrating F-actin filament distribution 
to primarily the leading edge rather than symmetrically dispersed around the cell body.  The rigid 
tubulin cytoskeleton is also moved during polarization.  Whereas the MTOC is adjoining the 
nucleus in spherical T cells, upon polarization the MTOC slips into the uropod and its splayed 
connected microtubules fold up into a narrow packed arrangement that allows the T cell 
increased malleability.  This form confers greater ability of the T cells to maneuver through 
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constricted spaces, e.g. between endothelial cells (122) but plays no role is generating the 
uropod.  In contrast, myosin II is vital to uropod formation as a myosin-disrupting agent 
completely prevents its formation and cell polarization (121).  The ERM protein radixin is also 
with myosin II in the uropod neck, differing from moesin which is adjacent to the distal end of 
the uropod.  There moesin associates with the cytosolic tails of CD 44 and ICAM-3, but not 
ICAM-1, linking them to the cytoskeleton and facilitating their movement to the uropod during 
polarization (123).   
1.7 Hypotheses, Specific Aims & Rationale 
Hypothesis 1:   
 MUC1 expressed by T cells is used to prevent and/or aid adhesion to blood vessels and 
thus modulate migration into tissues.  Because of this role it is expressed on the surface of 
activated but not resting T cells in the normally glycosylated form.  The location of MUC1 on 
the T cell surface changes as it shifts from an anti-adhesive to a pro-adhesive role, moving to the 
leading edge so as to be the first contact point with inflamed endothelium. 
Specific Aim 1: 
Determine when T cells express MUC1, where on the surface MUC1 is localized and the type of 
glycosylated form of MUC1 expressed on the surface of human T cells.  
Rationale: 
 As the role of a T cell changes so do the molecules on its surface.  Naïve T cells express 
adhesion molecules that specifically direct them to secondary lymphoid tissue where they can be 
activated.  Upon activation the spectrum of adhesion molecules changes so that the cells can 
home in on inflammatory sites.  Transitioning to a memory T cell population, the surface again 
contains a unique set of molecules.  Knowing at what stage(s) T cells are expressing MUC1 may 
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help in understanding its role.  In addition, MUC1 has been shown on tumor cells to both bind 
adhesion molecules and prevent cell-cell adhesion, the latter effect removed by capping MUC1.  
The location of MUC1 on the T cell surface, whether dispersed or localized to a particular area, 
is likely to alter the adhesion properties of the cell.  
 MUC1 can be expressed in different forms depending on the extent of glycosylation.  The 
form found throughout the body on epithelial surfaces is glycosylated with long branched chains 
of sugars on the majority of the molecules extracellular portion.  In contrast, when MUC1 
expressing cells alter glycosylation enzyme activities the glycosylation of MUC1 changes such 
that the sugar chains attached are much shorter.  The differences between these two forms of 
MUC1 would affect how the MUC1-bearing cell interacts with other cells.  In addition, cancer 
vaccines using MUC1 as an antigen specifically target the underglycosylated form of MUC1.  
For these reasons it is important to determine which form of MUC1 is expressed on activated 
human T cells.   
 
Hypothesis 2:   
 MUC1 on T cells interacts with one or more molecules on the surface of blood vessels as 
a means to initiate adhesion.  Upon interaction with a ligand MUC1 signals to the T cell via 
phosphorylation of its cytosolic tail and association with intracellular signaling proteins. 
Specific Aim 2: 
Determine if MUC1 on T cells affects their interactions with endothelial adhesion molecules and 
if there are changes in protein phosphorylation occurring within the T cell, to the MUC1 
cytosolic tail and/or other proteins, during interaction with endothelium. 
Rationale: 
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 Cell surface molecules enable the T cell to interact with and adhere to endothelium in the 
context of appropriate ligands.  Most T cell adhesion molecules project only a small distance 
above the cell.  MUC1, with its elongated rod-like structure, stretches above the cell surface and 
would be the first molecule of the T cell to make contact.  The results of this contact would likely 
play an initial role in the homing of a T cell to an immunologically active site.  Furthermore, 
phosphorylation and association with intracellular proteins, observed in MUC1 expressing tumor 
cells, may also be occurring in activated MUC1 expressing T cells in response to interaction with 
endothelium.  The role of MUC1 in adhesion and signaling would be important not only to 
understanding T cell biology but also in the hopes of manipulating T cell trafficking. 
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Figure 1.0-5  Model of activated MUC1 expressing T cell interacting with endothelium in a normal or 
inflamed site, illustrating the hypotheses guiding specific aims 1 and 2. 
 
Hypothesis 3:   
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 In vivo manipulation of T cell MUC1 would affect the ability of T cells to reach 
inflammatory sites.  As observed in humans, T cells from MUC1 transgenic mice should express 
MUC1 on their cell surface following activation and thus be susceptible to blocking MUC1 with 
antibodies.  Failure to express MUC1 would indicate either inability of mouse T cells to express 
the human transgenic MUC1 or an intrinsic difference between mouse and human T cells.   
Specific Aim 3: 
Determine expression of human MUC1 on the surface of MUC1 transgenic mouse T cells 
following activation and document any differences in the mouse model from human T cell 
expression of MUC1. 
Rationale: 
 An in vivo model is necessary to best study the effect of MUC1 on T cell migration.  
Mouse Muc-1 and human MUC1 have a homologous structure but differ in size, sequence, and 
the number of repeats in the extracellular region.  The mouse system cannot be used however 
because there are no reliable reagents such as anti-Muc-1 antibodies commercially available to 
study mouse Muc-1.  In order to take advantage of the numerous reliable well-characterized 
human MUC1 reagents, the human MUC1 transgenic mouse model (124) could be used.  It has 
been documented to express human MUC1 on the same epithelial surfaces where MUC1 is seen 
in humans.  Due to its fidelity in reproducing human MUC1 expression on epithelium, this 
model should be ideal to study the role of MUC1 on T cells via in vivo manipulation of the T cell 
MUC1.  Additionally, this transgenic mouse is used in many cancer vaccine studies.  Any 
differences seen between the mouse and human T cell would be relevant to comparisons made 
between humans and mice in numerous immune research studies. 
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2.0 FORM AND PATTERN OF MUC1 EXPRESSION ON T CELLS 
Hypothesis 1:   
 MUC1 expressed by T cells is used to prevent and/or aid adhesion to blood vessels and 
thus modulate migration into tissues.  Because of this role it is expressed on the surface of 
activated but not resting T cells in the normally glycosylated form.  The location of MUC1 on 
the T cell surface changes as it shifts from an anti-adhesive to a pro-adhesive role, moving to the 
leading edge so as to be the first contact point with inflamed endothelium. 
Specific Aim 1: 
Determine when T cells express MUC1, where on the surface MUC1 is localized and the type of 
glycosylated form of MUC1 expressed on the surface of human T cells.  
Rationale: 
 As the role of a T cell changes so do the molecules on its surface.  Naïve T cells express 
adhesion molecules that specifically direct them to secondary lymphoid tissue where they can be 
activated.  Upon activation the spectrum of adhesion molecules changes so that the cells can 
home in on inflammatory sites.  Transitioning to a memory T cell population, the surface again 
contains a unique set of molecules.  Knowing at what stage(s) T cells are expressing MUC1 may 
help in understanding its role.  In addition, MUC1 has been shown on tumor cells to both bind 
adhesion molecules and prevent cell-cell adhesion, the latter effect removed by capping MUC1.  
The location of MUC1 on the T cell surface, whether dispersed or localized to a particular area, 
is likely to alter the adhesion properties of the cell.  
 MUC1 can be expressed in different forms depending on the extent of glycosylation.  The 
form found throughout the body on epithelial surfaces is glycosylated with long branched chains 
of sugars on the majority of the molecules extracellular portion.  In contrast, when MUC1 
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expressing cells alter glycosylation enzyme activities the glycosylation of MUC1 changes such 
that the sugar chains attached are much shorter.  The differences between these two forms of 
MUC1 would affect how the MUC1-bearing cell interacts with other cells.  In addition, cancer 
vaccines using MUC1 as an antigen specifically target the underglycosylated form of MUC1.  
For these reasons it is important to determine which form of MUC1 is expressed on activated 
human T cells.   
 
This part has been modified from : 
Isabel Correa, Tim Plunkett, Anda Vlad, Arron Mungul, Jessica Candelora-Kettel, Joy M. 
Burchell, Joyce Taylor-Papadimitriou & Olivera Finn.  2003.  Form and pattern of MUC1 
expression on T cells activated in vivo or in vitro suggests a function in T-cell migration.  
Immunology 108: 32-41.  Copyright permission 2003 by Blackwell Publishing.   
SUMMARY 
MUC1 is a transmembrane mucin that is expressed on ductal epithelial cells and 
epithelial malignancies and has been proposed as a target antigen for immunotherapy. The 
expression of MUC1 has recently been reported on T and B cells.  In this study we demonstrate 
that following activation in vivo or activation by different stimuli in vitro, human T cells 
expressed MUC1 at the cell surface. However, the level of expression in activated human T cells 
was significantly lower than that seen on normal epithelial cells or on breast cancer cells. In 
contrast, resting T cells do not bind MUC1-specific monoclonal antibodies (mAb), nor is MUC1 
mRNA detectable by RT-PCR or Northern blot analysis in these cells. The profile of activated T 
cell reactivity with different MUC1-specific antibodies suggested that the glycoform of MUC1 
expressed by the activated T cells carried core 2-based O-glycans, as opposed to the core 1 
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structures that dominate in the cancer-associated mucin. Confocal microscopy revealed that 
MUC1 was uniformly distributed on the surface of activated T cells.  However, when the cells 
were polarized in response to a migratory chemokine, MUC1 was found on the leading edge 
rather than on the uropod where other large mucin-like molecules on T cells are trafficked. The 
concentration of MUC1 at the leading edge of polarized activated human T cells suggests that 
MUC1 could be involved in early interactions between T cells and endothelial cells at 
inflammatory sites. 
2.1 INTRODUCTION 
The human epithelial mucin, MUC1, is a heavily O-glycosylated type I transmembrane 
glycoprotein expressed at the luminal surface of most glandular epithelial tissues. Expression of 
MUC1 is increased in many epithelial malignancies, notably breast, pancreatic and ovarian 
cancers as well as in a proportion of colonic and lung cancers (for review see (125). The 
extracellular domain of MUC1 consists largely of tandemly repeated sequences of 20 amino 
acids with approximately 100 amino acids 5 to this region and 180 amino acids 3, followed by 
a transmembrane domain and cytoplasmic tail (2). The number of tandem repeats (TR) in the 
MUC1 allele can vary between 25 and 100. Each of the TR contains 5 potential O-glycosylation 
sites, and the glycoforms produced by cancer cells can differ from those expressed by normal 
tissues (126).  
There have been reports of humoral and cellular immune responses to MUC1 in 
multiparous women and in patients with cancer (127-132). These data, together with the high 
level of expression in tumor cells, have led to a focus on MUC1 as a potential target for tumor 
immunotherapy. Several MUC1-derived cytotoxic T cell (CTL) epitopes have been identified 
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(133-136) and immunization with vectors expressing the full length molecule or with peptides, 
have shown protection against MUC1-expressing tumors in mouse models (136, 137). However, 
in transgenic mouse models, where MUC1 is expressed as a self-antigen, it is more difficult to 
demonstrate immune responses against MUC1 (138-140), suggesting a degree of immunological 
tolerance. The degree of tolerance to a self-antigen is expected to be dependent on the level and 
location of expression of the self-antigen.  
Although the expression of MUC1 was originally thought to be restricted to epithelial 
tissues, recent work has suggested that MUC1 is also expressed by T and B cells (141-143).  
MUC1 expression on T cells has been documented through several experimental techniques: via 
immunohistochemistry (144), flow cytometry (141, 142, 145-148), RT-PCR (141, 142, 146, 
148), Northern blotting (142) and confocal microscopy (148).  Most studies have shown MUC1 
expression only on activated and not resting T cells (141, 145, 146, 148).  The expression of 
MUC1 on such cells has implications both for immune tolerance and autoimmunity. We 
therefore sought to investigate in detail the expression of MUC1 in human T cells documenting 
both the level and duration of expression, the distribution of MUC1 on the T cell surface and the 
specific form of the glycoprotein expressed.  
Our data demonstrate that MUC1 is expressed by T cells activated both in vivo and in 
vitro, but that the level of expression is low.  MUC1 on chronically stimulated T cells is co-
expressed with the memory phenotype marker CD45RO. The profile of reactivity of the T cell 
glycoprotein with MUC1-specific antibodies indicates that the O-glycans added to the core 
protein are extended core 2-based structures as seen in many normal tissues, rather than the 
truncated predominantly core 1-based structures added to mucin produced by tumor cells. 
Moreover, confocal microscopy revealed that MUC1 expression on T cells is dispersed over the 
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entire cell surface until polarization, at which point MUC1 becomes confined to the leading edge 
of the T cell.   
 
2.2 MATERIALS AND METHODS 
2.2.1 Cells and tissues 
All samples were obtained after acquiring informed consent from the study participants 
and according to Ethics Committee Guidelines. Peripheral blood was obtained from healthy 
volunteers, patients with breast cancer and a patient with rheumatoid arthritis, or as a 
leukopheresis research product from the Central Blood Bank (Pittsburgh, PA). Peripheral blood 
mononuclear cells (PBMC) were isolated from whole blood by Ficoll/Paque (Amersham 
Pharmacia Biotech, Uppsala, Sweden) density gradient centrifugation. The synovial fluid was 
obtained by sterile needle aspiration from the acutely inflamed knee joint of a patient with active 
rheumatoid arthritis. The human breast cancer tissue was obtained from a patient at the time of 
primary surgery.  
All cell lines (Jurkat, BT-20, DM6, DM6-MUC1) were grown in RPMI supplemented 
with 10% fetal bovine serum, 1% L-glutamine and 1% penicillin/streptomycin.  The 22 repeat 
MUC1-EGFP fusion construct (Figure 2.0-1) was cloned into the pLNCX2 (Clonetech) retroviral 
vector and then transfected into an amphotrophic packaging cell line by Dr. Andrea Gambotto.  
MUC1-EGFP expression is under control of the CMV promoter and the vector contains a 
neomycin resistance gene.  Jurkat cells were resuspended in retroviral supernatant containing 8 
µg/ml polybrene.  Cells were then aliquoted 2 ml/well to 24 well plate, centrifuged at 1,000 x g 
for 1 hour at room temperature and incubated at 37oC overnight.  The next day (day 2) 1 ml/well 
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of retroviral supernatant was replaced with new retroviral supernatant containing  8 µg/ml 
polybrene and centrifugation was repeated.  Cells were incubated overnight and the day 2 
procedure repeated on day 3.  On day 4 the cells were transferred to a tissue culture flask and 
grown in medium supplemented with 1 mg/ml G418. 
 
Figure 2.0-1  MUC1-EGFP construct transduced into Jurkat cells.  This diagram shows the restriction 
enzyme site used to insert the enhanced green fluorescence protein (EGFP) sequence in the N terminal region. 
Antibodies 
The monoclonal antibody (mAb) mouse anti-human CD3 (UCHT1), and mouse anti-
human MUC1 mAbs HMFG1, HMFG2 and SM3 were obtained from the Cancer Research UK 
Hybridoma and Monoclonal Antibody Facility. Other MUC1-specific mAbs were: 232A1 (a gift 
from Dr. J. Hilkens, the Netherlands Cancer Institute, Amsterdam, the Netherlands); mAb 12C10 
(obtained from Dr. R.B. Acres, Transgene, Strasbourg, France), mAb VU-3-C6 (obtained from 
Dr. J. Hilgers, Department of Obstetrics and Gynecology, Academisch Ziekenhuis, Vrije 
Universiteit, Amsterdam, The Netherlands).  Remaining anti-MUC1 antibodies were obtained 
from ISOBM TD4 International Workshop on Monoclonal Antibodies against MUC1 (10).  In 
some experiments, biotinylated HMFG1 and 12C10 were used.  Phycoerythrin (PE)-labeled 
mouse anti-human CD69, fluorescein isothiocyanate (FITC)-labeled mouse anti-human CD25, 
unlabeled isotype control mouse immunoglobulin G1 (IgG1), PE-labeled anti-human CD45RO, 
PE-labeled isotype control mouse immunoglobulin G2a (IgG2a) and PE-labeled anti-human 
CXCR4 antibodies were purchased from Becton-Dickinson Pharmingen (San Jose, CA). 
Polyclonal rabbit anti-chicken spectrin antibody was a gift from Dr. Elizabeth Repasky (Roswell 
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Park Cancer Institute, Buffalo, NY).  Alexa secondary antibodies and rhodamine phalloidin were 
purchased from Molecular Probes (Eugene, OR). 
2.2.2 Activation of human T cells in vitro 
PBMC were cultured (1 x 106 cells/well in a 24 well plate) in RPMI-1640 supplemented 
with 10% fetal calf serum (FCS), 2mM L-glutamine, 50µM β-mercaptoethanol (RPMI-10% 
FCS) and stimulated with phytohaemaglutinin (PHA; Abbot-Murex, Dartford, UK) at 1µg/ml or 
immobilized anti-CD3 mAb. Plates were incubated with 0.5ml of purified anti-CD3 mAb 
[10µg/ml in phosphate-buffered saline (PBS)] for 2 hours at 37oC. The plates were then washed 
three times with PBS and blocked with RPMI-10% FCS before use. Alternatively, PBMC in Fig. 
4 were incubated in AIM V medium (Gibco, Carlsbad, CA), supplemented with 10% human 
serum (Cellgro, Herndon, VA) and 1% L-glutamine, in the presence of PHA (1 µg/ml; Sigma, 
St. Louis, MO) and 20 U/ml interleukin-2 (IL-2) (Dupont, Wilmington, DE).  For antigen-
specific activation in vitro, PBMC in RPMI-10% FCS were stimulated in a mixed lymphocyte 
reaction (MLR). Responder PBMC (1.5 x 106 cells/well of a 24-well plate) were co-cultured with 
irradiated (2000 rads) allogeneic stimulator cells (responder:stimulator ratio of 1:1) for at least 6 
days. Cells from short-term MLR were purified by Ficoll-Paque centrifugation before staining. 
For chronic stimulation of T cells, PBMC were stimulated with irradiated allogeneic PBMC in 
AIM V-human serum medium containing 20 U/ml IL-2 (Dupont, Wilmington, DE).  Three to 
five days after stimulation, half of the medium from each well was replaced with new medium 
containing fresh IL-2.  The stimulation was repeated every 7 days.  
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2.2.3 Flow cytometric analysis 
Cells were stained with anti-MUC1 mAb HMFG1, HMFG2, SM3, 12C10 or 232A1, 
followed by FITC-conjugated rabbit anti-mouse immunoglobulins (Dako, High Wycombe, UK). 
When biotinylated antibodies were used, binding was detected with streptavidin-PE (Southern 
Biotechnologies, Birmingham, AL). Cells were also stained with directly conjugated antibodies 
to CD3, CD25, and CD69. For staining of chronically stimulated T cells, cells were stained with 
mouse anti-human MUC1 mAb MF06 or isotype control mouse antibody, followed by a 
secondary antibody, goat anti-mouse Alexa488. Cells were then fixed for 10 minutes at room 
temperature in 1% paraformaldehyde and empty binding sites of the goat anti-mouse secondary 
antibody were blocked with unlabelled mouse isotype control antibody. Cells were finally 
stained with directly PE-conjugated isotype control or PE-conjugated anti-CD45RO mAb.  Anti-
MUC1 staining of BT-20, DM6 and DM6-MUC1, resting T cells, activated T cells, MUC1-
EGFP Jurkat cells was done according to the procedure used with chronically activated T cells.   
Staining for SDF1α receptor was done with anti-CXCR4-PE  after a 30 minute 
incubation of MUC1-EGFP transduced Jurkat cells with SDF1α (PeproTech, Rocky Hill, NJ), 
(0, 2, 5, 10, 20, 50, 100 150, 300 ng/ml) in fibronectin coated wells.  MUC1-EGFP Jurkat cells 
exposed to the range of SDF1α were also analyzed to detect Enhanced Green Fluorescence 
Protein (EGFP) fluorescence.  Samples were analyzed using an XL Flow Cytometer (Beckman-
Coulter, High Wycombe, UK) and WinMDA software (Scripps Research Institute, La Jolla, CA) 
or a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA) and FlowJo 3.2 software 
(Tree Star, Inc., San Carlos, CA).  Dead cells were excluded on the basis of forward and side 
light scatter.  
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2.2.4 Confocal immunofluorescence microscopy 
PHA-activated T cells were separated from dead cells by Ficoll-Paque gradient 
centrifugation and cultured overnight on fibronectin (Sigma, St. Louis, MO)-coated 4-well 
chamber slides (Nalge Nunc, Naperville IL).  To induce polarization we added CCL5 (Regulated 
on Activation, Normal, T-cell Expressed, and Secreted; RANTES) chemokine (10 ng/ml, Sigma, 
St. Louis, MO) to the cells 30 minutes prior to staining.  Following chemokine treatment the 
cells were fixed in 2% paraformaldehyde for 10 minutes at room temperature and then washed 
extensively in PBS containing 10% FCS.  Indirect surface staining for MUC1 was performed 
using the mouse anti-human MUC1 mAb HMPV and Alexa488 labeled goat anti-mouse as a 
secondary antibody. Following the MUC1 staining, cells were fixed again and then 
permeabilized with 0.2% Triton X-100 for 10 minutes at room temperature. Intracellular staining 
was performed with rhodamine to stain the actin filaments or polyclonal rabbit anti-chicken 
spectrin followed by a red fluorescent Alexa546 goat anti-rabbit secondary antibody. Following 
staining, cells were immediately analyzed by confocal laser microscopy at the University of 
Pittsburgh Center for Biological Imaging Facility, using a Leica TCS NT confocal LSM 
microscope (Rockleigh, NJ). Images were collected as serial sections using (unless otherwise 
indicated) the x100 objective. Images are shown as either individual sections or as projections of 
stacked images. 
MUC1-EGFP Jurkat cells were cultured 30 minutes at 37oC on fibronectin coated 4-well 
chamber slides.  Polarization was induced by adding 10 ng/ml SDF1α for 30 minutes.  Cells 
were then fixed and permeabilized in 0.1% Triton X-100 in 2% paraformaldehyde for 15 minutes 
at room temperature.  Cells were rehydrated with 5 washes of PBS containing 0.1% Triton X-
100 then washed with PBS containing 0.5% bovine serum albumin, 0.15% glycine.  Non-specific 
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binding was blocked by first incubating in 4% normal goat serum for 45 minutes at room 
temperature.  Intracellular staining was performed with polyclonal rabbit anti-chicken spectrin 
followed by a red fluorescent Alexa546 goat anti-rabbit secondary antibody.  Following staining, 
cells were analyzed by confocal laser microscopy at the University of Pittsburgh Center for 
Biological Imaging Facility, using the Olympus Fluoview Confocal microscope. 
2.2.5 Fluorescent microscopy 
 Fluorescent images were collected of untransduced Jurkat and MUC1-EGFP transduced 
Jurkat in the absence or presence of SDF1α.  Cells were activated overnight in 1 µg/ml PHA and 
50 ng/ml PMA.  The next day they were placed on fibronectin-coated glass slides in the presence 
or absence of 50 ng/ml SDF1α for 30 minutes at 37oC.  After fixing in 2% paraformaldehyde 15 
minutes at room temperature the cells were stained with Hoescht dye to color the nuclei blue.  
Images were obtained with an Olympus Provis fluorescent microscope in the Center for Biologic 
Imaging, University of Pittsburgh. 
2.2.6 Live cell microscopy 
 Human microvascular endothelial cells (HMVEC) (Cambrex; Walkersville, MD) were 
grown to 70% confluency on 4-chambered coverglasses (Nalge Nunc; Naperville, IL) in EGM-2-
MV HMVEC medium.  MUC1-EGFP transduced Jurkat cells were resuspended at 2 x 107 cells 
/ml in PBS and 50 µl was added to each chamber of HMVEC containing 300ul HMVEC 
medium.  Images were collected at 30 second intervals over 15 minutes on the Nikon 300 
Eclipse inverted microscope with a Harvard Apparatus (Holliston, MA.) heated stage adapter. 
Multidimensional data sets were processed and avi files were generated through MetaMorph 
Software from Universal Imaging Corporation (Downington, PA). 
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2.2.7 Reverse Transcription-Polymerase Chain Reaction 
Total RNA was prepared using Trizol reagent (Gibco BRL) according to the 
manufacturers instructions. cDNA was generated from total RNA using the reverse 
transcription-polymerase chain reaction (RT-PCR) kit (Stratagene, La Jolla, CA), according to 
the manufacturers instructions (in all experiments 10µg total RNA was used to generate cDNA). 
The cDNA was subsequently amplified using MUC1-specific primers 5-
GCCAGCCATAGCACCAAGACTG-3 and 5AGCCCCAGACTGGGCAGAGAA-3. These 
primers correspond to a sequence 3 of the TR encoded by exons 2 and 5 and would result in the 
amplification of a 446bp fragment from RNA and a 838bp fragment from genomic DNA. For the 
semi-quantitative RT-PCR, cDNA was diluted as indicated before the PCR amplification and the 
same primer set was used. In other experiments, the following primer sets were also used: 5-
TCTCAAGCAGCCAGCGCCTGCCTG-3 and 5-TCCCCAGGTGGCAGCTGAACC-3 to 
yield a 331bp product, and 5-GCCAGCCATAGCACCAAGACTG-3 with 5-
TGAAGAACCTGAGTGGAGTGG-3 to yield an 816bp product. 
2.2.8 Northern Blotting 
Total RNA was extracted from cells using Trizol reagent (Gibco) according to 
manufacturers instructions. RNA (10 µg/lane) was run on a 1% agarose, 2.2M formaldehyde gel 
and then transferred onto optimized nylon membrane and fixed. The membrane was pre-
hybridized for 1hr at 65°C in hybridization buffer (1%BSA, 0.25M SDS, 0.25M disodium 
hydrogen orthophosphate, 0.25M sodium dihydrogen orthophosphate-1-hydrate). Probes (20ng) 
were labeled using random primers and the MegaPrime kit (Amersham Pharmacia Biotech), 
following manufacturers instructions. Probes were hybridized to the blot overnight at 65°C. 
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Membranes were washed for 1hr in buffer A (0.08M sodium phosphate, 2mM EDTA, 5% BSA, 
10% SDS) at 65°C, and then twice in buffer B (0.16M sodium phosphate, 4mM EDTA, 4% 
SDS) for 1hr at 65°C and then exposed to a phosphor screen (Amersham Pharmacia Biotech). 
Screens were exposed overnight at room temperature and visualized using a TYPHOON 8600 
scanner system (Molecular Dynamics, Little Chalfont, UK). Blots were stripped in a solution of 
0.06 x saline sodium citrate (SSC), 10mM EDTA and 0.1% SDS at 100°C for 10 minutes and 
then reprobed as described above.  
To verify the expression of MUC1 mRNA in normal human tissues, a multiple tissue-
expression array (Clonetech, Basingstoke, UK) containing RNA from normal human tissues was 
hybridized with the MUC1 probe, as described above. 
2.2.9 Probes  
The following probes were used:  MUC1, seven tandem repeats; C2GnT1, 950-bp PstI 
fragment; C2GnT2, 1234-bp EcoRI fragment; C2GnT3, 1361-bp EcoRI-BamHI fragment; 18S 
from Ambion (Austin, TX) 
2.3 RESULTS 
2.3.1 Expression of MUC1 on T cells activated in vivo. 
MUC1 expression on human T cells was investigated using MUC1-specific mAbs and 
flow cytometry. The mAbs used in all experiments on T cells were HMFG1, HMFG2 SM3, 
HMPV and MF06, all of which react with repetitive epitopes in the TR domain (149). mAbs 
232A1 and 12C10, which bind to epitopes outside of the TR region and therefore should react 
with all glycoforms, were also used.   
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Previously published work on the expression of MUC1 on T cells has employed in vitro 
methods of activation.  We sought to determine if this observation was true also for T cells 
activated in vivo.  To examine this issue, an aspirate from an acutely inflamed joint of a patient 
with rheumatoid arthritis was obtained, and MUC1 expression was ascertained by HMFG1 
binding and flow cytometric analysis. As shown in Figure 2.0-2, more than 10% of the T cells 
from the aspirate were HMFG1-positive, while no staining was observed on T cells from the 
patients blood.  The percentage of positive cells detected by 12C10 is lower and this is due to 
not picking up low MUC1 expressing T cells that HMFG1 can detect because it binds multiple 
times per molecule while 12C10 binds only once per MUC1 molecule.  Similar results were 
obtained with a joint aspirate from a patient with osteoarthritis (data not shown).  This indicates 
that T cells taken from a site of an active immune response, i.e. activated in vivo, also express 
MUC1.  
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Figure 2.0-2  Expression of MUC1 on T cells activated in vivo.  Peripheral blood mononuclear cells (PBMC) 
from blood or a joint aspirate of a patient with rheumatoid arthritis were stained with the indicated 
antibodies and analyzed by flow cytometry.  Numbers indicate the percentage of gated cells in the quadrant. 
 
2.3.2 Reactivity of MUC1 specific antibodies with human T cells activated in vitro 
We were interested in documenting the reactivity of a variety of different antibodies on T 
cells to see if there would be differential binding depending on the activation state of the T cell 
or the epitope of the antibody.  To do this we selected a broad panel of antibodies from the 1997 
workshop characterizing the epitopes of known anti-MUC1 antibodies (10).  These were first 
tested on MUC1 expressing tumor cells (BT-20) that make the underglycosylated form of MUC1 
and on MUC1 transfected cells (DM6-MUC1) that make the glycosylated form of MUC1.  Table 
2.0-1 lists the antibodies and the mean fluorescent intensities of each cell line after flow 
cytometric staining.  Comparison with parental DM6 cells is given to show MUC1 specific 
reactivity.  The majority of antibodies showed reactivity with both BT-20 and MUC1-transfected 
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DM6 cells, though some antibodies showed a tendency to react better with one or the other cell 
type.   
Table 2.0-1   Antibodies used to analyze MUC1 expression on BT-20, DM6 and MUC1 transfected DM6 cell 
lines.  Epitopes listed are from (10).  +Mean fluorescence intensity (MFI) detected by flow cytometry is given 
in parentheses.  *Normalized MFI calculated as the ratio of anti-MUC1 antibody MFI to isotype control 
antibody MFI.  The starred antibodies were used in Figure 2.0-3 and Figure 2.0-4. 
Antibody Epitope BT-20 DM6 DM6-MUC1 
SH1 Lex 12*  (44) + 1  (4.02) 3  (11) 
BW835 Carbohydrate? 298 (1289) 2  (5.94) 251  (1199) 
27.1 Carbohydrate? 748  (3231) 10  (41.15) 929  (4430.36) 
KC4 Carbohydrate? 255  (937) 1  (7.8) 27  (118) 
Ma695 Sialic acid dependent. 582  (3811) 6  (35.82 573  (5229) 
HH6 BG a or A type 1 22  (80.6) 1  (7.2) 6  (25) 
43 Galactose dependen/Tn 
(+TAP-2), H-type 
59  (1042) 13  (62.84) 60  (256) 
FH6 SLex 120  (2108) 5  (22.06) 6  (19) 
BCRU-G7 GalΒ1-3GlcNAc? 1  (11.49) 7  (34) 15  (65) 
7539MR Carbohydrate?. 326  (1378) 3  (11) 639  (3132) 
115D8 Sialic acid dependent 354  (1498) 4  (15) 846  (4143) 
VU-3-C6 GVTSAPDTRPAP 323  (1394) 11  (43.9) 458  (2186) 
BC4E549 TSAPDTRPAP 884  (3818) 3  (13) 720  (3434) 
VU-11-D1 TSAPDTRP 80  (346) 1  (4) 186  (885) 
VU-11-E2 TSAPDTRP 160  (692) 2  (7) 361  (1724) 
VU-3-D1 SAPDTRPAP 180  (448) 3  (10) 294  (1404) 
BC3 APDTR 25  (140) 2  (9.57) 39  (287) 
E29 APDTRP 401  (1750) 1  (5.77) 300  (2548.35) 
VA2 APDTRPA 59  (257) 2  (9.6) 160  (761 
Sec1 APDTRPAP 14  (59.72) 1  (5.85) 10  (50.85) 
214D4 PDTR 11  (49) 4  (15.15) 8  (40) 
VU-12-E1 PDTRPAP 227  (982.22) 2  (7.83) 257  (1364) 
b-12 PDTRPAP 293  (1921) 2  (14) 98  (895.32) 
GP1.4 PDTRPAPGS 474  (3103) 6  (36.83) 609  (5556) 
Mc5 DTRPAP 629  (2717 5  (19) 311  (1483) 
Va1 TRPAP 28  (123) 4 (14) 87  (414) 
M38 PAPGSTAPPAHG 774  (3342) 1  (5.34) 258  (1232) 
MF11 PPAH 919  (3971) 7  (26.11) 930  (4437) 
BCP7 HGVST 4  (18.49) 1  (5) 5  (42.1) 
SMA-1 Unknown (Non-VNTR) 3  (14.45) 1  (6.9) 1  (10.26) 
12C10 Unknown (Non-VNTR) 176  (1153) 5  (27.66) 368  (3309) 
HH14 Unknown (Non-VNTR) 1  (5.32) 1  (6.31) 1  (7.18) 
M29 Unknown (Non-VNTR) 57  (373) 4  (15) 638  (3132) 
 
From this panel we selected antibodies (SH1, KC4, FH6, BCRU-G7, 7539MR, 115D8 and VU-
3-D1) reactive to the VNTR region that showed this preferential binding towards the different 
forms of MUC1 and used them to stain resting and activated T cells.  Other antibodies not used 
here may be useful in future studies.  As expected, resting T cells did not express MUC1 
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detectable by any of these antibodies covering a range of epitopes (10).  Antibodies that showed 
a preference for the normal form of MUC1 (Figure 2.0-3), show higher overall reactivity with 
activated T cells than do the antibodies which prefer the tumor form of MUC1 (Figure 2.0-4).  In 
addition to the antibodies from Table 2.0-1 other anti-MUC1 antibodies with desired 
characteristics were later obtained and used in subsequent experiments (SM3, HMFG1, 232A1, 
MF06, HMPV).  Staining of activated T cells by SM3, an exquisitely specific tumor MUC1 
antibody agrees with previous results (Figure 2.0-5) (150). 
 
Resting T cells Activated T cellsAb clone Epitope
(SA dependent)115D8
(carbohydrate?)7539MR
(Galβ1-3GlcNAc?)BCRU-G7
(SAPDTRPAP)VU-3-D1 
 
 
 
Figure 2.0-3  Resting and PHA activated human T cells stained by anti-MUC1 antibodies with preference 
towards the normal form of MUC1, followed by Alexa488 labeled goat anti-mouse antibody.  Shaded 
histograms are isotype control antibody fluorescence, open histograms are anti-MUC1 antibody fluorescence.  
Epitopes listed are from (10). 
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Figure 2.0-4  Resting and PHA activated human T cells stained by anti-MUC1 antibodies with preference 
towards the tumor form of MUC1, followed by Alexa488 labeled goat anti-mouse antibody.  Shaded 
histograms are isotype control antibody fluorescence, open histograms are anti-MUC1 antibody fluorescence.  
Epitopes listed are from (10). 
 
Flow cytometric analysis of human T cells with multiple anti-MUC1 mAbs showed that 
none bound to resting T cells and most bound to activated T cells (Figure 2.0-3; Figure 2.0-4; 
Figure 2.0-5).  mAb HMFG1, HMPV and MF06 reproducibly bound to activated T cells and 
were used in further experiments. Staining of activated T cells with mAb 232A1 was detectable, 
but the fraction of cells recognized by this antibody was low (Figure 2.0-5).  
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Figure 2.0-5  Expression of MUC1 on activated T cells.  Resting and phytohaemagglutinin (PHA)-activated T 
cells were stained using different MUC1-specific monoclonal antibodies (mAbs) followed by fluorescein 
isothiocyanate (FITC)-labeled rabbit anti-mouse immunoglobulin. 
 
To increase the intensity of signal, 12C10 and HMFG1 mAbs were biotinylated and streptavidin-
PE was used for detection. Staining of T cells with HMFG1 was demonstrable 24 hours after in 
vitro activation with immobilized anti-CD3 mAb, and after 4 days more than 90% of cells were 
stained by the antibody (Figure 2.0-6). Staining with biotinylated 12C10 mAb (also an IgG1 like 
HMFG1) was also seen, but at a much lower level than that for HMFG1 (Figure 2.0-6).  Staining 
for the activation marker CD69, indicated that MUC1 expression was a later event than CD69 
expression during T cell activation (Figure 2.0-6).  Expression of MUC1 on activated T cells was 
similar on both CD4+ and CD8+ T cells (data not shown). 
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Figure 2.0-6  Expression of MUC1 on activated T cells.  Unstimulated peripheral blood mononuclear cells 
(PBMC) (day 0) or PBMC stimulated with anti-CD3 mAb for the indicated periods of time were stained with 
anti-CD3-FITC, in combination with anti-CD69-PE, HMFG1-biotin or 12C10-biotin, and analyzed by flow 
cytometry.  Numbers indicate the percentage of gated cells in the quadrant. 
 
The above experiments utilized potent polyclonal stimuli that might not be considered 
physiological, and in further studies we examined MUC1 expression by T cells stimulated by 
alloantigens in an MLR. After 6 days in culture with allogeneic stimulator cells, approximately 
25% of responding T cells stained with HMFG1 mAb (Figure 2.0-7A). The pattern of HMFG1 
staining mirrored the expression of the activation marker CD25. There was no significant 
staining of the non-stimulated T cells from the same donor. Cells repeatedly stimulated every 7 
days over a 1 month period demonstrated persistent MUC1 expression.  During this chronic 
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stimulation T cells acquired the memory phenotype, gaining expression of CD45RO, which was 
co-expressed with MUC1 on the majority of T cells (Figure 2.0-7B).   
 
Figure 2.0-7  Expression of MUC1 on activated T cells in a mixed lymphocyte reaction. (A.) Responder 
PBMC, incubated for 6 days in the presence or absence of irradiated allogeneic stimulator cells, were stained 
with HMFG1-biotin, in association with CD3-fluorescein isothiocyanate (FITC) or CD25-FITC and analyzed 
by flow cytometry.  Numbers indicate the percentage of gated cells in the quadrant.  (B.) Cells activated with 
allogeneic PBMC every 7 days for a month were stained for CD45RO and MUC1 (MF06 monoclonal 
antibody) then analyzed by flow cytometry. 
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2.3.3 Differential distribution of MUC1 on the surface of activated and polarized T cells 
The distribution of MUC1 on the surface of T cells was studied by confocal microscopy 
using the MUC1-specific mAb HMPV.  Activated, non-polarized T cells displayed MUC1 
evenly over the entire surface (Figure 2.0-8A).  When these cells were then exposed to the 
chemokine RANTES they responded predictably by changing morphologically and assuming a 
polarized shape needed for migration, with a leading edge and a trailing edge (uropod).  In these 
polarized cells MUC1 was immediately sequestered to one of the poles (Figure 2.0-8B).  By 
staining for spectrin (in red), which is a known marker of the T cell uropod (151, 152), and for 
MUC1 (in green), we were able to determine that MUC1 is concentrated opposite the uropod and 
on the leading edge of the T cell (Figure 2.0-8B).   
 A.  Non-polarized     B.  Polarized  
 
Figure 2.0-8  Analysis by confocal microscopy of MUC1 on activated T cells. (A. Non-polarized) Activated T 
cells were stained for MUC1 (green) and then counterstained for actin (red).  The top image shown in (A. 
Non-polarized) represents a projection of eight images acquired as 0.5-µm-thick scanned sections, four of 
which are shown in b–e. Magnification is 100x. (B. Polarized) Activated T cells adherent to fibronectin-
treated slides were treated with regulated on activation, normal, T-cell expressed, and secreted (RANTES) 
chemokine prior to staining for MUC1 (green; thick arrows). Cells were then permeabilized and stained for 
spectrin (red; thin arrowheads), a marker for uropods. The magnification of the top-left image in (B. 
Polarized) is 40x. The magnification of remaining images b–d is 100x.  These confocal microscopy images are 
projections of 16 stacked sections through the cells. 
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For further study of polarization of MUC1 to the leading edge of T cells we decided to 
generate a model MUC1 expressing T cell line with which we could watch the movement of 
MUC1.  The use of fluorescent MUC1 would allow observation of MUC1 movement.  Jurkat 
cells were transduced with a MUC1-EGFP vector and positively selected.  Flow cytometry of 
unstained cells looking at just EGFP fluorescence (Figure 2.0-9) shows that the MUC1-EGFP 
transduced Jurkat cells are expressing EGFP.   
 
 
Figure 2.0-9  Fluorescence of EGFP from MUC1-EGFP transduced Jurkat cells.  After transduction and 
positive selection, MUC1-EGFP Jurkat cells were analyzed by flow cytometry in the absence of antibody 
staining.  Shaded histogram is the fluorescence of untransduced Jurkat cells.  Open histogram is the 
fluorescence of MUC1-EGFP transduced Jurkat. 
However, EGFP fluorescence could be detected through the cell membrane from MUC1-EGFP 
that is not expressed on the cell surface.  It is also possible that expression of the construct could 
have been altered in some way that results in EGFP expression without full-length MUC1 
protein.  Flow cytometry staining was done on intact transduced Jurkat cells using an antibody 
reactive to the VNTR region to verify surface expression of MUC1 (Figure 2.0-10).  Fluorescent 
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microscopy demonstrating MUC1-EGFP expression also indicates successful transduction of the 
Jurkat cells (Figure 2.0-11). 
 
 
 
Figure 2.0-10  Surface expression of MUC1 on MUC1-EGFP transduced Jurkat cells.  After transduction and 
positive selection, MUC1-EGFP Jurkat cells were stained with isotype control or anti-MUC1 antibody VU-3-
C6 followed by anti-mouse Alexa647, whose emission is distinct from EGFP emission, then analyzed by flow 
cytometry.  Shaded histogram is the fluorescence of isotype control staining.  Open histogram is the 
fluorescence of anti-MUC1 staining. 
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Figure 2.0-11  Fluorescent microscopy of untransduced and MUC1-EGFP transduced Jurkat cells.  After 
transduction and positive selection of transduced cells, fluorescent microscopic pictures were taken of 
untransduced Jurkat cells (Jurkat) or MUC1-EGFP transduced Jurkat cells (tdJurkat).  Cells were activated 
overnight to enhance expression of MUC1-EGFP then placed on fibronectin coated slides and stained with 
Hoescht to dye the nuclei (blue); MUC1-EGFP appears green.   
These cells were stimulated with the chemokine SDF1α and examined for polarization 
and MUC1 localization by fluorescent microscopy, confocal microscopy and live cell 
microscopy.  Slides were coated with fibronectin to both aid in cell attachment, since Jurkat cells 
are non-adherent, and to aid in presenting chemokine to the cells (118).  With fluorescent 
microscopy there were indications of polarized cell morphology in some cells and bright spots on 
the cells where MUC1 was focused (Figure 2.0-12).   
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Figure 2.0-12  Fluorescent microscopy of MUC1-EGFP transduced Jurkat cells in the absence or presence  of 
polarizing chemokine.  Cells were first activated overnight to enhance expression of MUC1-EGFP and then 
placed on fibronectin coated slides without (A. TdJurkat) or with (B. tdJurkatSDF1α) SDF1α.  After a 30 
minute incubation, slides were washed and stained with Hoescht to dye the nuclei (blue); MUC1-EGFP 
appears green. 
However, it could not be conclusively determined that MUC1 was being localized to the leading 
edge as seen with primary cultures of activated human T cells since we did not have a similar 
phenotype.  The polarized MUC1-EGFP Jurkat cell population does appear to be dimmer but 
MUC1EGFP expression is unaffected by a wide range of SDF1α concentrations.  SDF1α 
concentrations ranging from 0 to 300 ng/ml did not affect the fluorescence of MUC1-EGFP 
transduced Jurkat cells, as seen by flow cytometry analysis (Figure 2.0-13).   
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Figure 2.0-13  MUC1-EGFP expression on MUC1-EGFP transduced Jurkat cells following incubation with 
SDF1α.  Cells were placed in fibronectin-coated wells containing 0 to 300 ng/ml of SDF1α for 30 minutes then 
analyzed for EGFP fluorescence by flow cytometry.  Differently colored histograms from cells incubated at 
each concentration were overlaid.  The shaded histogram represents cells incubated with no chemokine. 
 
In agreement with recent characterization of chemokine receptors on Jurkat cells (153), our 
MUC1-EGFP Jurkat cells do express the receptor for SDF1α, CXCR4, and can respond to 
SDF1α by down-regulating receptor expression with increasing doses of chemokine (Figure 
2.0-14). 
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Figure 2.0-14  CXCR4 expression on MUC1-EGFP transduced Jurkat cells following incubation with SDF1α.  
MUC1-EGFP Jurkat cells were placed in fibronectin-coated wells containing 0 to 300 ng/ml SDF1α for 30 
minutes.  Cells were then stained with anti-CXCR4-PE and analyzed by flow cytometry.  Shaded histograms 
are the fluorescence of isotype control staining.  Open histograms are the fluorescence of anti-CXCR4-PE 
staining on cells incubated with different SDF1α concentrations (ng/ml). 
 
It is possible that the dimness observed by fluorescent microscopy may be due to 
movement of leading edge localized MUC1-EGFP underneath the cell.  Pelletier et al reported 
that SDF1α is presented by matrix and causes the receptor for SDF1α, CXCR4, to polarize to the 
leading edge of migrating cells, particularly to the basal surface touching the matrix (118).  
Similar localization has been reported for other chemokine receptors (119).  Del Pozo et al 
likewise reported that leading edge localized LFA-1 was distributed along the contact area 
between T cells and endothelium (121).  Perhaps the dimness of MUC1-EGFP on the transduced 
Jurkat cells following polarization is due to the intervening cell body.  To see whether MUC1-
EGFP was moving to the leading edge opposite of the uropod, confocal microscopy was done to 
polarized cells.  Following incubation with SDF1α, cells were stained for intracellular spectrin, a 
marker for uropods (Figure 2.0-15).   
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Figure 2.0-15  Analysis by confocal microscopy of MUC1-EGFP on MUC1-EGFP transduced Jurkat cells in 
the absence or presence of SDF1α.  Cells were incubated in the absence (top row) or presence (bottom row) of 
SDF1α in fibronectin coated 4-well chamber slides and stained for intracellular spectrin (red); MUC1-EGFP 
appears green.  Light images shown on left to visualize cell shape. 
 
It is difficult to draw conclusions because some of the cells appear to have MUC1 and spectrin in 
distinct areas but in other cells they appear to overlap.  This is probably due to partial 
polarization of the cell population during the exposure to SDF1α.  When the MUC1-EGFP 
transduced Jurkat cells were allowed to simply interact with endothelium during live cell 
microscopy we can watch definite changes in cell morphology and distribution of fluorescent 
MUC1 on the cell surface on some cells (Figure 2.0-16).  Though our live cell microscopy 
cannot pinpoint the focal plane to conclusively demonstrate MUC1 has localized to only the 
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leading edge, as shown by confocal microscopy of normal human T cells, these data indicate that 
MUC1 is moved on the cell surface when MUC1-expressing cells interact with endothelium.   
 
Figure 2.0-16 Live cell microscopy of MUC1-EGFP Jurkat cells interacting with endothelium.  HMVEC 
monolayers were grown on 4-chambered coverglasses.  MUC1-EGFP Jurkat cells were added to chambers 
and images collected over 15 minutes as the cells began to interact.  The same field of view is shown in both 
microscopic images, DIC (left) and fluorescent (right). 
 
2.3.4 Expression of MUC1 mRNA in activated T cells.  
The results from the antibody staining suggested that MUC1 was expressed in activated, 
and not resting, human T cells. We confirmed this observation at the level of MUC1 RNA by 
RT-PCR from T cells at different times after activation. Figure 2.0-17A shows the presence of 
the predicted 446bp RT-PCR fragment using primers 3 to TR domain of MUC1 on T cells 
activated with anti-CD3 antibody. No RNA was detectable on day 0 but the level of expression 
appears to increase with time after activation (Figure 2.0-17A). Extraction of the bands and DNA 
sequencing confirmed these to be the expected fragment of MUC1 mRNA. Similar results were 
obtained using primers yielding a 331bp fragment from the region 5 to the TR domain (data not 
shown) and for T cells activated with phytohemagglutinin.  Sequencing of this fragment also 
showed it to correspond to the expected MUC1 nucleotide sequence. Using semi-quantitative 
RT-PCR, a comparison was made of levels of MUC1 mRNA in activated T cells and breast 
cancer cells from the same individual. Figure 2.0-17B shows that using cDNA from the breast 
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cancer cells, strong bands were produced up to dilutions of 1/100, whereas a weak band was 
obtained from equivalent amounts of undiluted cDNA from activated T cells, which was lost 
rapidly on dilution. The data suggest that the level of expression of the glycoprotein in activated 
T cells was at least 50 times lower than in the breast cancer cells.  
 
Figure 2.0-17  Detection by reverse transcription-polymerase chain reaction (RT-PCR) of MUC1 transcript 
in activated T cells.  (A) Human T cells were activated in vitro by anti-CD3 antibody.  Total RNA was 
extracted and RT-PCR performed on the indicated days (D0, day 0; D1, day 1; D2, day 2; D3, day 3; D4, 
day4).  MUC1 transcript (446 bp) was identified after at least 24 hr.  Human β−actin was included as a 
positive control, and a molecular weight marker is present in lane 1.  (B) Semiquantitative RT-PCR for 
MUC1 in activated T cells and autologous breast cancer.  Total RNA was extracted from autologous breast 
cancer cells and from purified human T cells following 4 days of in vitro activation using anti-CD3 antibody.  
cDNA was synthesized and then used as the template for RT-PCR at the dilutions shown.  Human β−actin 
was included as a positive control. 
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Northern blot analysis of MUC1 RNA expression after stimulation of T cells with PHA or CD3 
antibody also showed expression, but at very low levels, beginning to appear after 1 day. Figure 
2.0-18A shows that with a level of sensitivity sufficient to detect a strong signal for MUC1 RNA 
expressed by a breast cancer cell line, T47D, no transcript was detected in activated T cells. A 
much higher level of sensitivity was necessary to detect MUC1 RNA in the activated T cells. In 
the Northern blots the probe used was from the TR domain, and the size of the transcripts was as 
expected for full length MUC1. We conclude that activation of T cells is accompanied by low 
level expression of the full length MUC1 RNA. 
   
Figure 2.0-18 Northern blot analysis of resting and activated human T cells. (A) Resting T cells (D0) or T cells 
activated by anti-CD3 antibody for the indicated periods of time (D0, day 0; D1, day 1; D2, day 2; D3, day 3; 
D4, day4) were analyzed by Northern blot analysis for expression of MUC1.  MUC1* represents the same 
blot with increased sensitivity.  The cell lines T47D, MTSV1-7 and HPAF were included as positive controls 
for MUC1. (B) The O-glycosylation enzymes C2GnT1, C2GnT2 and C2GnT3 from resting T cells (D0) or T 
cells activated by anti-CD3 antibody for the indicated time periods were analyzed for expression by Northern 
blot analysis and compared to MUC1 expressing tumor cell lines.   
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2.3.5 Expression of glycosyl transferases synthesizing core 2 structures in activated T 
cells.  
The lack of reactivity of the SM3 and HMFG2 antibodies with MUC1 expressed on 
activated T cells suggested that the O-glycans on the MUC1 expressed by these cells were core 2 
-based (150, 154).  Indeed the first cDNA coding for a core 2 synthesizing enzyme, β6GlcNAc-
transferase 1 (C2GnT1), was isolated by expression cloning from activated T cells (155). Two 
additional β6GlcNAc transferase enzymes, C2GnT2, and C2GnT3 have now been isolated (156, 
157) and we examined the expression of transcripts coding for each of the three enzymes by 
Northern blot analysis in resting and in activated T cells (Figure 2.0-18B). An increase in the 
expression of C2GnT1 mRNA was seen upon T cell activation, C2GnT2 transcripts were not 
detected, whereas the level of expression of C2GnT3 appeared to fluctuate, both in size and level 
of expression. We conclude from this data that the increased activity responsible for synthesizing 
core 2 structures in activated T cells is likely to be due to increased expression of the C2GnT 1 
enzyme as had been previously assumed (96).  
2.3.6 Expression of MUC1 mRNA in normal adult tissues.  
Expression of MUC1 in normal adult tissues has been documented by 
immunohistochemical staining using antibodies to epitopes in the TR domain. These studies 
have suggested that MUC1 expression is largely seen in epithelial cells, particularly those of the 
lung, stomach, pancreas, kidney lactating mammary gland and salivary gland (158-160).  While 
mRNA levels do not necessarily predict the levels of expressed glycoprotein, detection of the 
transcript avoids the problem of different glycoforms being differentially recognized by 
antibodies to the TR domain. To define the profile of expression of MUC1 mRNA in normal 
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adult tissues, a dot blot of polyA+ RNA was subjected to Northern analysis using a probe to the 
TR domain of MUC1. Figure 2.0-19 shows that, as expected, high expression of MUC1 is seen 
in the epithelial tissues. However the levels of transcript detected in the intestinal tract and in 
trachea were much higher than those seen with antibody staining (161), presumably because of 
the extensive glycosylation, which blocks access of antibody to TR epitopes.  Foetal lung and 
kidney also showed high expression levels. Significantly, MUC1 transcripts were not detected in 
thymus, spleen and PBL, confirming our observation that MUC1 is not expressed in resting T 
cells and only at low levels in activated T cells.  
1    2    3    4    5    6     7    8    9    10  11   12
A
B
C
D
E
F
G
H
1 2 3 4 5 6 7 8 9 10 11 12
A whole
brain
cerebellum substantia
nigra
heart esophagus transverse
colon
kidney lung liver HL-60 fetal
brain
yeast total RNA
B cerebral
cortex
cerebellum accumbens
nucleus
aorta stomach descending
colon
skeletal
muscle
placenta pancreas HeLa fetal
heart
yeast tRNA
C frontal
lobe
corpus
callosum
thalamus atrium duodenum rectum spleen bladder adrenal K562 fetal
kidney
E. coli rRNA
D parietal amygdalla pituitary atrium jejenum thymus uterus thyroid MOLT-4 fetal liver E. coli DNA
E occipital caudate
nucleus
spinal cord ventricle ileum PBLs prostate salivary
gland
Raji fetal
spleen
Poly r(A)
F temporal
lobe
hippocampus ventricle iliocecum lymph
node
testis breast Daudi fetal
thymus
human  Cot-1
DNA
G medulla
oblongata
septum appendix bone
marrow
ovary SW 480 fetal lung human DNA
100 ng
H pons putamen apex ascending
colon
trachea A549 human DNA
500 ng
 
Figure 2.0-19  The presence of MUC1 mRNA transcript in fetal and adult human tissues.  A commercial 
multiple tissue expression array was assayed for MUC1 transcript using a probe to the tandem repeat (TR) 
region. 
More detailed analysis by flow cytometry of some other hemopoietic lineages using the same 
antibodies indicated that MUC1 is not expressed on monocytes or monocyte-derived dendritic 
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cells, and only very low levels could be detected on B cells (data not shown). Finally, T cells in 
lymph nodes removed at surgery for breast cancer did not stain with the antibodies in 
immunohistochemistry, whereas metastatic breast cancer cells in the lymph nodes did stain 
strongly with all the antibodies.  
 
2.4 Discussion 
In this study, we have analyzed in detail the expression of MUC1 in human T cells. 
Following activation in vivo and by different stimuli in vitro, human T cells expressed MUC1 at 
the cell surface, although the level of expression was much lower than that seen in breast cancer 
cells.  Our findings demonstrated that resting T cells do not bind anti-MUC1 mAbs, nor is 
MUC1 mRNA detectable by RT-PCR or Northern blot analysis in these cells. As the activated T 
cells progress to the memory state they maintain MUC1 on the cell surface.  Confocal 
microscopy revealed that MUC1 was uniformly expressed at the cell surface until a migratory 
chemokine was present; following such a stimulus, the cells focused MUC1 to the leading edge.  
The Jurkat cell line transduced with MUC1-EGFP showed a similar tendency to localize MUC1 
when exposed to chemokines or an endothelial monolayer.  The profile of reactivity with 
different antibodies suggests that the glycoform of MUC1 expressed by the activated T cells 
carries core 2-based O-glycans as opposed to the core 1 structures that dominate in the cancer-
associated mucin. 
It is well established that the glycosylation pattern of MUC1 can vary with the cell type 
expressing the glycoprotein (126, 162, 163). The binding of antibodies to epitopes in the TR 
domain of MUC1 is strongly influenced by the composition and density of the O-glycans 
attached to serines and threonines in this domain. The preferential reactivity of the HMFG1 mAb 
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with activated T cells probably reflected the fact that it can recognize MUC1 carrying core 2-
based structures (as well as the cancer-associated glycoforms; see refs (150, 154)). The same 
must be true for mAbs HMPV and MF06. As activated T cells are known to synthesize core 2 O-
glycans (155), MUC1 will probably carry core 2-based structures. In contrast, the mAbs SM3 
and HMFG2, which react better with MUC1 glycoforms carrying core 1-dominated structures 
(150), bound activated T cells poorly.  This preferential reactivity of T cells with antibodies 
recognizing the normal form of MUC1 holds true for a variety of antibodies with different 
epitopes.  Northern analysis of the transcripts for the three enzymes able to synthesize core 2 O-
glycans in the activated cells, suggested that the increase in C2GnT1 was responsible for the 
increased capacity to synthesize core 2 structures in activated T cells, although a role for 
C2GnT3 cannot be excluded.  C2GnT1 expression in lymphocytes is also involved in the optimal 
expression of selectin ligands for adhesion and lymphocyte homing properties, and it has been 
reported that its expression is regulated by the cytokine milieu subsequent to T cell activation 
(96, 97). 
The mAbs 232A1 and 12C10, reactive with single epitopes outside of the tandem repeat 
region and therefore unaffected by glycosylation patterns, did show positive staining of a fraction 
of activated T cells, but the percentage of cells staining was less than that seen with HMFG1. 
This is probably a result of the fact that lower levels of expression of MUC1 could be detected 
using an antibody recognizing an epitope repeated 25-100 times (depending on the allele), such 
as HMFG1, as compared to the level which can be detected by an antibody binding to a single 
epitope. The mAb B27.29, used in the previous study where expression of MUC1 in activated T 
cells was described (141), also recognizes an epitope in the TR region, overlapping with that 
recognized by HMFG1, HMPV and MF06 mAb (149). 
 65 
Previous reports had examined MUC1 expression by human T cells. One of these studies 
used the mAb DF3-P and suggested that MUC1 was present in resting human T cells and the 
leukemia cell line Jurkat (142). This antibody, like mAb SM3, has been reported to bind to 
cancer-associated glycoforms of MUC1, where core 1 structures predominate. However, in our 
study, the antibody SM3 did not bind to resting T cells, neither could MUC1 mRNA be detected. 
The HMFG1 antibody, which can recognize MUC1 carrying extended core 2-based O-glycans, 
as well as cancer associated glycoforms, also did not bind to resting T cells.  Our findings are 
substantiated by other studies that demonstrated minimal staining of Jurkat cells using DF3-P 
and no staining of resting T cells with MUC1-specific mAbs VU-4H5 and VU-3C6 (143), and no 
staining of resting T cells with MUC1-specific mAb B27.29 (141). Therefore, the majority of 
published reports support our observation that MUC1 is not expressed by resting human T cells. 
The different reactivities of antibodies, which are affected by the glycosylation pattern of 
the cell producing the glycoprotein, emphasize the importance of documenting expression of 
MUC1 mRNA transcripts. The expression of full length MUC1 was confirmed by sequencing 
the products of RT-PCR and by Northern blot analysis. Very low levels of transcripts were 
detected by Northern blot analysis as compared to levels in breast cancer cells, and in semi-
quantitative RT-PCR, the level of MUC1 transcript in activated human T cells was found to be at 
least 50-fold lower than that seen in human breast cancer. It is also important to note that using 
immunohistochemistry, there was no significant staining of T cells within activated lymph nodes. 
In contrast, micrometastases from breast cancer were readily identifiable within these same 
lymph nodes using HMFG1 or the other MUC1-specific mAbs used in the study. Therefore, the 
data presented here demonstrate that although MUC1 is expressed by activated human T cells, 
the level of expression is very low and certainly much lower than seen in breast cancer and 
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normal epithelial tissues. The relative levels of target antigens are important in determining 
whether a cellular immune response is activated or is effective.  The low level of expression in T 
cells probably precludes induction of autoimmunity as a result of MUC1 immunization 
strategies.  In addition when immune responses elicited by vaccines are focused on tumor-
specific forms of MUC1 these immunogens generate immune cells specific for epitopes present 
only on tumor cells.  Activated T cells express the glucosyltransferase enzymes that lead to long, 
highly branched polysaccharides on MUC1 (164) and do not present the same MUC1 epitopes 
found on tumor cells.  Thus it is highly unlikely that an immune response elicited by MUC1 
cancer vaccines would target activated T cells.   
This information is of interest as MUC1-based immunotherapy is under investigation in 
the clinic, and the induction of autoimmunity or the lack of response, due to immunological 
tolerance must be considered. In the trials carried out with radiolabelled HMFG1 mAb, no side 
effects suggestive of toxicity to lymphocytes have been noted (165). On the other hand, the 
expression of MUC1 by cells of the immune system could result in higher-than-expected levels 
of immunological tolerance. Also, the high expression of MUC1 mRNA in the gastrointestinal 
tract (Figure 2.0-19), if translated into protein, could also lead to high levels of immunological 
tolerance, as described for ovalbumin when expressed by intestinal cells (166).  
The function of MUC1 in activated T cells is uncertain. It has been proposed that MUC1 
has a role in immune response regulation (141), but the evidence is controversial. Inhibition of T 
cell proliferation by synthetic MUC1 peptides (covering the TR sequence) (167), or MUC1 from 
tumor cell supernatants (168), has been reported. In another report, the T cell-inhibitory factor in 
tumor-cell supernatants could be separated from MUC1 (169). We have found no effect of 
MUC1 TR peptides on the activation or function of T cells, and the level of MUC1 in the 
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supernatants from activated T cells is barely detectable (T. Plunkett, J. Taylor-Papadimitriou, 
unpublished).  In addition T cells, stimulated with MUC1-peptide-pulsed dendritic cells, express 
MUC1 on the T cell surface while the culture proliferates without evidence of T cell-T cell 
killing (J. Kettel, unpublished).  It seems more likely that it is the expression of MUC1 on the 
surface of T cells which plays some role, as yet undefined, in T cell function. Previous reports 
using tumor cells over-expressing MUC1 have indicated a role for MUC1 molecules in 
inhibition of intercellular adhesion (170-172). However, a certain density of surface expression 
may be required for blocking such cell-cell interactions.  The distribution of MUC1 over the cell 
surface is also a factor, as it was shown that MUC1 capped by anti-MUC1 antibodies no longer 
inhibited cell adhesion to extracellular matrix components (173). 
The confocal microscopic analysis of activated T cells showed two distinct patterns of 
MUC1 expression. The molecule is uniformly expressed over the entire cell surface in non-
polarized T lymphocytes but, interestingly, it forms polar aggregates in T cells undergoing 
cytoskeletal rearrangements in response to a chemokine.  It is known that to initiate migration, T 
lymphocytes switch from a spherical to a polarized shape and that actin is enriched in the cytosol 
of the leading edge of polarized T cells (114).  We have correlated the spatial distribution of 
MUC1 with that of other molecules associated with cytoskeletal rearrangement (151, 152).  
Following RANTES-induced cell polarization we found MUC1 at the leading edge of the 
polarized T cell.  To visualize MUC1 movement we generated a cell line expressing fluorescent 
MUC1 using a MUC1-EGFP fusion construct.  The Jurkat cell line has been shown to respond to 
CD3 engagement by moving its microtubule-orienting center, localizing polymerized actin (174), 
and undergoing similar shape changes in response to CD3 engagement (175) just as normal T 
cells do.  In addition, Jurkat cells have been used in studies examining T cell polarization (115, 
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118, 153, 176, 177).  It has also specifically been shown that Jurkat cells polarize in response to 
the chemokine SDF1α:  the SDF1α receptor CXCR4 is moved to the leading edge (115, 118) 
and basal surface (118), migration and actin polymerization are induced (178).  Because of its 
similarity to activated human T cells we chose this as our cell model.  The MUC1-EGFP 
transduced Jurkat cells strongly express the fusion construct, as seen by EGFP fluorescence and 
antibody staining for MUC1.  Polarization of these cells did not produce the same static 
elongated phenotype seen in polarized activated human T cells but MUC1 was focused opposite 
of spectrin on some cells.  Interestingly, when MUC1-EGFP Jurkat cells were allowed to interact 
with endothelium in the absence of exogenous chemokine there was active shape change 
accompanied by altered brightness of MUC1-EGFP, possibly due to asymmetrical movement of 
MUC1-EGFP on the cell surface.  This is consistent with reports of Jurkat and T cell shape 
change in response to integrin engagement (110, 175) and work showing the gradual 
spontaneous polarization of resting PBL co-cultured with endothelium in the absence of 
exogenous stimuli (179, 180).  The latter observations were not pursued using activated T cells 
or Jurkat cells but our results indicate that Jurkat cells may replicate their findings in a much 
shorter time span.   
The movement of MUC1 on the cell surface suggests that activated T cells may use 
MUC1 on their leading edge to affect interactions with endothelial cells as they travel to 
inflammatory sites and/or MUC1 plays a role in events that occur after the lymphocytes have 
passed through the endothelium into the underlying tissues (e.g. migration through tissue or 
interactions with target cells).  It is possible that the large size of MUC1 molecules promotes 
interactions at a long distance and mediates the initial contact between the T cell and 
endothelium or other cells. Which molecules on endothelial or other cells might be responsible 
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for the interaction with MUC1, and the nature of this interaction, are yet to be defined.  The E- 
and P-selectins are well-studied surface molecules on endothelial cells known to bind to 
carbohydrate ligands such as Lewis x (Lex) and the sialylated form of Lewis x (sLex).  Although 
MUC1 may carry specific O-glycans (e.g. sLex) that are recognized by selectins, it is unlikely 
that MUC1 is interacting with selectins on endothelial cells because the functionality of selectin 
ligands appears to depend on modifications of the core protein as well as the specific O-glycans 
(181).  It needs to be said that by virtue of the extended structure of the MUC1 molecules, they 
can inhibit cell interactions such as those mediated by integrins and E-cadherin (173, 182), as 
well as participate in cell adhesion through interaction with lectins such as sialoadhesin (183).  
Which of these effects predominate in the polarized T cell could depend on the immediate 
environment.  
The function of MUC1 on activated T cells has not been clearly defined but indications 
of its role in vivo may come from determining where MUC1 expressing T cells are found.  
Rheumatoid arthritic joints are sites of chronic inflammatory disease, and activated 
effector/memory T cells are the dominant cell type present in synovial tissue (184).  CD45RO+ T 
cells from these inflammatory infiltrates display a polarized morphology (120).  In addition, 
there is increased expression of adhesion molecules on inflamed endothelium in arthritic joints 
(185).  As MUC1 is expressed on the surface of activated memory T cells, it has the potential to 
play a role in T-cell migration into inflamed arthritic joints and/or events inside the joints.  
Finding MUC1 expressing T cells in synovial fluid from a person with rheumatoid arthritis 
supports this idea. 
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3.0 CONSEQUENCES OF MUC1 EXPRESSION ON T CELLS 
Hypothesis 2:   
 MUC1 on T cells interacts with one or more molecules on the surface of blood vessels as 
a means to initiate adhesion.  Upon interaction with a ligand MUC1 signals to the T cell via 
phosphorylation of its cytosolic tail and association with intracellular signaling proteins. 
Specific Aim 2: 
Determine if MUC1 on T cells affects their interactions with endothelial adhesion molecules and 
if there are changes in protein phosphorylation occurring within the T cell, to the MUC1 
cytosolic tail and/or other proteins, during interaction with endothelium. 
Rationale: 
 Cell surface molecules enable the T cell to interact with and adhere to endothelium in the 
context of appropriate ligands.  Most T cell adhesion molecules project only a small distance 
above the cell.  MUC1, with its elongated rod-like structure, stretches above the cell surface and 
would be the first molecule of the T cell to make contact.  The results of this contact would likely 
play an initial role in the homing of a T cell to an immunologically active site.  Furthermore, 
phosphorylation and association with intracellular proteins, observed in MUC1 expressing tumor 
cells, may also be occurring in activated MUC1 expressing T cells in response to interaction with 
endothelium.  The role of MUC1 in adhesion and signaling would be important not only to 
understanding T cell biology but also in the hopes of manipulating T cell trafficking. 
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3.1 INTRODUCTION 
3.1.1 MUC1 in adhesion 
The possible function of MUC1 on T cells can be hypothesized by looking at the work 
done studying the function of MUC1 on other MUC1 expressing cells.  Such functions may also 
be carried out in the T cell.  Studies have looked at MUC1 as having a potential role in cell 
adhesion.  This topic has been nicely reviewed by Hilkens et al (186).  Because of its rigidity, 
size and high negative charge due to sialic acid groups, MUC1 would likely be an anti-adhesive 
molecule. Studies by Ligtenberg et al (187) using MUC1 transfected cell lines showed that 
MUC1 expression inhibits cell aggregation.  Removing the sialic acids only partially decreased 
the anti-aggregation effect of MUC1.  Wesseling et al (173) looked at the effect of MUC1 
expression all over the surface of transfected cells and observed inhibition of integrin mediated 
binding to extracellular matrix components.  Activating β1 integrins or using anti-MUC1 
antibodies to cap MUC1 on the cell surface prevented the MUC1-mediated inhibition of binding.  
Contributions of MUC1 cytosolic portion were ruled out by using a tailless form of MUC1.  
Consistent with this, MUC1 was shown to decrease binding to type I collagen, with increasing 
size of extracellular MUC1 having a greater effect, though much less of a decrease in binding to 
fibronectin was observed (188). 
Kondo et al (171) examined how sodium butyrate caused breast cancer cell lines 
increased adherence to each other as well as to tissue culture surfaces.  By antibody blocking 
experiments the adherence was shown to be E-cadherin mediated.  By Northern and by FACS 
staining they showed that MUC1 expression decreased in response to sodium butyrate.  The 
association between decreased MUC1 expression and increased adherence following sodium 
butyrate treatment was confirmed by introducing MUC1 anti-sense DNA into the cells.  Another 
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group looking at E-cadherin mediated cell adhesion found that steric hindrance was the primary 
mechanism for MUC1 inhibition of adhesion.  They compared aggregation of fibroblasts before 
and after transfection with MUC1 of different lengths.  While both sizes of MUC1 inhibited 
aggregation, the smaller MUC1 had much less of an effect.  Removing sialic acids did not affect 
the inhibition of large MUC1 molecules (36 repeats in the VNTR region), though smaller MUC1 
molecules (eight repeats in the VNTR region) did show less inhibition without sialic acids.  
Using anti-MUC1 antibodies on cells expressing the large MUC1 removed anti-aggregation 
effects (182).  They concluded that the extracellular portion of MUC1 mediated the inhibitory 
effect with steric hindrance being the main mechanism, though charge repulsion could play a 
role depending on the size of MUC1 and its density on the cell surface.  These and other studies 
(172) have established that MUC1 can act as an anti-adhesive molecule.  However, the story of 
MUC1 in cell adhesion may not be limited to anti-adhesive effects.  Recent works have also 
shown that MUC1 can bind to lectin-like receptors (183) and to ICAM-1 (189, 190)   Taken 
together, all of this information indicates that MUC1 on the surface of T cells may help prevent 
or facilitate cell-cell interaction. 
 
3.1.2 Signaling by MUC1 
The cytosolic tail of MUC1 is well conserved among many species (7).  Seven tyrosines 
are present in that region (13) and available for phosphorylation.  According to work done with 
tumor cells, MUC1 transfected cells, or CD8/MUC1 chimeric fusion protein expressing cells, 
these tyrosines can be phosphorylated (191-194).  Since the MUC1 tail has no apparent intrinsic 
enzyme activity (16), the phosphorylation must be done by an associated kinase.  In a variety of 
cells and conditions MUC1 co-immunoprecipitates several intracellular protein(s) (16, 191, 192, 
195, 196).  Pandey et al (191) showed that tyrosine phosphorylated MUC1 associates with Grb2, 
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an adapter protein involved in signaling pathways.  Grb2 complexed with MUC1 connects with 
the guanine exchange protein Sos, which can activate Ras.  Though not able to replicate the Grb2 
association, Quin et al (192) did however co-immunoprecipitate with MUC1 a 60 kDa 
phosphorylated molecule as yet unidentified.  Associations between MUC1 and the c-Src 
tyrosine kinase have been reported (197-199) as well as activation of ERK1/2 in vivo (196) and 
indirect activation of ERK2 via Ras and MEK in vitro (200).  MUC1 also interacts with the 
catenin, p120, increasing the nuclear localization of p120 (201).  Association of MUC1 with 
transmembrane tyrosine kinases, erbB1 (epidermal growth factor receptor), erbB2, erbB3 and 
erbB4 has been shown in vivo (196).  The combination of available phosphorylation sites and 
association with kinases makes it highly likely that MUC1 plays an active role in cell signaling, 
perhaps as a transmembrane receptor.  This has yet to be shown for full-length MUC1 expressed 
on the cell surface though MUC1/Y has been proposed to act in a analogous manner to cytokine 
receptors (193). 
MUC1 in tumor cells has been associated with β-catenin (195, 197, 202-206), a protein 
involved in cadherin-mediated cell adhesion.  Binding to β-catenin is affected by 
phosphorylation of the MUC1 tail.  There is increased binding following MUC1 threonine 
phosphorylation by protein kinase C δ (PKCδ) (204) or tyrosine phosphorylation by c-Src (197) 
or Lyn (205), but decreased binding to β-catenin following serine phosphorylation by glycogen 
synthase kinase 3β (GSK-3β) (203).  The interaction between MUC1 and β-catenin has been 
proposed to explain the inhibitory effect of MUC1 expression on cadherin mediated adhesion 
(207).  However, though the biochemical studies indicated competition for β−catenin between 
MUC1 and E-cadherin (203), MUC1 inhibition of E-cadherin binding still occurs with tail-less 
mutants of MUC1 (173).  Though signaling may play a role, E-cadherin inhibition is probably 
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due to the high degree of steric hindrance that MUC1 provides on the cell surface (187), 
illustrated by experiments using MUC1 with varying numbers of repeats (182, 188).  Whether 
competition for β−catenin enhances MUC1-mediated inhibition of E-cadherin expressing cells 
remains to be determined.  Much further work is needed to illuminate these interesting 
associations between MUC phosphorylation, interactions with other proteins inside the cell and 
the effect on adhesion. 
 
 
Figure 3.0-1  Role of MUC1 cytoplasmic domain in β-catenin binding.  Sequence of cytoplasmic domain of 
MUC1, showing binding sequence for β-catenin (green) and phosphorylation sites for its regulation.  
Threonine 41 is phosphorylated by PKCδ to increase β-catenin binding to MUC1.  The serine highlighted in 
blue is phosphorylated by GSK-3β to decrease binding of β-catenin.  Tyrosine 46 is phosphorylated by c-Src 
to increase β-catenin binding and decrease GSK-3β binding.  The binding sequence for Grb2 is shown in 
lavender.  Modified from (207). 
3.2 MATERIALS AND METHODS 
3.2.1 Cells and antibodies 
Jurkat cells were grown in RPMI supplemented with 10% fetal bovine serum (FBS), 1% 
L-glutamine and 1% penicillin/streptomycin.  Jurkat cells were transfected with a MUC1 22 
tandem repeat expression vector (pRc/CMV-MUC1).  MUC1 expression is under the control of 
the CMV promoter and the vector contains a neomycin resistance gene.  Twenty micrograms of 
pRc/CMV-MUC1 DNA were linearized with the Xba1 restriction enzyme and electroporated 
into 5 x 106 Jurkat cells.  Electroporation was done in 0.4 cm electroporation cuvettes using 
BioRad (BioRad Laboratories, Hercules CA) Gene Pulser at 800 volts and 3 µF settings.  Cells 
were kept on ice for an additional 10 minutes and then transferred into culture flasks.  After 48 
41 46
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hours, selection began by growing the cells in normal growth medium supplemented with 1 
mg/ml G418.   
Human microvascular endothelial cells (HMVEC) were purchased from Cambrex and 
grown according to manufacturers instructions.  HMVEC were used in experiments at the end 
of passage 2 or 3.  All Chinese hamster ovary (CHO) cells were grown in RPMI supplemented 
with 10% fetal bovine serum, 1% L-glutamine and 1% penicillin/streptomycin.  3T3 cells were 
grown in DMEM supplemented with 10% FBS.  3T3-PECAM-1 cells were grown in DMEM 
supplemented with 10% FBS and 0.3 mg/ml G418.  ICAM-1, VCAM-1 and E-selectin 
transfected CHO cells were by provided Dr. Timothy Carlos (University of Pittsburgh, PA).  P-
selectin transfected CHO cells were provided by Dr. Geoffrey Kansas (Northwestern University 
Medical School, IL).  3T3 and PECAM-1 transfected 3T3 cells were provided by Dr. Steven 
Albelda (University of Pennsylvania, PA).   
 Unlabeled antibodies against L-seletin, PSGL-1, CD11a, P-selectin, PECAM-1, PE-
labeled antibodies against CD38, VLA-4, ICAM-1, and FITC-labeled antibodies against CD43, 
MUC1 (clone HMPV), and their isotype controls were purchased from BD Pharmingen (San 
Jose, CA).  Goat anti-mouse Alexa488 secondary antibody was purchased from Molecular 
Probes (Eugene, OR).  Antibody against ICAM-2 and MUC1 (clone BC2) were purchased from 
Chemicon (Temecula CA).  Antibodies against VCAM-1 (clone 5E1) and E-selectin (clone 7G8) 
were provided by Dr. Timothy Carlos.  Anti-phosphotyrosine antibody (clone 4G10) was 
purchased from Upstate Biotechnology, Lake Placid NY.   
3.2.2 Flow cytometric analysis 
Jurkat cells were stained with directly conjugated antibodies to CD43, CD38, and VLA-
4.  Staining of other adhesion molecules, CD11a (LFA-1), PECAM-1, PSGL-1 and L-selectin 
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was followed by a secondary antibody, goat anti-mouse Alexa488.  For experiments involving 
resting and activated HMVEC, half of the cells were incubated in 10ng/ml IL-1β (R&D Systems, 
Minneapolis MN) in fresh medium, while the other half received unsupplemented fresh medium, 
for 5-7 hours at 37oC.  HMVEC cells were stained with directly conjugated antibody against 
CD54 while staining for other adhesion molecules, ICAM-2, PECAM-1, E-selectin, VCAM-1 
and P-selectin was followed by a secondary antibody, goat anti-mouse Alexa488.   
3.2.3 Cell-cell adhesion assay 
HMVEC or cell lines expressing individual adhesion molecules were grown as a 
monolayer in flat-bottomed 96-well plates.  Upon reaching confluency the plates were used in 
the adhesion assay.  For experiments involving resting and activated HMVEC, half of the wells 
on each plate received 10 ng/ml IL-1β (R&D Systems, Minneapolis MN) in fresh medium while 
the other half received unsupplemented medium.  HMVEC were incubated 5-7 hours at 37oC and 
then washed three times with PBS before use to eliminate residual IL-1β.   
Jurkat and MUC1-Jurkat cells, suspended at 5 x 106 cells/ml, were labeled for 30 minutes 
with 5 µl/ml calceinAM (Molecular Probes, Eugene OR), a lipophilic ester that is cleaved 
intracellularly to yield fluorescent calcein.  After washing off unincorporated calceinAM, PBS or 
2-2.5 x 105 Jurkat or MUC1-Jurkat cells were added to each well containing the adherent cell 
line, either HMVEC or the cell lines expressing individual adhesion molecules.  Each cell-cell 
combination was tested in either triplicate or quintuplicate.  Plates were incubated at 37oC for the 
indicated times and then, using a multichannel pipettor, the wells were washed to remove non-
adherent Jurkat or MUC1-Jurkat cells.  The monolayer was inspected after the final wash to be 
sure it had remained intact.  A replica control plate with wells containing the adherent monolayer 
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and the maximum amount of labeled cells was not washed so that the maximum fluorescence 
could be measured.   
Fluorescence of labeled cells (excitation 485 nm/emission 530 nm) was measured on a 
SPECTRAmax GeminiXS fluorimeter using the accompanying SOFTmax Pro software program 
(Molecular Devices, Sunnyvale CA).  Percent of maximum adhesion was calculated by 
subtracting the fluorescence of wells containing only PBS from the fluorescence of each well 
containing cells.  The resulting fluorescence value of each experimental well was then divided by 
the average maximum amount of fluorescence from wells containing the whole volume of 
labeled cells to indirectly measure the percentage of cells still adherent to the monolayer.  
Statistical analysis was performed by Dr. Doug Potter (Biostatistics Facility, University of 
Pittsburgh Cancer Institute, PA) using the stratified Wilcoxon test with ranks computed 
independently within each stratum.  The statistical package used was StatXact-5. 
3.2.4 T cell - Endothelial Interaction Assay 
HMVEC cells were grown to confluency in 6 well plates and then half were activated 
with 10 ng/ml IL-1β for 5-7 hours on the day of the assay.  Equal numbers of Jurkat or MUC1-
Jurkat cells were added to endothelium containing wells or left in the tube to represent no 
endothelial interaction.  Plates were then incubated at 37oC for 15 minutes to allow interaction to 
occur and then placed on ice while the Jurkat and MUC1-Jurkat cells were collected from the 
wells using ice cold PBS containing phosphatase inhibitors (1 mM activated sodium fluoride, 1 
mM sodium orthovanadate).  Microscopic examination showed that the monolayers remained 
intact and that all Jurkat and MUC1-Jurkat cells had been collected from each well.  Cells were 
pelleted by centrifugation at 4oC and then lysed in modified RIPA buffer (50 mM Tris-HCl, pH 
7.4; 1% NP-40, 0.25% sodium deoxycholate; 150 mM sodium chloride; 1 mM EDTA; 1 mM 
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PMSF; 1 µg/ml leupeptin; 1 µg/ml aprotinin; 1 µg/ml pepstatin A; 1 mM activated sodium 
orthovanadate; 1 mM sodium fluoride) for 40 minutes on ice, vortexing every 10 minutes.  
Lysates were centrifuged in a cold room at 13,000 x g for 15 minutes.  Supernatants were 
collected to new tubes, aliquoting equal cell equivalents (4 x 106 cells) to each tube, and frozen 
until use. 
3.2.5 Immunoprecipitation and immunoblotting for phosphorylated MUC1 
Aliquots of supernatants from MUC1-Jurkat cell lysates were thawed on ice, diluted up to 
0.5 ml with modified RIPA lysis buffer and then pre-cleared by rotating with 25 µl of protein G 
bead slurry for 1 hour at 4oC (Amersham Biosciences, England).  Five micrograms of 4G10 
antibody was loaded onto protein G slurry by rotating for 2 hours at 4oC followed by removal of 
unbound antibody.  Pre-cleared lysates were then rotated overnight at 4oC with 4G10 (Upstate 
Biotechnology, Lake Placid NY) coated beads.  After washing, the beads were suspended in 
NuPage LDS Sample buffer (Invitrogen, Carlsbad CA), and dithiothreitol (DTT) to yield a final 
concentration of 0.05 M DTT.  Samples were heated for 3 minutes at 95oC and the supernatants 
electrophoresed on a 1.5 mm 4-12% Bis-Tris polyacrylamide gel (Invitrogen, Carlsbad CA) 
alongside SeeBlue Plus1 molecular weight markers in MOPS (3-(N-morpholino) propane 
sulfonic acid) SDS running buffer at 200 volts.  Proteins were transferred onto nitrocellulose 
membranes (BioRad Laboratories, Hercules CA) in 10% Towbin buffer using 30 volts overnight 
at 4oC.   
The membrane was blocked with 10% dry milk in PBS by rocking for 45 minutes at 
room temperature then immunoblotted with 0.5 µg/ml mouse anti-MUC1 antibody (clone BC2; 
Chemicon, Temecula CA).  Bound primary antibody was detected with a 1:2000 dilution of 
sheep anti-mouse horseradish peroxidase conjugated secondary antibody (Amersham 
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Biosciences, England).  ECL detection reagents (Amersham Biosciences, England) were added 
to the membrane as directed by the manufacturer and proteins were visualized using X-Omat 
film (Kodak, Rochester NY).  Quantitation of BC2 signal was obtained with Versadoc imaging 
system model 3000 using the Quantity One software (BioRad Laboratories, Hercules CA).  
Calculation of MUC1 signal intensity in Versadoc intensity units was determined by subtracting 
background signal from raw MUC1 signal in each lane.  A431 cell lysate (human epidermoid 
carcinoma line; Upstate Biotechnology, Lake Placid NY) was used as a negative control for 
MUC1 expression. 
3.2.6 Immunoblotting for phosphorylated tyrosines and for β−catenin 
Aliquots of supernatants from indicated cell lysates were thawed on ice, mixed with 
NuPage LDS Sample buffer (Invitrogen, Carlsbad CA), and dithiothreitol (DTT) added to yield a 
final concentration of 0.05 M DTT.  A431 cell lysate (Upstate Biotechnology, Lake Placid NY) 
was used as a positive control for immunoblotting phosphotyrosine and β−catenin.  Samples 
were heated for 10 minutes at 70oC then electrophoresed on 1.0 mm 10% Bis-Tris 
polyacrylamide gels (Invitrogen, Carlsbad CA) alongside SeeBlue Plus1 molecular weight 
markers in MOPS (3-(N-morpholino) propane sulfonic acid) SDS running buffer at 200 volts.  
Proteins were transferred onto nitrocellulose membranes (BioRad Laboratories, Hercules CA) in 
10% Towbin buffer using 30 volts overnight at 4oC.   
Membranes were blocked by rocking for 20 minutes in 3% dry milk in PBS and then 
immunoblotted with 1 µg/ml mouse anti-phosphotyrosine antibody 4G10 (Upstate 
Biotechnology, Lake Placid NY) followed by 1:2000 dilution of sheep anti-mouse horseradish 
peroxidase conjugated secondary antibody (Amersham Biosciences, England).  ECL detection 
reagents (Amersham Biosciences, England) were added to the membrane and proteins were 
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visualized using X-Omat film (Kodak, Rochester NY).  Membranes were reblotted for β−catenin 
using 1:1000 dilution of polyclonal rabbit anti-β−catenin (Sigma, St. Louis MO), using a new 
species as the primary antibody to prevent cross-reactivity of the secondary, followed by 1:2500 
dilution of donkey anti-rabbit horseradish peroxidase conjugated secondary antibody (Amersham 
Biosciences, England). 
 
3.3 RESULTS 
3.3.1 Expression of adhesion molecules on Jurkat, HMVEC and transfected 
cell lines 
The extended structure of MUC1 leads us to believe that the presence of MUC1 on the T 
cell surface would impact T cell adhesion to other molecules.  To investigate this aspect we 
wanted to compare adhesion by T cells with and without MUC1.  However the activation state of 
T cells greatly alters their adhesive state as well as inducing MUC1 expression.  Since this 
precludes comparing MUC1 negative cells, which are resting, to MUC1 positive cells, which are 
activated, we needed to generate a T cell model with and without MUC1 expression.  Jurkat cells 
are a well established model to study resting T cells and these cells do not have endogenous 
MUC1 expression (Figure 3.0-2B).  A 22 tandem repeat MUC1 construct was successfully 
expressed on the surface of Jurkat cells (Figure 3.0-2A).  These cells express MUC1 at a higher 
level than seen on normal activated human T cells and we hoped this would highlight the effect 
of MUC1 as compared other molecules on the Jurkat cell surface.  Jurkat cells also express 
adhesion molecules seen on T cells (Figure 3.0-3).   
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Figure 3.0-2 Expression of MUC on the surface of transfected Jurkat cells.  (A) After transfection and 
positive selection, MUC1-Jurkat cells were stained with FITC labeled isotype control or FITC labeled anti-
MUC1 antibody (clone HMPV).  (B) Untransfected Jurkat cells were similarly stained for comparison.  
Shaded histograms are the fluorescence of isotype control staining.  Open histograms are the fluorescence of 
anti-MUC1 staining. 
 
Figure 3.0-3 Expression of adhesion molecules on Jurkat cells.  Jurkat cells were stained with antibodies 
against (A) LFA-1, (B) CD43, (C) VLA-4, (D) PECAM-1, (E) PSGL-1 (F) CD38 (G) L-selectin and with the 
isotype control antibodies.  Shaded histograms are the fluorescence of isotype control staining.  Open 
histograms are the fluorescence of adhesion molecule staining. 
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First we wanted to see the effect of MUC1 in adhering to endothelium, with all the 
molecules and complex interactions involved.  Endothelium in the region of an immune response 
is much altered to attract and allow passage of effector cells, as compared to resting endothelium.  
We decided to look for a MUC1 effect in both situations to see if there was a different impact 
depending on the state of the endothelium.  The human microvascular endothelial cell line 
(HMVEC), a model cell line recommended to study adhesion (Dr. Joost Oppenheim, personal 
communication) was examined to document its expression profile in the resting (Figure 3.0-4, 
top) and activated (Figure 3.0-4, bottom) state.  As expected, ICAM-2 and PECAM-1 were 
constitutively expressed on both resting and activated HMVEC.  Also as expected, ICAM-1 
expression on resting endothelium was enhanced while E-selectin and VCAM-1 were induced in 
response to activation.  Only P-selectin was not seen on the surface of HMVEC cells.   
             
    
Figure 3.0-4 Adhesion molecules expressed on resting and activated endothelium.  Resting HMVEC (top) and 
IL-1β activated HMVEC (bottom) were stained for adhesion molecules:  (A.) PE-labeled antibody against 
ICAM-1.  (B) Unlabeled antibodies against ICAM-2 (light blue), PECAM-1 (pink), E-selectin (light green), P-
selectin (dark green) and VCAM-1 (dark blue) followed by goat anti-mouse Alexa488.  Shaded histograms 
represent staining with isotype control antibodies.   
A. 
A. 
B.
B.
 We examined earlier time points during activation (Figure 3.0-5), since P-selectin is stored pre-
formed in endothelium and could be expressed much sooner than other induced molecules; 
however we still could not detect P-selectin, though it may have been present at an even earlier 
time than we examined.  This appeared to be the only inconsistency of the HMVEC line from 
expectations but is consistent with findings using the human umbilical vein endothelial cell line 
(208).   
 
 
Figure 3.0-5 P-selectin and E-
30 minutes of activation, and 
P-selectin (blue) or E-selectin
antibodies. 
 
 Adhesion to endot
involved.  In addition to l
look for interactions with 
individual adhesion molec
not shown).   
 .A.83 
selectin on the surface of HMVEC.
(C) after 2.5 hours of activation wer
 (light green).  Shaded histogram
helium is a complex cascade 
ooking at the impact of MUC1
specific molecules.  To do this 
ules and documented their expB  HMVEC in the (A) resting state, (
e stained with unlabeled antibodies
s represent staining with isotype 
of interactions with many mo
 on the overall process we wa
we obtained cell lines transfecte
ression profile (Figure 3.0-6 anC. 
B) after 
 against 
control 
lecules 
nted to 
d with 
d data 
 84 
 
Figure 3.0-6 Expression of individual adhesion molecules on cell lines.  (A) CHO-ICAM-1 cells, (B) 3T3 –
PECAM-1 cells, (C) CHO-VCAM-1 cells, (D) CHO-P-selectin cells, and (E) CHO-E-selectin cells were stained 
with antibodies against the indicated adhesion molecules.  Unlabeled primary antibodies were followed by 
Alexa488 labeled goat anti-mouse antibody.  Shaded histograms represent staining with isotype control 
antibodies. 
The parental cell lines CHO and 3T3 do not express any adhesion molecules (data not shown).  
Each of the transfected cell lines expressed the expected molecule with one exception.  CHO-E-
selectin cells are also positive for VCAM-1 expression (named E-selectin/VCAM-1 cells) 
(Figure 3.0-6 E).  The expression level of VCAM-1 is much higher on the CHO-VCAM-1 cells 
than on the CHO-E-selectin/VCAM-1 cells so any effect VCAM-1 has will be more apparent on 
the single transfectants.  Since we can examine VCAM-1 by itself (Figure 3.0-6 C), we will infer 
the interaction of MUC1 with E-selectin through comparisons between CHO-VCAM-1 and 
CHO-E-selectin/VCAM-1 cells.   
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3.3.2 Cell-cell adhesion assays 
 Because MUC1 is so much longer than other molecules on the T cell surface we expected 
that its effect would be seen earlier rather than later, when the MUC1-expressing cells first begin 
to interact with endothelium.  To test this we looked at adhesion after short periods of incubation 
(5-20 minutes) versus long periods of incubation (45-60 minutes) with resting or activated 
endothelium.  The baseline binding of both Jurkat cells and MUC1-Jurkat cells to activated 
endothelium is greater, as expected due to the additional adhesion molecules expressed.  At the 
early timepoints (Figure 3.0-7) we see that MUC1 enhances the binding to endothelium.  This is 
true regardless of whether the endothelium is resting or activated.   
 
Figure 3.0-7 Adhesion of Jurkat and MUC1-Jurkat cells to resting and activated endothelium after a short 
incubation.  HMVEC monolayers were grown to confluency and half activated with IL-1β.  Fluorescently 
labeled Jurkat or MUC1-Jurkat cells were allowed to adhere prior to washing.  Adhesion was calculated by 
subtracting background fluorescence and dividing by the maximum possible fluorescence.  Each point 
represents a single well of adherent cells.  Experiment was performed three times and data analyzed together.   
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When incubated for longer times the enhancing effect of MUC1 expression is eliminated (Figure 
3.0-8).  It is likely that after 45  60 minutes the other molecules on the Jurkat cell surface have 
taken over and their interactions dominate over the effect MUC1 exerts.   
 
Figure 3.0-8 Adhesion of Jurkat and MUC1-Jurkat cells to resting and activated endothelium after longer 
incubation.  HMVEC monolayers were grown to confluency and then half activated with IL-1β.  
Fluorescently labeled Jurkat or MUC1-Jurkat cells were allowed to adhere prior to washing.  Adhesion was 
calculated by subtracting background fluorescence and then dividing by the maximum possible fluorescence.  
Each point represents a single well of adherent cells.  Experiment was performed three times and data 
analyzed together. 
 
Because the effect of MUC1 was seen only during early interaction with endothelium, we looked 
at individual adhesion molecules at either 5 or 20 minutes of incubation to more closely gauge 
when MUC1 has an effect on adhesion.  At 5 minutes there is no statistically significant effect of 
 87 
MUC1 expression on the adhesion of Jurkat to ICAM-1 or to E-selectin/VCAM-1 expressing 
cells (Figure 3.0-9).  There is a slight indication that adhesion to E-selectin/VCAM-1 cells is 
diminished when MUC1 is present.   
 
Figure 3.0-9 Adhesion of Jurkat and MUC1-Jurkat cells to CHO, CHO-ICAM-1 or CHO-E-selectin/VCAM-1 
cells after a 5 minute incubation.  Monolayers were grown to confluency and fluorescently labeled Jurkat or 
MUC1-Jurkat cells were allowed to adhere prior to washing.  Adhesion was calculated by subtracting 
background fluorescence and then dividing by the maximum possible fluorescence.  Each point represents a 
single well of adherent cells.  Experiment was performed three times and data analyzed together. 
 
At the 20 minute timepoint the effect of MUC1 is significant (Figure 3.0-10).  Adhesion to 
ICAM-1 is enhanced by MUC1 while adhesion to E-selectin/VCAM-1 is diminished.   
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Figure 3.0-10 Adhesion of Jurkat and MUC1-Jurkat cells to CHO, CHO-ICAM-1 or CHO-E-selectin/VCAM-
1 cells after a 20 minute incubation.  Monolayers were grown to confluency and fluorescently labeled Jurkat 
or MUC1-Jurkat cells were allowed to adhere prior to washing.  Adhesion was calculated by subtracting 
background fluorescence and then dividing by the maximum possible fluorescence.  Each point represents a 
single well of adherent cells.  Experiment was performed three times and data analyzed together. 
 
When we examined VCAM-1 and P-selectin expressing cells there were no significant 
differences seen at 5 minutes (Figure 3.0-11).   
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Figure 3.0-11 Adhesion of Jurkat and MUC1-Jurkat cells to CHO, CHO-VCAM-1 or CHO-P-selectin cells 
after a 5 minute incubation.  Monolayers were grown to confluency and fluorescently labeled Jurkat or 
MUC1-Jurkat cells were allowed to adhere prior to washing.  Adhesion was calculated by subtracting 
background fluorescence and then dividing by the maximum possible fluorescence.  Each point represents a 
single well of adherent cells.  Experiment was performed three times and data analyzed together. 
 
Later, at 20 minutes, differences in adhesion due to MUC1 start to emerge but do not reach 
statistical significance.  MUC1 tends to diminish binding to both VCAM-1 and P-selectin 
expressing cells (Figure 3.0-12).   
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Figure 3.0-12 Adhesion of Jurkat and MUC1-Jurkat cells to CHO, CHO-VCAM-1 or CHO-P-selectin cells 
after a 20 minute incubation.  Monolayers were grown to confluency and fluorescently labeled Jurkat or 
MUC1-Jurkat cells were allowed to adhere prior to washing.  Adhesion was calculated by subtracting 
background fluorescence and then dividing by the maximum possible fluorescence.  Each point represents a 
single well of adherent cells.  Experiment was performed three times and data analyzed together. 
 
VCAM-1 levels are different on CHO-VCAM-1 cells (broad range of expression, predominantly 
higher) as compared to the CHO-E-selectin/VCAM-1 cells, (tighter range of expression, 
predominantly lower) (see Figure 3.0-6).  Keeping this in mind, since cells expressing VCAM-1 
alone do not show significant effect of MUC1 on adhesion, despite their higher level of VCAM-
1, it seems that the MUC1-mediated decreased adhesion to E-selectin/VCAM-1 cells is due to E-
selectin expression, (compare Figure 3.0-12 to Figure 3.0-10).  This observation bears further 
analysis using singly transfected cells.  We were unable to obtain ICAM-2 transfected cells.  The 
final endothelial adhesion molecule we examined was PECAM-1.  As seen with the other 
adhesion molecules, at 5 minutes MUC1 does not make a statistical difference in the adhesion of 
Jurkat cells (Figure 3.0-13).   
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Figure 3.0-13 Adhesion of Jurkat and MUC1-Jurkat cells to 3T3 or 3T3-PECAM-1 cells after a 5 minute 
incubation.  Monolayers were grown to confluency and fluorescently labeled Jurkat or MUC1-Jurkat cells 
were allowed to adhere prior to washing.  Adhesion was calculated by subtracting background fluorescence 
and then dividing by the maximum possible fluorescence.  Each point represents a single well of adherent 
cells.  Experiment was performed three times and data analyzed together. 
 
Given more time, there is a strongly significant MUC1 enhancement in adhesion to untransfected 
3T3 cells but this is not seen with the PECAM-1 expressing cells (Figure 3.0-14)  This may 
indicate that PECAM-1 prevents MUC1-mediated adhesion to 3T3 cells.   
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Figure 3.0-14 Adhesion of Jurkat and MUC1-Jurkat cells to 3T3 or 3T3-PECAM-1 cells after a 20 minute 
incubation.  Monolayers were grown to confluency and fluorescently labeled Jurkat or MUC1-Jurkat cells 
were allowed to adhere prior to washing.  Adhesion was calculated by subtracting background fluorescence 
and then dividing by the maximum possible fluorescence.  Each point represents a single well of adherent 
cells.  Experiment was performed three times and data analyzed together. 
 
 Within the first 20 minutes of interaction, MUC1 enhanced Jurkat cell adhesion to both 
resting and activated endothelium.  Looking at individual adhesion molecules, ICAM-1 showed 
MUC1-mediated enhancement of binding while adhesion to E-selectin seemed to decrease.  
These effects are seen by 20 minutes of cell-cell interaction.  Other adhesion molecules show an 
increased effect of MUC1 over time, greater difference at 20 minutes compared to 5 minutes, but 
do not reach as significant levels as ICAM-1 and E-selectin.  Though it is possible that given 
more time we might see an effect of MUC1 on the other individual adhesion molecules, this 
would probably be irrelevant to endothelial adhesion since MUC1 had no effect on binding to 
resting or activated endothelium over longer time periods. 
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3.3.3 Phosphorylation of MUC1 
The amino acid sequence of the MUC1 cytosolic tail is well-conserved among species.  It 
is believed that the tail may play an important role in the function of MUC1, a belief bolstered by 
the presence of seven tyrosines in the fairly short tail.  These tyrosines can be phosphorylated 
and this has been extensively studied in tumor and transfected cells.  Interestingly, the 
phosphorylation of MUC1 by tumor cells has been shown to correlate with their adhesion (192).  
To see whether T cells might exhibit similar behavior in modifying MUC1 phosphorylation in 
response to adhesive interactions, we examined MUC1 phosphorylation in MUC1 transfected 
Jurkat cells in the absence or presence of endothelium.   
We indirectly detected MUC1 tail phosphorylation by first immunoprecipitating with 
antibody against phosphorylated tyrosines and then immunoblotting with an antibody against the 
extracellular region.  As shown in Figure 3.0-15, whole cell lysates of MUC1-Jurkat cells either 
left alone (lane 1) or placed on resting (lane 2) or activated (lane 3) endothelium all have MUC1.  
When those same cells are immunoprecipitated with antibody against phosphorylated tyrosine 
(lanes 4, 5, 6) MUC1 can still be detected, indicating phosphorylation of the MUC1 tail has 
occurred.   
 Figure 3.0-15 Phosphorylation of MUC
incubated with nothing (∅) or resting (
phosphatase inhibitors.  Whole cell lysa
electrophoresed alongside of anti-phosph
6) and a MUC1 negative cell lysate (lane
against the extracellular region of MUC
camera imaging in Figure 3.0-16 and Fig
 
The previous data indicated 
of interacting with endothelium.  H
amount of phosphorylated MUC1.  T
camera imaging immediately after
extracellular VNTR region.  Figure 
MUC1-Jurkat cells either left alone
same amount of MUC1 detected.  M
about 25% less signal.  In con
immunoprecipitates from MUC1-Ju
have approximately equal amounts 
∅      R      A 
 1 2 3
Whole Cell 
Lysate ∅      R     A 94 
 
1 in MUC1 transfected Jurkat cells.  MUC1-Jurkat cells were 
R) or activated (A) endothelium and then lysed in the presence of 
tes of MUC1-Jurkat cells from each condition (lanes 1, 2, 3) were 
otyrosine immunoprecipitates from MUC1-Jurkat lysates (lanes 4, 5, 
 7).  After transfer, the membrane was immunoblotted with antibody 
1.  The boxes indicate the regions used for quantitation by Versadoc 
ure 3.0-17. 
that phosphorylation of MUC1 tail was occurring regardless 
owever, there appeared to be quantitative differences in the 
o detect this, the MUC1 signal was quantitated by Versadoc 
 immunoblotting with anti-MUC1 antibody reactive to the 
3.0-16 shows the quantitation of MUC1 in whole cell lysates.  
 or placed on resting endothelium have approximately the 
UC1-Jurkat cells incubated with activated endothelium have 
trast, Figure 3.0-17 shows that while phosphotyrosine 
rkat cells left alone or placed on resting endothelium still 
of MUC1 detected, the phosphotyrosine immunoprecipitate 
5 74 6
Anti-phosphotyrosine 
immunoprecipitates 
 95 
from MUC1-Jurkat cells incubated on activated endothelium have much less MUC1 signal, 
roughly 80% less signal.  This decrease in MUC1 signal is much greater than when looking at 
the whole cell lysates, indicating that phosphorylation of MUC1 is decreased by interacting with 
activated endothelium.   
 
 
Figure 3.0-16 Quantitation of MUC1 signal from the immunoblot of MUC1-Jurkat whole cell lysate exposed 
to no endothelium, resting endothelium or activated endothelium.  The initial MUC1 signal from the 
immunoblot in Figure 3.0-15 lanes 1, 2, and 3 was quantitated with a Versadoc camera image collecting 
system.  The bottom box in each lane was subtracted as background signal from the top box in each lane 
containing the MUC1 signal.   
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Figure 3.0-17 Quantitation of MUC1 signal from the immunoblot of MUC1-Jurkat cell lysates 
immunoprecipitated with anti-phosphotyrosine antibody following exposure to no endothelium, resting 
endothelium or activated endothelium.  The initial MUC1 signal from the immunoblot in Figure 3.0-15 lanes 
4, 5, 6, 7 was quantitated with a Versadoc camera image collecting system.  The bottom box in each lane was 
subtracted as background signal from the top box in each lane containing the MUC1 signal. 
 
3.3.4 Differences in phosphorylated protein pattern within Jurkat cells 
Given the indication for differential phosphorylation of MUC1, we were interested in 
seeing if there were other differences in intracellular protein phosphorylation.  We looked at 
tyrosine phosphorylated proteins in Jurkat and MUC1 Jurkat cells either left alone or incubated 
with an endothelial monolayer.  Figure 3.0-18 shows the results of immunoblotting for 
phosphorylated tyrosines in lysates of Jurkat (J) or MUC1-Jurkat cells (M).  Lanes 5 and 6 are 
lysates from cells that were not put into contact with endothelium.  There are 3 bands that are 
different between Jurkat and MUC1-Jurkat cells, in the roughly approximate 39 kDa, 64-97 kDa 
and 190 kDa regions.  As we looked at Jurkat and MUC1-Jurkat interacting with endothelium, 
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these 3 bands were consistently the distinguishing bands, though their pattern of appearance is 
not always the same, likely due to experimental variation.  In Figure 3.0-18 the pattern seen in 
lanes 5 and 6 is the repeated in cells interacting with resting endothelium, lanes 3 and 4.  In 
contrast, when Jurkat and MUC1-Jurkat cells were placed on a monolayer of activated 
endothelium, lanes 1 and 2, there was no difference in the phosphorylated protein pattern (Figure 
3.0-18).  Rather, it appears that MUC1 no longer makes a difference in phosphorylation of those 
3 bands.   
 
 
 
Figure 3.0-18 Phosphorylated proteins from Jurkat (J) and MUC1-Jurkat (M) cells after interacting with 
activated endothelium (lanes 1 and 2), resting endothelium (lanes 3 and 4) or no endothelium (lanes 5 and 6). 
Jurkat and MUC1-Jurkat cells were incubated with the indicated cell type and then lysed in the presence of 
phosphatase inhibitors.  Whole cell lysates of Jurkat and MUC1 Jurkat cells were electrophoresed and then 
immunoblotted with antibody against phosphotyrosine.  A431 cell lysate containing tyrosine phosphorylated 
proteins was used as a positive control (lane 7).   
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tyrosine phosphorylation (209-211).  This warrants further investigation to look for 
phosphorylated β-catenin in MUC1 expressing T cells.   
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20 minutes of interaction (Figure 3.0-7).  After that MUC1 expression made no difference in cell 
adhesion (Figure 3.0-8).  This is probably due to increased involvement of other adhesion 
molecules on the Jurkat surface dominating over the effect of MUC1.  As expected, the increase 
in adhesion molecule expression following activation of endothelium (Figure 3.0-4) caused 
greater Jurkat and MUC1-Jurkat cell adhesion.  MUC1 enhanced adhesion to both resting and 
activated endothelium, indicating that MUC1 can interact with molecule(s) expressed in both 
conditions.   
 Looking at individual adhesion molecules, ICAM-1 expressing cells showed MUC1-
mediated enhancement of binding (Figure 3.0-10).  This result with our MUC1 transfected Jurkat 
cells is consistent with other work examining MUC1 interactions with ICAM-1.  Regimbald et al 
(189) showed that MUC1 expressed on tumor and transfected cells could bind to ICAM-1.  They 
tested both plate-bound ICAM-1 and ICAM-1-expressing cells.  Binding specificity between 
MUC1 and ICAM-1 was confirmed by blocking assays, using soluble MUC1 peptide and an 
anti-MUC1 antibody against a peptide epitope in the tandem repeat region.  They later showed 
that at least six tandem repeats were required in a MUC1 peptide for binding with ICAM-1 to 
take place (190).  Another group looked at cell-cell aggregation assays with ICAM-1 expressing 
cells and showed that MUC1 binds ICAM-1 in a tandem repeat dependent manner.  This binding 
was enhanced by decreased glycosylation of MUC1, not affected by antibodies against sLex or 
sLea, but was inhibited by antibodies against ICAM-1 or against the tandem repeat of MUC1 
(172).  These results looking at ICAM-1 binding were virtually repeated in a separate report that 
also indicated that domain 1 of ICAM-1 is responsible for MUC1 binding (212), the same 
domain LFA-1 utilizes.  ICAM-1 is constitutively expressed by most endothelial cells and we 
also saw it expressed on our resting HMVEC line, followed by upregulation after HMVEC 
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activation (Figure 3.0-4).  Since MUC1 enhanced Jurkat cell binding to endothelium in both the 
resting and activated states (Figure 3.0-7), the MUC1 mediated attachment of Jurkat cells to 
ICAM-1 expressing cells is consistent with ICAM-1 being a ligand for MUC1 in our T cell 
model as well.  Using MUC1 peptides to specifically block ICAM-1 binding to MUC1-Jurkat 
cells would substantiate this.  MUC1 binding to ICAM-1 in vivo could take place not only to 
endothelium, as we have examined here, but could also play a role in bystander leukocyte 
recruitment.  This process uses the T cell uropod, expressing ICAM-1 and -3, and extending 
above a polarized, adherent T cell to seize other passing T lymphocytes.  Antibodies against 
ICAM-1, -3 and LFA-1 can decrease T cell recruitment but do not eliminate it (120).  Binding 
between MUC1 and ICAM-1 could augment uropod mediated recruitment. 
 Adhesion of Jurkat cells to E-selectin decreased when MUC1 was expressed by the 
Jurkat cells (Figure 3.0-10).  E-selectin is known to bind to carbohydrate ligands.  Although 
MUC1 may carry specific O-glycans (e.g. sLex) that are recognized by selectins, it is unlikely 
that MUC1 can bind to selectins because the functionality of selectin ligands appears to depend 
on modifications of the core protein as well as the specific O-glycans (148), as discussed in 
chapter 2.  Using soluble MUC1 secreted from a colon cancer line there have been reports of 
binding to E-selectin (213-215).  This may not hold true when examining membrane bound 
MUC1 on the surface of cells.  Recent work looking at specific molecular interactions between 
MUC1 and adhesion molecules showed that while tumor cells could bind E- and P-selectin, 
MUC1 expressed on their cell surface could not.  Additionally, tumor cell binding of E-selectin 
was blocked by MUC1 expression on the tumor cell when the tandem repeat was of sufficient 
size.  In agreement with our data (Figure 3.0-11, Figure 3.0-12), binding to P-selectin was not 
affected, indicating a specific inhibition to E-selectin (172).  It is likely that the different results 
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concerning E-selectin binding are due to looking at secreted MUC1 versus cell bound MUC1.  
Consistent with reports looking at tumor MUC1, we also observed an E- selectin inhibitory 
effect when MUC1 was expressed by Jurkat cells (Figure 3.0-10).  This is despite the expression 
of E-selectin ligand PSGL-1 on Jurkat cells (Figure 3.0-3).   
 The overall enhanced adhesion between MUC1 expressing Jurkat cells and activated 
endothelium suggests that MUC1  ICAM-1 binding overrides the repulsion between MUC1 and 
E-selectin in our in vitro system.  Our in vitro data (Figure 3.0-4) showed that the inflammatory 
cytokine IL-1 induces expression of E-selectin and upregulates ICAM-1 on endothelial cells.  In 
vivo the kinetics for expression of each molecule are different with E-selectin expression 
detected much sooner but with a shorter half-life than ICAM-1.  Maximum E-selectin expression 
can be detected within two to four hours of endothelial activation but ICAM-1 peak expression 
does not occur until 12 hours after activation.  E-selectin is generally down to basal levels 24 
hours after activation while ICAM-1 persists for at least 3 days (36).  This means that the effect 
of MUC1 may hinder T cell binding to endothelium that has just been activated, allowing strong 
E-selectin binding cells such as neutrophils early access to inflammatory sites.  Later when the 
endothelium is expressing ICAM-1, MUC1 may give a binding advantage to MUC1 expressing 
T cells that generally reach inflammatory sites after neutrophils and monocytes. 
The Jurkat T lymphoblastoid cell line is a well-established model to study mature T cells.  
It has been used extensively to examine T cell signaling (216) and adhesion via selectins (92, 99, 
153, 217, 218), integrins (175, 177, 179, 219-224) and endothelium (153, 219, 225, 226) over the 
years.  Glycosylation by Jurkat cells was studied by in depth analysis of leukosialin (CD43), a 
sialoglycoprotein found on normal leukocytes.  Piller et al unexpectedly found that 83% of the 
O-linked saccharides on leukosialin were composed of only N-acetylgalactosamine (227).  This 
 102 
was attributable to very low levels of the enzyme core 1 GalNAc;β1,3Galactosyltransferase, the 
enzyme responsible for adding an additional galactose N-acetylgalactosamine to form the core 1 
structure, so that more complex oligosaccharide structures can be synthesized.  Only 17% of the 
O-linked saccharides on leukosialin from Jurkat cells had more complex structures than the N-
acetylgalactosamine (227).  The lack of core 1 GalNAc;β1,3Galactosyltransferase activity was 
not due to a defect in the core 1 GalNAc;β1,3Galactosyltransferase protein but rather due to a 
mutation in a chaperone protein, Cosmc (core 1 β3-Gal-T-specific molecular chaperone) (228).  
A single nucleotide mutation in the gene for Cosmc was found in Jurkat cells which resulted in 
lack of most of the cytosolic tail of Cosmc.  When wild type Cosmc was expressed in Jurkat 
cells, the activity of intrinsic core 1 GalNAc;β1,3Galactosyltransferase was restored (228).  
Additionally, it was very recently shown that Jurkat cells show much lower levels of mRNA for 
the enzyme FucT-VII unless constitutively active Ras was present (99) although earlier work 
reported that PMA activation of Jurkat cells increased the steady-state level of FucT-VII mRNA 
(92).  The physiological significance of these findings is confusing since Jurkat adhesion to 
endothelium has been shown to be inhibited by anti-E-selectin antibodies (226).  Though we 
need to fully characterize the O-glycosylation occurring to MUC1 in our MUC1 transfected 
Jurkat cell line, it is possible that the MUC1 is lacking complex O-linked saccharides.  This 
could be a reason why our results are so similar to work looking at the adhesion of tumor MUC1.   
 Most work examining MUC1 adhesion has involved peptides or tumor MUC1.  It is not 
known what normal MUC1 binds to, or even if it does bind differently than the commonly 
studied tumor form of MUC1.  Enhanced glycosylation of MUC1 by normal cells makes a 
different binding profile likely, but this remains to be proven.  We have developed a model that 
shows the impact of MUC1 on T cell binding; the next step is to demonstrate the impact of 
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normally glycosylated MUC1.  It would be fruitful to characterize the MUC1 expressed on our 
model, to verify that it is underglycosylated, and then add wild type Cosmc to the MUC1 
transfected Jurkat cells.  If we could verify that MUC1 glycosylation was changed, it would be 
interesting to then repeat our assays to see if MUC1 still enhances Jurkat cell binding to 
endothelium and ICAM-1 but decrease binding of Jurkat cells to E-selectin.  Comparing the 
results would give insight into adhesion differences between the normal and tumor forms of 
MUC1.   
 Glycosylation deficiency in Jurkat cells does not seem to have come up in other work 
looking at adhesion of Jurkat cells.  However, there is a much higher degree of glycosylation that 
occurs on MUC1 as compared to other smaller molecules.  Even though our MUC1 construct has 
only 22 repeats, smaller than the number commonly seen in human cells (41-85 (1, 2)), there are 
still a great deal more glycosylation sites than on other cell surface proteins.  As a result a 
glycosylation deficiency may be more conspicuous on MUC1.   
 In our model, MUC1 transfected Jurkat cells are expressing a much higher level of 
MUC1 than is seen on activated T cells, so that we could highlight MUC1 mediated interactions.  
However, it may be more difficult to distinguish an effect due to MUC1 when examining normal 
activated human T cells since a certain density of surface expression may be required.  On the 
other hand, MUC1 on normal T cells would likely have more repeats than the 22 in our 
construct.  Depending on whether the MUC1 VNTR region is responsible for MUC1 mediated 
cell adhesion, as seems likely, the avidity of interaction may be greater for activated normal 
human T cells.  It would be interesting to repeat the adhesion assays with Jurkat cells expressing 
a much lower level of MUC1 and with a larger MUC1 construct, to better mimic the activated 
human T cells and to compare with our observations.   
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 The adhesion of T cells to the blood vessel wall is only the beginning of what happens to 
a T cell as it interacts with endothelium.  There are signaling pathways initiated that prepare it to 
tightly bind the vessel wall and then move through the wall and into the tissue.  Adhesion 
between cells and signaling within cells are inextricably linked.  Adhesion molecules that are 
binding to the endothelium can initiate their own signaling pathways.  Similar to MUC1, 
integrins such as LFA-1, which can also bind to ICAM-1, do not have their own ability to 
catalyze signaling events but they do associate with intracellular proteins that can mediate 
signaling.  Intracellular molecules involved in integrin outside-in signaling include c-Src which 
has also been associated with MUC1 (197-199).  Bianchi et al (109) showed that the LFA-1 
integrin can mediate signals affecting gene expression.  Other groups have demonstrated LFA-1 
signaling to modify the cytoskeleton, enhance binding to ICAM-1, and regulate the adhesiveness 
of β1 integrins (106, 110, 113).  Our data showing changes in the phosphorylation of MUC1 and 
other proteins indicate that MUC1 is also likely to be involved in signaling to the T cell that 
extracellular interaction has occurred.   
Phosphorylation of the MUC1 cytosolic tail has been shown to occur in tumor cells and 
transfected cells (191-193).  We show here that MUC1 expressed in Jurkat cells is 
phosphorylated.  However, during interaction of MUC1 expressing Jurkat cells with activated 
endothelium this phosphorylation decreases (Figure 3.0-17).  Adhesion-dependent alteration in 
MUC1 phosphorylation has been observed by others (192).  In MUC1-expressing tumor cells, 
the adhesive state was associated with the extent of MUC1 phosphorylation.  As tumor cells 
adhered, their MUC1 phosphorylation decreased over time.  When a series of decreasing 
amounts of cells were seeded in separate tissue culture flasks, those at higher density that became 
confluent sooner had less tyrosine phosphorylation.  Cells seeded at a lower concentration, and 
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therefore not confluent at the same timepoint, had more tyrosine phosphorylation.  This same 
phenomenon seems to be occurring when MUC1 expressing Jurkat cells adhere to activated 
endothelium.  The tighter interaction is associated with a decrease in the phosphorylation of 
MUC1.  This work should be repeated using human T cells activated to express MUC1, though it 
is likely the results would be same as Jurkat cells since they are a well known model for 
signaling in T cells.   
Tyrosine phosphorylation of the MUC1 tail is decreased in the context of interacting with 
activated endothelium, likely as part of a mechanism regulating adhesion.  Phosphorylated 
MUC1 was reported to bind the SH2 domain of Grb2 whose SH3 domain then associated with 
the guanine nucleotide exchange protein Sos (191).  Grb2 is involved in integrin mediated 
signaling (229).  Competition for Grb2 binding may be regulated by dephosphorylating MUC1 to 
decrease Grb2 association so that it would be available for use by integrins.  However these 
results bear further exploration as Quin et al (192) were unable to detect Grb2 in association with 
MUC1.  MUC1 in tumor cells has been shown to co-immunoprecipitate β−catenin, a protein 
involved in cadherin-mediated cell adhesion.  Yamamoto et al (195) found that MUC1 in human 
tumor cells co-immunoprecipitated with β-catenin only when the cells were adherent.  Cells in 
suspension showed no association of MUC1 with β-catenin.  The phosphorylation of MUC1 in 
this tumor cell model was not examined.  Whether MUC1 in Jurkat cells also has an association 
with β−catenin may indicate adhesion signaling pathways involved in T cell binding to 
endothelium. 
Regulation of the association of MUC1 with β-catenin has been explored (195, 197, 198, 
203, 204). The β−catenin binding motif in the MUC1 cytosolic tail is affected by surrounding 
phosphorylation sites.  The tyrosine kinase c-Src binds adjacent to the β−catenin motif.  C-Src 
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phosphorylation in the YEKV c-Src binding site enhances β−catenin binding (197).  In multiple 
myeloma cells it has been shown that Lyn can bind to and phosphorylate MUC1 at the same site 
as c-Src to similarly increase β−catenin binding (205).  Adjacent to the β−catenin motif is a 
binding site for glycogen synthase kinase 3β (GSK3β) and phosphorylation of a serine in this 
site by GSK3β decreases β−catenin binding to MUC1 (203).  This same group found that the 
presence of MUC1 decreases E-cadherin β−catenin interaction, but this effect could be reversed 
by GSK3β (203).  It would be important to also look at serine/threonine phosphorylation in our 
MUC1 expressing Jurkat cells to see if there are changes associated with binding to endothelium. 
Decreased cytosolic tail tyrosine phosphorylation in MUC1 expressing Jurkat cell would 
inhibit binding of MUC1 and β−catenin, thus freeing it to bind other molecules.  The effects of 
this on cell adhesion may be mediated through a cadherin expressed on Jurkat and T cells (230).  
It is also possible that cell adhesion may not be the primary target, as β−catenin is also involved 
in gene regulation.  It was recently shown that the association between MUC1 and β−catenin 
plays a role in nuclear β−catenin localization in tumor cells (206) and in multiple myeloma cells 
(205).   
When we examined the impact of MUC1 on the tyrosine phosphorylation of proteins in 
Jurkat cells we observed three sizes of proteins that were differentially phosphorylated.  There 
were alterations in the phosphorylation of these proteins in the absence and presence of 
endothelium (resting and activated).  Evidently phosphorylation of MUC1 is not the only change 
occurring inside Jurkat cells following endothelial interaction.  Identifying these differentially 
phosphorylated proteins and the kinase(s) responsible would indicate which signaling pathways, 
are affected by 1) MUC1 expression and 2) by adhesion of MUC1 expressing cells to 
endothelium.  Adhesion dependent phosphorylation and activation of FAK and PYK-2 tyrosine 
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kinases has been demonstrated in T lymphoblasts adhering via LFA-1 to ICAM-1 (111).  
Phosphotyrosine immunoprecipitates showed that these proteins fall within the 110-180 kD 
region.  Though there have been no reports of MUC1 association with FAK or PYK-2, they 
would be candidate to look at since their phosphorylation was mediated by ICAM-1 binding 
which MUC1 can also do.  This would be especially interesting as activation of FAK and PYK-2 
was associated with converting cell morphology from spherical to elongated (111).   
Blotting for β−catenin indicated it was one of the differentially phosphorylated proteins, 
depending on whether MUC1 was expressed and whether cells were incubated with 
endothelium.  β−catenin is in PHA activated peripheral blood T cells (230), in Jurkat cells, but 
not resting lymphocytes, and was shown to regulate PHA stimulated cell aggregation (231).  The 
tyrosine kinase c-Src can phosphorylate tyrosines in β−catenin and this modification has been 
shown to decrease its affinity for E-cadherin (211).  In MUC1 expressing cells binding of c-Src 
occurs close to the β−catenin binding site so c-Src would have access to phosphorylate β−catenin 
bound to MUC1.  Once phosphorylated, β−catenin may be released into the cytosolic pool, as 
has been shown in epithelial cells (210), and free to engage in nuclear translocation, perhaps 
bringing along the cytosolic tail of MUC1 (206).   
 In our endothelial assays there actually are two types of cell-cell interactions occurring: 
Jurkat cells with Jurkat cells as well as Jurkat cells with endothelium.  Though we did not 
directly examine a MUC1 effect on Jurkat cell-Jurkat cell interaction, MUC1 would likely have 
an effect.  It has been shown that the mucin-like molecule, CD43, increases homotypic 
aggregation of Jurkat cells and T cells in a β2 integrin dependent manner (232).  CD43 
intracellular signaling, via phosphorylation and association with cytosolic proteins (233, 234) 
likely mediated the enhanced adhesion.  Similarly MUC1 in our system may be influenced by 
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and/or influencing Jurkat cell aggregation, as well as binding to endothelium.  It has also been 
shown that blocking protein tyrosine kinases can inhibit homotypic aggregation of Jurkat cells 
(235), implying that Jurkat adhesion depends on phosphorylation of tyrosines.  It would be 
interesting to see whether blocking tyrosine kinases would alter our adhesion assay results 
linking MUC1 to enhanced adhesion to endothelium and ICAM-1 expressing cells.  Further work 
is needed to illuminate these interesting associations between MUC adhesion, phosphorylation, 
and interactions with other proteins inside the cell. 
 
4.0 MUC1 EXPRESSION ON MOUSE T CELLS 
Hypothesis 3:   
 In vivo manipulation of T cell MUC1 would affect the ability of T cells to reach 
inflammatory sites.  As observed in humans, T cells from MUC1 transgenic mice should express 
MUC1 on their cell surface following activation and thus be susceptible to blocking MUC1 with 
antibodies.  Failure to express MUC1 would indicate either inability of mouse T cells to express 
the human transgenic MUC1 or an intrinsic difference between mouse and human T cells.   
Specific Aim 3: 
Determine expression of human MUC1 on the surface of MUC1 transgenic mouse T cells 
following activation and document any differences in the mouse model from human T cell 
expression of MUC1. 
Rationale: 
 An in vivo model is necessary to best study the effect of MUC1 on T cell migration.  
Mouse Muc-1 and human MUC1 have a homologous structure but differ in size, sequence, and 
the number of repeats in the extracellular region.  The mouse system cannot be used however 
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because there are no reliable reagents such as anti-Muc-1 antibodies commercially available to 
study mouse Muc-1.  In order to take advantage of the numerous reliable well-characterized 
human MUC1 reagents, the human MUC1 transgenic mouse model (124) could be used.  It has 
been documented to express human MUC1 on the same epithelial surfaces where MUC1 is seen 
in humans.  Due to its fidelity in reproducing human MUC1 expression on epithelium, this 
model should be ideal to study the role of MUC1 on T cells via in vivo manipulation of the T cell 
MUC1.  Additionally, this transgenic mouse is used in many cancer vaccine studies.  Any 
differences seen between the mouse and human T cell would be relevant to comparisons made 
between humans and mice in numerous immune research studies. 
 
4.1 INTRODUCTION 
To explore the effect of MUC1 on T cell migration in vivo, a mouse model would be 
valuable.  Mouse Muc-1 and human MUC1 have a homologous structure but differ in size, 
sequence, and the number of repeats in the extracellular region.  These differences may not give 
a true picture of human MUC1 on human T cells.  In addition, there is a dearth of reliable 
reagents commercially available to study mouse Muc-1.  In order to take advantage of the 
numerous reliable human MUC1 reagents, the human MUC1 transgenic mouse model could be 
used.  It has been documented to express human MUC1 on the same epithelial surfaces where 
MUC1 is seen in humans (124).  Due to its fidelity in reproducing human MUC1 expression on 
epithelium, we decided to use this model to study the role of MUC1 on T cells.   
4.1.1 Human MUC1 transgenic mouse model 
MUC1 transgenic mice have been developed in an effort to create a better model for 
MUC1 immunotherapy of human cancers.  Rowse et al have generated mice that contain the 
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entire gene sequence for the human form of MUC1 (124).  These mice express MUC1 under the 
control of its endogenous promoter and immunohistochemical staining has shown that it is 
expressed in a similar tissue pattern and level as in humans.  This modeling of MUC1 expression 
has also been demonstrated in a spontaneous tumor model in which MUC1 transgenic mice have 
been crossed with mice that develop pancreatic cancer.  The pancreatic disease that develops in 
these double transgenic mice is analogous to human pancreatic cancer in the overexpression and 
underglycosylation of MUC1 (236).  Significantly, the spleen from MUC1 transgenic mice 
shows no MUC1 expression (124), consistent with our data showing that the human spleen does 
not contain MUC1 transcripts (Figure 2.0-19).  All indications point to a fully suitable mouse 
model in which to study human MUC1 expression on T cells.   
4.1.2 Mouse Muc-1 
The mouse homolog of human MUC1, referred to as Muc-1, was cloned in 1991 (237, 
238) and subsequently mapped to mouse chromosome 3 (239).  The genomic structure between 
the human MUC1 and mouse Muc-1 are similar, both contain six introns and seven exons with 
conserved boundaries and similar sizes.  Unlike human MUC1 (11, 13-18), there is no 
suggestion of alternative splicing of murine Muc-1.  The promoter regions of both are highly 
homologous, 74%, as are the transmembrane and cytosolic regions, 87% at the protein level 
(237).  Both MUC1 and Muc-1 have the two cysteines at the junction of the transmembrane 
domain and cytosolic tail that are partially responsible for MUC1 trafficking (7), agreeing with 
observed apical expression of Muc-1 (240).  Underscoring the signaling function of MUC1/Muc-
1 in cells, the seven tyrosines in the cytoplasmic tail are conserved (237, 238).   
In the extracellular portion there is less homology (237, 238).  Though the region of 
proteolytic cleavage responsible for human MUC1 being expressed as a heterodimer is fairly 
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well conserved in the mouse, this has not yet been documented to occur in Muc-1.  In contrast to 
human MUC1, the repeat region in rodent Muc-1 is not polymorphic (237).  There are always 16 
repeats of either 20 or 21 amino acids each.  At the nucleotide level the repeats share only 75% 
homology with each other, as compared to MUC1 in which the repeats are nearly identical.  
Within each repeat of murine Muc-1 is an average of 9 sites for O-linked glycosylation, nearly 
double the number in MUC1.  As a result Muc-1 may be even more glycosylated than MUC1 
which is consistent with the longer transit time from the Golgi to the cell surface for mouse Muc-
1 as compared to human MUC1 on tumor cells (241).  Despite the expected 65kDa mass of the 
Muc-1 core protein (237), Muc-1 is larger than 200 kDa when run on a protein gel, indicating 
that extensive glycosylation does occur.  Greater glycosylation in combination with the lower 
proline content may make the structure of Muc-1 more extended than MUC1 (238).  The 
extracellular domain of Muc-1 would be predicted to be 70 nm (242) so like MUC1 would still 
stretch far above the cell surface.  The immunodominant sequence in human MUC1, PDTRP, is 
not conserved in the mouse Muc-1, rather uncharged residues are in the place of the charged 
amino acids aspartic acid (D) and arginine (R).  Comparisons following MUC1 vaccination of 
wild type mice and MUC1 transgenic mice have shown significantly different responses (124, 
140, 243) highlighting in vivo the differences between murine Muc-1 and human MUC1. 
 
4.2 MATERIALS AND METHODS 
4.2.1 Cells, mice and antibodies 
BT-20 tumor cells were grown in RPMI supplemented with 10% fetal bovine serum, 1% 
L-glutamine and 1% penicillin/streptomycin.  HBL/Y2 cells, a human mammary epithelial cell 
line immortalized by SV40 T antigen, were grown in DMEM supplemented with 10% fetal 
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bovine serum, 1% L-glutamine and 1% penicillin/streptomycin.  These cells had been transfected 
with an expression vector containing MUC1/Y (Dr. Daniel Wreschner).  Peripheral blood was 
obtained as a leukopheresis research product from the Central Blood Bank (Pittsburgh, PA). 
Peripheral blood mononuclear cells (PBMC) were isolated from whole blood by Ficoll/Paque 
(Amersham Pharmacia Biotech, Uppsala, Sweden) density gradient centrifugation.  MUC1 
transgenic mice, inbred on a C57BL/6 background, were purchased from the Mayo Clinic 
(Scottsdale, AZ).  Wild type C57BL/6 mice were purchased from The Jackson Laboratory (Bar 
Harbor, ME).  Mice were housed at the University of Pittsburgh Cancer Institute animal facility 
under standard pathogen-free conditions. 
FITC labeled mouse isotype control mouse IgG1, FITC labeled mouse anti-human 
MUC1 (clone HMPV), PE-labeled isotype control rat IgG2b, PE-labeled rat anti-mouse CD25, 
PerCP labeled isotype control hamster IgG group 1 and PerCP hamster anti mouse CD3, PE-
labeled isotype control mouse IgG1, PE labeled mouse anti-human CD25, PerCP-labeled isotype 
control mouse IgG1, and PerCP-labeled mouse anti-human CD3 were purchased from BD 
Pharmingen.  Anti-human MUC1 monoclonal antibody VU-3-C6 was provided by Dr. J. Hilgers 
(Department of Obstetrics and Gynecology, Academisch Ziekenhuis, Vrije Universiteit, 
Amsterdam, The Netherlands).  Anti-human MUC1 monoclonal antibody BC3 was provided by 
Dr. I. McKenzie (The Austin Research Institute , Heidelberg, Vic., Australia). 
4.2.2 Activation of human PBMC and mouse splenocytes  
PBMC were cultured in RPMI-1640 supplemented with 10% human serum (Cellgro, 
Herndon, VA), 1% L-glutamine, 1% penicillin/streptomycin, and activated with PHA (5 µg/ml; 
Sigma, St. Louis, MO) and 20 U/ml interleukin-2 (IL-2) (Dupont, Wilmington, DE).  Mouse 
splenocytes were cultured in RPMI-1640 supplemented with 10% fetal calf serum, 1% L-
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glutamine, 1% penicillin/streptomycin, 1% non-essential amino acids, 1% sodium pyruvate, 
0.1% β-mercaptoethanol and activated with ConA (10 µg/ml; Amersham Biosciences, England) 
and 20 U/ml interleukin-2 (IL-2) (Dupont, Wilmington, DE).  Activation of T cells was verified 
by flow cytometry staining for CD3 and CD25 prior to using cells in experiments.   
 
4.2.2. Extracellular flow cytometry 
Activated PBMC and mouse cells were stained with directly conjugated antibodies 
against MUC1 (clone HMPV), CD25 and CD3.  Samples were analyzed by first gating out dead 
cells on the basis of forward and side light scatter.  Then the CD3 positive population was 
examined for CD25 expression and MUC1 expression.  Resting cells were stained with directly 
conjugated antibodies against MUC1 (clone HMPV) and CD3.  Live cells were examined for 
CD3 expression and CD3 positive cells were assessed for MUC1 expression.  Samples were 
analyzed using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA) and FlowJo 
3.2 software (Tree Star, Inc., San Carlos, CA).   
4.2.3 Intracellular flow cytometry for human MUC1  
Human PBMC, MUC1 transgenic and wild type splenocytes were activated as described 
for seven days.  Live PBMC were purified by Lymphocyte Separation Medium (ICN, Aurora 
OH) centrifugation and live splenocytes were purified by Lympholyte-M (Cedarlane 
Laboratories, Ontario Canada) centrifugation before staining.  Live cells were then stained for 
extracellular MUC1 and for intracellular MUC1, no additional markers were examined.  
Intracellular staining was done by first fixing the cells in 4% formaldehyde for 20 minutes at 
room temperature.  This was followed by washing in FACS medium (5% FBS, 0.1% sodium 
azide in PBS) and permeabilization with 0.5% saponin in FACS medium (permeabilization 
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FACS medium) for 10 minutes at room temperature.  Keeping the cells in permeabilization 
FACS medium, FITC labeled anti-MUC1 or FITC labeled isotype control antibody was added to 
cells for 45 minutes at 4oC.  Cells were then washed in permeabilization FACS medium followed 
by normal FACS medium and analyzed alongside cells stained for extracellular MUC1.  Samples 
were analyzed using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA) and 
FlowJo 3.2 software (Tree Star, Inc., San Carlos, CA). 
4.2.4 RT-PCR for human MUC1 and MUC1/Y 
Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia CA) according to 
the manufacturers instructions.  cDNA was generated from total RNA using Gene Amp RNA 
PCR kit (Roche Molecular Systems, Branchburg NJ) according to the manufacturers 
instructions, using random hexamer or oligo d(T)16 primers as indicated.  In all experiments, 1 
µg of total RNA was used to generate cDNA.  The cDNA was amplified using one of three sets 
of primers.  Primers to amplify GAPDH (glyceraldehydes 3 phosphate dehydrogenase), a 
housekeeping gene, were used as a control.  These forward, 5-GGG GAG CCA AAA GGG 
TCA TCA TCT 3 and reverse 5-GCC ATC ACG CCA CAG TTT C-3, primers amplify a 
257bp fragment.  MUC1 forward 5-CTT GCC AGC CAT AGC ACC AAG-3 and reverse 5-
CTC CAC GTC GTG GAC ATT GAT G-3 primers, used in screening to identify MUC1 
transgenic mice (124), bind to human MUC1 genomic sequence spanning an intron so that a 
341bp product is amplified from RNA and a 600bp product is amplified from genomic DNA.  
MUC1/Y forward 5-T ACT GAG AAG AAT GCT TTT AAT-3 and reverse 5-C AGA CTG 
GGC AGA GAA AGG A-3 primers yield a 313bp product.  The first primer sequence GCT * 
TTT binds over the unique joining site generated during alternative splicing so that this primer 
can only bind MUC1/Y (* represents the unique joining site).   
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4.2.5 Immunoblotting for MUC1 from resting and activated MUC1tg 
Human PBMC, wild type or MUC1 transgenic splenocytes were activated as described 
above and then analyzed by flow cytometry verify we have live, activated (CD25+) T cells 
(CD3+).  Cell pellets were made of these cells and stored at -80oC until lysed for 
immunoblotting.  BT-20 cell pellets containing 5 x 105 cells each were also stored at -80oC until 
lysed for immunoblotting.  Cell pellets (5 x 106 or 10 x 106) of resting and activated human, wild 
type or MUC1 transgenic T cells were thawed on ice and lysed with Lysis Buffer I (50mM Tris-
HCl, 150mM NaCl, 1% TritonX, 0.1% SDS, 100 µg/ml PMSF, 5 µg/ml Leupeptin, 2 µg/ml 
Aprotinin) on ice for 40 minutes, vortexing every 10 minutes.  Lysates were centrifuged at 4oC 
for 15 minutes at 13,000 x g.  Supernatants were collected to new tubes, mixed with reducing 
loading buffer (62.5 mM Tris/HCl, 10% glycerol, 5% β−mercaptoethanol, 1.05% SDS, 0.004% 
bromophenol blue) and boiled for 3 minutes.  Samples were electrophoresed alongside Rainbow 
molecular weight markers (BioRad RPN756, BioRad Laboratories, Hercules CA) through a 7% 
acrylamide gel in Glycine-Tris-SDS running buffer (0.192M Glycine, 0.025M Tris, 0.035M 
SDS) at 150 volts.  Proteins were transferred onto nitrocellulose membranes (BioRad 
Laboratories, Hercules CA) in 10% Towbin buffer using 30 volts overnight at 4oC.  Membranes 
were blocked by rocking in 10% dry milk in PBS and then immunoblotted with anti-MUC1 
antibodies BC3 and/or VU-3-C6.  Bound anti-MUC1 antibody was detected by sheep anti-mouse 
horseradish peroxidase secondary antibody (Amersham Biosciences, England).  ECL detection 
reagents (Amersham Biosciences, England) were added to the membrane and proteins were 
visualized by X-Omat film development (Kodak, Rochester NY).   
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4.3 RESULTS 
4.3.1 Lack of human MUC1 on MUC1 transgenic mouse T cells 
To explore the effect of MUC1 on T cell migration in vivo, a mouse model would be 
informative.  Mouse Muc-1 and human MUC1 have a similar structure but differ in size, 
sequence, and the number of repeats in the extracellular region.  These differences may not give 
a truly analogous picture of human MUC1 on human T cells.  In addition, there is a dearth of 
reliable reagents commercially available to study mouse Muc-1.  In order to take advantage of 
the numerous reliable human MUC1 reagents, we decided to use the human MUC1 transgenic 
mouse model.   
The first step was to see if the MUC1 transgenic mouse T cells express MUC1 on their 
surface following activation, as human T cells do.  Splenocytes from the MUC1 transgenic 
mouse were activated for seven days alongside wild type splenocytes as a negative control and 
human PBMC as a positive control.  All three sets of cells were stained for expression of MUC1, 
CD25 and CD3.  Analysis was performed by gating on live CD3 expressing cells; by this point in 
the culture all of the live cells were CD3+, indicating that non-T cells in the original pool of 
PBMC and splenocytes have died.  All samples were activated, as indicated by strong expression 
of the IL-2 receptor (CD25), (top panel, Figure 4.0-1).  However, MUC1 expression seen on the 
activated human T cells was not reproduced on the activated MUC1 transgenic mouse T cells 
(bottom panel, Figure 4.0-1).  There was no MUC1 expression on either the activated MUC1 
transgenic mouse T cells or wild type mouse T cells.   
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Figure 4.0-1 Activated T cells from human PBMC, MUC1 transgenic mice and wild type mice.  PBMC and 
splenocytes were activated with PHA or ConA, respectively, and then stained for expression of CD3, CD25 
and MUC1.  CD3 expressing cells were examined for CD25 expression (top) and MUC1 expression (bottom).  
Shaded histograms are isotype control antibody fluorescence, open histograms are anti-CD25 (top panel) or 
anti-MUC1 (bottom panel) antibody fluorescence 
 
Resting T cells from wild type and MUC1 transgenic mice predictably also showed no 
expression of MUC1 (Figure 4.0-2).   
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Figure 4.0-2 Resting splenocytes from MUC1 transgenic mice and wild type mice.  Splenocytes were stained 
for expression of CD3 and MUC1.  CD3 expressing cells were examined for MUC1 expression.  Shaded 
histograms are isotype control antibody fluorescence, open histograms are anti-MUC1 antibody fluorescence 
 
4.3.2 RT-PCR for MUC1 in mouse T cells 
Since we did not see MUC1 on the surface of activated MUC1 transgenic mouse T cells, 
we asked whether the gene was being expressed.  Primers against MUC1 were used to perform 
RT-PCR on resting and activated splenocytes from MUC1 transgenic mice.  MUC1 RT-PCR 
was also done on wild type mouse cells as a negative control and the MUC1 expressing BT-20 
tumor cell line as a positive control.  The MUC1 primers were selected to amplify a region 
containing an intron so that amplification of genomic human MUC1 would produce a 600 base 
pair band while amplification of processed RNA would produce a 341 base pair band.  In Figure 
4.0-3, a 100  1000 base pair ladder is in lane 1 of both gels.  BT-20 cells are shown in lanes 2 
and 3 of both gels.  The genomic MUC1 amplification product from BT-20 cells is seen in lane 2 
in which no reverse transcriptase (RT) was added to the reaction.  MUC1 RNA amplification 
product from BT-20 cells is seen in lane 3 in which RT was added to the reaction.   
Splenocytes from a MUC1 transgenic mouse are shown in the top gel (Figure 4.0-3A) 
while splenocytes from a wild type mouse are shown in the bottom gel (Figure 4.0-3B).  Lanes 4 
 7 in both gels are RT-PCR reactions on resting splenocytes, while lanes 8 - 11 in both gels are 
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from activated splenocytes.  Resting splenocytes from MUC1 transgenic mice show the genomic 
MUC1 amplification product (Figure 4.0-3A, lane 5), verifying that we are looking at MUC1 
transgenic mouse cells.  Activated splenocytes from MUC1 transgenic mice show the processed 
RNA MUC1 amplification product when RT was added (Figure 4.0-3A, lane 9).  In contrast, 
splenocytes from wild type mice show neither the MUC1 genomic nor processed RNA 
amplification products (Figure 4.0-3B, lanes 4, 5, 8, 9), verifying that the primers were not 
binding in mouse splenocytes non-specifically.  Lanes 6, 7, 10, and 11 in both gels are control 
RT-PCR reactions with primers against a housekeeping gene.  These results demonstrate that 
MUC1 transgenic splenoctyes do transcribe the MUC1 gene upon activation.   
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Figure 4.0-3 Detection of MUC1 transcript in resting and activated MUC1 transgenic and wild type mouse 
splenocytes by RT-PCR.  Total RNA was collected from resting (lanes 4-7) or ConA activated (lanes 8-9, 10-
11) MUC1 transgenic splenocytes (A) or wild type splenocytes (B).  BT-20 cells (lanes 2 and 3) were run 
alongside splenocytes as a positive control.  RT-PCR was performed using random hexamer primers and the 
cDNA was amplified with MUC1 specific primers (lanes 2-5, 8, 9) or with GAPDH specific primer (lanes 6, 7, 
10, 11).  The amplified MUC1 genomic fragment is 600bp, processed MUC1 RNA fragment is 341bp and the 
GAPDH fragment is 257bp.   
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As further confirmation that MUC1 messenger RNA is being made, we repeated the RT-PCR 
reactions on resting and activated MUC1 transgenic splenocytes using reverse transcriptase 
oligo(T) primers that specifically bind mRNA via the poly A tail.  As before, we see MUC1 
mRNA is expressed in activated MUC1 transgenic splenocytes (Figure 4.0-4). 
 
 
 
Figure 4.0-4 Detection of MUC1 messenger RNA in resting and activated MUC1 transgenic splenocytes by 
RT-PCR.  Total RNA was collected from resting (lanes 4 – 7) or ConA activated (lanes 8 – 11) MUC1 
transgenic splenocytes.  BT-20 cells (lanes 2 and 3) were run alongside splenocytes as a positive control.  RT-
PCR was performed using oligo(T) primers and the cDNA was amplified with MUC1 specific primers (lanes 
2-5, 8, 9) or with GAPDH specific primer (lanes 6, 7, 11, 12).  The amplified MUC1 genomic fragment is 
600bp, processed MUC1 mRNA fragment is 341bp and the GAPDH fragment is 257bp. 
4.3.3 Intracellular flow cytometry for MUC1 
Since we had observed that MUC1 mRNA was being made but that MUC1 protein was 
not expressed on the cell surface, we asked whether MUC1 protein was made but not transported 
to the cell surface.  We first performed intracellular flow cytometry on permeabilized activated 
MUC1 transgenic cells, using the BT-20 tumor cell line as a positive control and wild type 
activated splenocytes as negative control.  Resting and activated human PBMC were also 
analyzed for comparison.  After a week of activation, dead cells were removed by gradient 
centrifugation and the remaining cells were analyzed for extracellular and intracellular MUC1 
(Figure 4.0-5).  The BT-20 cells (Figure 4.0-5A) show strong staining for both extracellular and 
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intracellular MUC1.  There is a slight increase of intracellular staining above extracellular. 
Similarly, though to a much lesser extent, the activated human T cells (Figure 4.0-5B) also show 
definite extracellular staining with a slight increase in intracellular staining.  The MUC1 
transgenic (Figure 4.0-5C) and wild type (Figure 4.0-5D) T cells show no surface staining for 
MUC1.  A slight shift is seen in intracellular staining, however this shift is seen in both 
transgenic and wild type mice.  Since wild type mice do not contain the MUC1 gene, the 
observed shift in mouse T cells is likely non-specific.  This data suggest that MUC1 protein is 
not being made in activated MUC1 transgenic mouse T cells. 
 
 
 
Figure 4.0-5 Extracellular and intracellular flow cytometry for MUC1 protein expression.  (A) BT-20 cells are 
shown as a positive control for strong MUC1 expression.  (B) Human PBMC, (C) MUC1 transgenic, and (D) 
wild type splenocytes were activated for 1 week, the live cells isolated by gradient centrifugation and stained 
for surface and cytosolic MUC1.    
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4.3.4 Immunoblotting for MUC1 
In addition to intracellular flow cytometry we wanted to use another method to test for 
intracellular MUC1 in MUC1 transgenic splenocytes.  Activated and resting wild type 
splenocytes, MUC1 transgenic splenocytes, human PBMC and BT-20 were immunoblotted for 
MUC1 (Figure 4.0-6).  As expected BT-20 cells show a strong, high molecular weight MUC1 
signal (lane 7); a comparable signal is not seen in any of the other lanes.  There are some bands 
seen in the other lanes but these are all in molecular weight regions lower than expected for 
MUC1 (Figure 4.0-6).  It is possible that MUC1 expressed by BT-20 cells is significantly bigger 
than that of PBMC and the MUC1 transgene.  The DNA fragment used to generate these MUC1 
transgenic mice (124) contains a 2.3kbp tandem repeat sequence (160), which would translate to 
a roughly 35 repeat VNTR region.  Resting wild type (lane 4) and MUC1 transgenic (lane 5) 
splenocytes have virtually identical appearance.  The pattern of bands in activated splenocytes 
from wild type (lane 1) and MUC1 transgenic (lane 2) mice are also similar but there may be an 
additional band in a doublet not seen in resting MUC1 transgenic splenocytes; however it was 
not unequivocally clear if this was MUC1.  
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Figure 4.0-6 Immunoblotting for MUC1 in resting and activated wild type and MUC1 transgenic splenocytes, 
and human PBMC.  Splenocytes and PBMC were activated for 6 days and each population verified to be 
activated T cells by flow cytometry.  Activated cells were electrophoresed alongside resting cells and then 
immunoblotted with antibody against human MUC1 extracellular region.  BT-20 cells were used as a positive 
control. 
 
Since we wanted to look more convincingly for MUC1 in the transgenic splenocytes, and 
had expected to detect MUC1 in the activated PBMC, we repeated this experiment using twice as 
many resting and activated PBMC and MUC1 transgenic splenocytes per lane (Figure 4.0-7).  
Though MUC1 is still strongly detected from the much lower number of BT-20 cells (lane 5), we 
did not detect a high molecular weight band in activated PBMC (lane 2) or activated MUC1 
transgenic splenocytes (lane 4).  The pattern of bands is similar between resting and activated 
1 2 3 4 5 6 7 
______Activated_______ ________Resting_______
W.T. W.T.MUC1 tg MUC1 tgPBMC PBMC
 cells, from both human PBMC (lanes 1 and 2) and MUC1 transgenic splenocytes (lanes 3 and 4) 
with no additional bands appearing following activation.  It seems that the level of MUC1 
expressed by activated human T cells as compared to tumor cells is not enough to pick up by 
immunoblotting, even though it is clearly seen by other means (see chapter 2.0).  The possible 
doublet previously seen in the activated MUC1 transgenic splenocytes (Figure 4.0-6) is not 
evident here, despite the increased number of cells.  It is likely that the possible MUC1 band 
seen previously in activated MUC1 transgenic splenocytes was artifactual.  Combined with the 
intracellular flow cytometry data, we cannot show that T cells from MUC1-transgenic mice 
synthesize MUC1 from their transcribed mRNA. 
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lotting for MUC1 in resting and activated human PBMC and MUC1 transgenic 
nes 1 and 2) and MUC1 transgenic splenocytes (lanes 3 and 4) were activated for 6 
on verified to be activated T cells by flow cytometry.  Resting (lanes 1 and 3) and 
) cells were electrophoresed alongside BT-20 tumor cells (lane 5) as a positive control 
 with antibody against human MUC1 extracellular region. 
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4.3.5 RT-PCR for MUC1/Y in mouse T cells 
Since no MUC1 protein could be detected in activated MUC1 transgenic T cells, what is 
becoming of the MUC1 mRNA we detected?  A possibility is that the transcript is being 
alternatively spliced to produce a different form of human MUC1, one that is not detected by 
antibodies against the tandem repeat region of MUC1.  MUC1/Y can be expressed on the surface 
of human tumor cells (16).  It is transcribed from the MUC1 gene but the VNTR region is 
spliced out before the message can be translated into protein.  Since the antibodies we used to 
detect MUC1 are specific to peptide sequence in the VNTR region, we would not detect 
MUC1/Y in our flow cytometry or immunoblotting.  To see if we could detect MUC1/Y message 
we designed primers specific to MUC1/Y and used them in RT-PCR of resting and activated 
MUC1 transgenic splenocytes.  The HBL/Y2 cell line has been transfected with MUC1/Y and 
was used as our positive control.  Resting and activated wild type splenocytes were used as the 
negative control (Figure 4.0-8).   
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Figure 4.0-8 RT-PCR for MUC1/Y in resting and activated MUC1 transgenic and wild type splenocytes.  
HBL/Y2 cells (lane 2) were run alongside splenocytes as a positive control for MUC1/Y expression.  Total 
RNA was collected from resting or ConA activated MUC1 transgenic splenocytes (lanes 3 and 4, respectively) 
and resting and activated wild type splenocytes (lanes 5 and 6, respectively).  RT-PCR was performed using 
oligo(T) primers and the cDNA was amplified with (A) MUC1/Y specific primers or with (B) GAPDH specific 
primers.  The –RT control amplification products are shown in the top row of each gel. 
 
Figure 4.0-8A shows results from RT-PCR using the MUC1/Y primers.  Control 
reactions without RT are shown in the top row and RT was added to reactions shown in the 
bottom row.  Lane 1 contains a 100 - 1000 base pair ladder.  Lane 2 in both rows contains RT-
PCR amplification products from the HBL/Y2 cell line.  The 313bp MUC1/Y amplification 
product is detected in the HBL/Y2 line in RT-PCR reactions done with and without the reverse 
transcriptase enzyme, due to the presence of the transfected construct.  Lanes 3 and 4 are resting 
and activated MUC1 transgenic splenocytes, respectively.  No MUC1/Y is detected with or 
without RT.  This is repeated in the resting and activated wild type splenocytes, lanes 5 and 6 
respectively. Figure 4.0-8B shows the same cell samples used in RT-PCR with primers against a 
housekeeping gene to check that the PCR reaction worked for each sample.  These data 
demonstrate that MUC1/Y is not being produced in the activated MUC1 transgenic splenocytes 
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and so cannot account for the MUC1 message being detected while MUC1 protein was not 
found.  There may be other alternatively spliced MUC1 gene products expressed in these cells 
but that remains to be determined.   
4.4 Discussion 
The need for a mouse model to study the effect of MUC1 on the migration of T cells led us 
to explore the MUC1 transgenic mouse.  This model has been well-documented to express 
MUC1 in a manner similar to that seen in humans and so we expected that T cells from this 
model would also express MUC1.  However, this turned out to not be the case.  No surface 
MUC1 protein was observed by flow cytometry nor intracellular MUC1 protein by intracellular 
flow cytometry or immunoblotting.  This was not due to ineffective activation or lack of 
transcription or processing of MUC1 mRNA.  Since we could not find evidence that the full-
length MUC1 protein was being translated from mRNA, we explored whether an alternatively 
spliced form of MUC1 was synthesized in the mouse cells.  This was not the case for MUC1/Y 
though we did not rule out the possibility that other alternative splice variants could be made 
from mRNA in the transgenic mouse T cells.   
Why would MUC1 be transcribed but the protein not sent to the cell surface?  A likely 
possibility is that the mRNA is never translated to protein.  This is consistent with our findings.  
However this would mean that the transgenic mouse T cells are uniquely unable to synthesize 
MUC1, as it is expressed on epithelial surfaces through out the mouse (124, 236).  There have 
been efforts by other groups to study T cell expression by MUC1 transgenic mice.  These groups 
have communicated either expression following stimulation (Dr. S. Gendler) or lack of 
expression by activated T cells (Dr. J. Taylor-Papadimitriou) using the same transgenic line.  
However, none of this work has yet been published.  It is also possible that the transcribed 
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mRNA is being translated but the protein is secreted rather than put on the cell surface.  
However, this would be contrary to human T cell cultures in which MUC1 was reliably 
identified on the T cell surface while soluble MUC1 was barely detectable (Chapter 2.0).   
Our findings that T cells from MUC1 transgenic mice do not express MUC1 in a manner 
similar to humans ruled out their use in studying the role of MUC1 in T cell migration.  However 
it did raise a separate interesting question.  Is the difference in MUC1 expression on T cells due 
to the model itself or is there a fundamental biological difference between mouse and human T 
cells?  It is possible that whatever genetic elements are needed for T cell expression are simply 
not present in the material used to produce the transgenic mice.  An alternative is that mouse T 
cells do not use Muc-1 protein as human T cells use MUC1.  To address this possibility it is 
necessary to determine whether murine T cells express murine Muc-1 after activation.  If they do 
then the failure of the transgenic mice to express MUC1 is likely simply an artifact of the model.  
If murine T cells do not express murine Muc-1 then this indicates that the function of MUC1 on 
human T cells is not needed by mouse T cells or that another molecule is used in place of Muc-1.   
We began by searching for antibodies against the extracellular region of Muc-1 so that we 
could measure surface expression on mouse T cells.  There have been studies examining Muc-1, 
but these have used either antibodies reactive to carbohydrate domains (244), and thus not 
specific to Muc-1 or reactive to the cytosolic tail so that surface expression is not explicit (240, 
245).  Our search yielded only one report claiming to have generated antibodies against 
extracellular Muc-1 (246).  Attempts to verify this work using an antibody provided by Dr. Xing 
has thus far been inconclusive, in agreement with efforts by others (Dr. S. Gendler, personal 
communication).  We have recently generated our own anti-Muc-1 antibodies by a novel chicken 
immunization strategy with Aves Labs, Inc.  Work with these antibodies (data not shown) has 
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indicated that mouse T cells do express Muc-1 following allogeneic mixed leukocyte 
stimulation.  Muc-1 can be detected at low levels early on and is maintained over one week, 
though the intensity decreases.  An additional technique, perhaps biotinylation of surface 
proteins on activated mouse T cells followed by immunoprecipitation with the antibody reactive 
against MUC1/Muc-1 cytosolic tail, would be a useful confirmation of these results. 
 
SUMMARY 
 The finding that MUC1 is expressed on the surface of T cells has expanded its 
physiological role, previously considered in the context of epithelial cells, to include playing a 
part in the function of T cells.  We have here shown that MUC1 is expressed only on activated, 
and not resting T cells, following either in vitro or in vivo activation.  MUC1 expression is then 
maintained over long time periods as the T cells acquire the memory phenotype.  The 
glycosylation of MUC1 on T cells is similar to that on normal epithelial cells.  Location of 
MUC1 on the T cell surface changes as cells are exposed to inflammatory conditions with 
MUC1 being focused to the leading edge, in contrast to other large or mucin like molecules on T 
cells that are moved to the trailing edge (the uropod).  At the leading edge, and facilitated by its 
long, extended rod-like structure, MUC1 could be expected to be one of the first molecules to 
interact with the endothelium during T cell adhesion to blood vessels.  Indeed we show in a 
model system with the Jurkat T cell leukemia cell line that MUC1 expression enhances binding 
to endothelium and the adhesion molecule ICAM-1 while inhibiting binding to E-selectin.  The 
MUC1 cytosolic tail is constitutively phosphorylated in T cells, presumably as a result of cell-
cell interactions, and this phosphorylation is maintained as T cells interact with resting 
endothelium.  However, upon interaction with activated endothelium the phosphorylation of T 
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cell MUC1 drastically decreases.  MUC1 expression on T cells and its interaction with 
endothelium also results in differential phosphorylation of at least three other proteins (39 kDa, 
64-97 kDa and 191 kDa) with β-catenin tentatively identified as the 64-97 kDa protein.  B-
catenin is known to play a role in cell-cell adhesion and regulating gene transcription.   
The expression of MUC1 by activated T cells and its influence on T cell adhesion and 
signaling support its  role in the migration of activated T cells across the endothelium.  One of 
the outcomes of this work is the possibility to block T cell migration by blocking the ability of 
MUC1 to bind to the endothelium.  This would be especially of interest in alleviating the 
symptoms of diseases such as arthritis, diabetes, and other autoimmune disorders, as well as graft 
rejection, where activated T cells are the primary mediators.  By preventing their adhesion to the 
endothelium, it may be possible to prevent their continuous migration to the diseased tissue.  One 
approach would be to immunize the patient with MUC1 to generate a high titer of anti-MUC1 
antibodies capable of blocking its function.  This approach can be tried first in animal models.  
We have generated an antibody reactive with the mouse homologue of MUC1 (Muc-1) and used 
it to show that mouse cells also upregulate Muc1 expression after activation.  The role of mouse 
Muc1 on T cells can now be examined in vivo in mouse models of autoimmune diseases. 
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